Stock code：*4737*

BIONIME CORPORATION

# 2025 Annual Report

The Annual Report post：https://mops.twse.com.tw
Company website：https://www.bionime.com

Printed on May 15, 2026

BIONIME

**1. Company Spokesman:**

Spokesman

Name: Huang, Chun-Mu

Title: Chairman

Tel: (04) 2369-2388

Email: investor@bionime.com

Acting Spokesman

Name: Huang, Chien-Yu

Title: Manager

Tel: (04) 2369-2388

Email: investor@bionime.com

**2. Address and telephone number of the Company:**

Address: No. 100, Section 2, Daqing Street, Southern District, Taichung

Tel: (04)2369-2388

Fax: (04)2261-7586

**3. Name, address and telephone number of the stock transfer agency:**

Agency: Transfer Agency Department, CTBC Bank Co., Ltd.

Address: 5F., No. 83, Sec. 1, Chongqing S. Rd., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

Tel: +886-2-6636-5566

Website: https://www.ctbcbank.com

**4. CPAs certifying the latest financial statements**

Names of CPAs: Chen Yen- Hui, Kuo Shyh-Huar

Name of CPA firm: KPMG Taiwan

Address: 68th Floor, No. 7, Section 5, Xingyi Road, Xingyi District, Taipei

Website: www.kpmg.com.tw

Tel: (02) 8101-6666

**5. Venue for trading the Company's listed overseas securities and inquiry method for such overseas securities: None.**

**6. Company website:** https://www.bionime.com

# Table of Contents

**I. Letter to Shareholders ..... 1**

**II. Corporate Governance .....7**

**III. Capital Overview .....107**

1. Capital and Shares.....107
2. Corporate Bonds .....114
3. Preferred Shares .....114
4. Global Depository Receipts (GDR).....114
5. Employee Stock Warrants.....115
6. New Restricted Employee Shares.....117
7. Issuance of New Shares for Acquisition or Exchange of Other Companies' Shares .....117
8. Financing Pans and Implementation .....118

**IV. Operations Profile..... 119**

1. Business Scope .....119
2. Market and Sales Overview .....138
3. Employee Information for the Past Two Year and as of the Publication of the Annual Report .....149
4. Environmental Expenditure Information .....149
5. Labor Relations .....149
6 Cybersecurity management.....153
7. Important Contracts .....156

**V. A Review and Analysis of the Company's Financial Position and Financial Performance, and a Listing of Risks ..... 157**

1. Financial Position.....157
2. Financial Performance…… .158
3. CashFlow……159
4. Major Capital Expenditures During the most Fiscal Year……159
5. Investment Policy for the most Recent Year, the Reasons or the Profits or Losses, Improvement Plans, and Investment Plans for the Coming Year……159
6. Risk Management……162
7. Other Important Matters……167

**VI. Special Disclosure ..... 168**

1. Information Related to the Company's Affiliates……168

2. Transactions about the Company's Private Placement of Securities……172

3. Other Matters that Require Additional Description…….... 172

**VII. Substantial Impact on Owner's Equity or Securities' Prices ..... 172**

# I. Letter to Shareholders

1. 2025 Annual operating report

(1) 2025 Business result: (Unit: NT$ thousand)

| Annual | 2025 | 2024 | Increase/Decrease |
|---|---|---|---|
| Net Operating Revenue | 1,838,588 | 1,933,746 | (95,158) |
| Gross Profit | 627,810 | 768,383 | (140,573) |
| Operating Expenses | 825,166 | 923,570 | (98,404) |
| Operating Income | (197,356) | (155,187) | (42,169) |
| Income after Tax | (179,320) | (125,999) | (53,321) |

Note：Net operating revenue in 2025 decreased by 4.9% compared to 2024. Operating expenses decreased by 10.7% compared to 2024; overall, net loss after tax increased by 42.3% compared to 2024.

(2) The analysis of 2025 and 2024 financial structure and profitability:

| Items \ Annual | | 2025 | 2024 |
|---|---|---|---|
| Financial Structure | Debts ratio(%) | 69.22 | 67.32 |
| | Long Term Funds to Fixed Assets(%) | 142.98 | 134.05 |
| Profitability | Return on Assets(%) | -2.21 | -1.37 |
| | Return On Equity(%) | -9.84 | -6.49 |
| | Profit Margin(%) | -9.75 | -6.51 |
| | Earnings Per Share | -2.68 | -1.90 |

Note：Strategic investments in automated production equipment and international clinical trial expenses for the CGM product have led to an increase in the debt ratio, impacting the company’s profitability.

(3) Budget implementation: The execution of budget is not disclosed, as the 2025 financial forecast was not publicly released.

(4) Status of research and development:

(a). The ratio of research and development fee in net amount of revenue and the result of research and development in last 3 years

| Annual / Items | 2025 | 2024 | 2023 |
|---|---|---|---|
| R&D Expenses | 354,755 | 322,326 | 242,338 |
| R&D Expenses to Net Operating Revenue ratio | 19.3% | 16.7% | 13.8% |

(b). Machine types expected to be developed in 2025:

A. Bionime has developed the next-generation GS765 blood glucose test strip for use with conventional Blood Glucose Monitoring (BGM) devices. The strip is not subject to interference from xylose and expands the measurement range to 10–900 mg/dL, providing greater competitive advantages in the tender market for professional healthcare settings.

B. Bionime's miniaturized Continuous Glucose Monitoring (CGM) devices. Following improvements to the manufacturing process and enhancements to CGM specifications, the warm-up time has been reduced from 2 hours to 1 hour, and the duration of use has been extended from 10 days to 15 days. Clinical trial reports were obtained in March and May 2025, respectively, and applications for medical device licenses in Taiwan and Europe were submitted in the same year.

C. Bionime has developed the next-generation receiver HR510, dedicated to CGM data display, and can be used with the iFree2 CGM. Developed on the Android platform, the receiver allows system maintenance to be synchronized with smartphones and supports Wi-Fi connectivity, enabling data to be uploaded and shared with family members, friends, and healthcare providers, thereby supporting family care and collaborative healthcare.

D. By the end of 2025, regarding CGM, we had applied for 501 Taiwanese and international patents in total. More than 317 patent applications have passed Taiwanese and international reviews and obtained patent certificates.

(c). Product technology development in 2026

A. The mainstream CGM products currently available on the market generally have a wear duration of 10–15 days. However, some competing products are being developed toward a wear duration of 21 days or even longer. Bionime will continue its R&D efforts to further enhance the specifications of its CGM products, including extending their wear duration and shelf life.

B. The values provided by CGM devices may be used by users, under the guidance of healthcare professionals, as a basis for insulin administration. CGM devices may also be used in combination with insulin pumps for blood glucose management. Bionime plans to collaborate with insulin pump companies in 2026 to develop related software and hardware to connect CGM devices with insulin

pumps, thereby expanding market opportunities and increasing customer stickiness for CGM products.

C. To support the subsequent regulatory approval and shipment requirements for the iFree2 CGM, Bionime will develop corresponding automated equipment and intelligent control systems. Building on its existing automated equipment, the Company will continue to enhance and refine its production technologies to facilitate the smooth mass production of continuous glucose monitoring devices.

D. Bionime's CGM products enter the market, tests will be conducted to evaluate their effectiveness, collecting data on the level of improvement in users' HbA1c and TIR (Time in Range) after long-term wearing of Bionime's CGM device, thereby verifying the substantive benefits of CGM for users.

2. 2026 Business Plan

(1) Operating Strategies

(a). Create high-quality and affordable Continuous Glucose Monitoring (CGM) devices to make CGM accessible to those in need of them.

(b). Continue to advance the certification process for the iFree2 CGM products in key markets, including Taiwan, Europe, and Mainland China. Upon obtaining certifications, assist cooperation partners in each country in obtaining local sales certificates to expand sales channels.

(c). Keep enhancing the accuracy and long-term performance of CGM devices, and optimize the overall user experience by evaluating the effectiveness of users wearing CGM devices, thereby building market trust and brand competitiveness.

(d). In response to certification progress and order demand, replicate the automated modules of the CGM production line in phases to build production capacity in a step-by-step approach.

(e). Deepen cooperation with existing distributors of traditional blood glucose monitoring (BGM) products, leveraging years of established sales channels to promote and sell CGM products. At the same time, based on Bionime's core CGM technologies, expand cooperation with major international brand customers, establish long-term strategic partnerships, and enhance brand value and market share.

(f). Implement budget control, along with energy and supply chain management, to reduce operating costs and strengthen product pricing competitiveness and profitability.

(g). Incorporate ESG sustainability principles and environmental responsibility throughout the entire process from product R&D and design to mass production, transforming green value into corporate competitive advantages and achieving the goal of advancing both business growth and sustainable operations.

(2) Sales volume and estimations

The Company's estimated sales volume is based on the following conditions: sales performance in past years, references to the industrial environment, market demands, and considerations of the Company's production capacity and future requirements of customers. As for CGM, we must wait for the product to be launched before it can contribute to the revenue. As the CGM products obtained international certifications and sales licenses in various countries, the new product will officially enter international markets, injecting growth momentum into the Company and contributing to revenue.

(3) Production and sales policy

(a). Regular production and sales coordination meetings are held to align sales forecasts from the business side with capacity planning on the production side, thereby improving supply-demand matching efficiency and ensuring stable supply.

(b). Given the stringent quality requirements for key raw materials used in blood glucose monitoring products, the Company has established a backup supplier mechanism to reduce the risk of material shortages. In addition, for precious metal materials, the Company adopts strategic inventory management and procurement planning to address fluctuations in international prices and ensure a stable supply of materials.

(c). The Company makes capacity arrangements in response to changing circumstances. For BGM products, production schedules are adjusted appropriately based on sales forecasts. For CGM products, production capacity is built up in a step-by-step approach according to the progress of acquiring sales certification in each country.

(d). To improve inventory turnover, the Company conducts rolling demand forecasts for its top ten key raw materials and strengthens bargaining power and supply stability through long-term procurement contracts, thereby reducing the risk of inventory accumulation. At the same time, the Company regularly reviews inventories of finished goods that have not yet been shipped, enhances shipment and scheduling management, and shortens the holding period of finished goods.

(4) The Expected Development Strategy

(a). In response to the functional requirements of different markets, the Company continues to develop and refine its CGM products and obtain international sales certifications.

(b). Based on customer demand, following the grant of certifications in international markets, the Company will replicate automated machinery and intelligent control systems in phases, with the planning of establishing high-volume, high-efficiency automated production lines.

(c). The Company leverages its existing BGM distribution channels in various countries to promote CGM products. It will also establish strategic partnerships with major international brand customers to enhance brand value and expand market share.

(d). The Company is committed to implementing ESG-oriented sustainable operations. In

recent years, it has successively obtained ISO 14064-1 greenhouse gas inventory verification and ISO 50001 energy management certification, and issued its first sustainability report in 2025. Looking forward, the Company plans to obtain additional international certifications, such as ISO 14067: Carbon footprint of products.

3. External competition environment, Legislation and the influence of Overall Management

(1). External competition environment

As national health insurance reimbursement policies become more relaxed and related laws and regulations continue to mature across countries, the penetration rate of CGM products has continued to rise, accelerating the erosion of the traditional BGM market. At present, the global market is dominated by three major international manufacturers—Abbott, Dexcom, and Medtronic—which together account for approximately 98% of the market share. As a result, market demand is becoming increasingly strong for third-party alternatives that offer both high accuracy and price competitiveness.

Bionime has independently developed its CGM technologies and established an intellectual property protection framework. The Company has filed more than 500 international patent applications and obtained 317 patent certificates, ranking as the world's fifth-largest company in terms of the number of CGM patents. Over the years, Bionime has conducted patent infringement comparison analyses of its CGM products in collaboration with several international customers. In addition to analyses performed by the internal teams of both parties, external international law firms were also entrusted with conducting patent infringement analyses of CGM products to ensure Freedom to Operate (FTO) and to sell under a low patent infringement risk.

Bionime will leverage highly automated production lines to enhance product quality and reduce manufacturing costs, enabling the Company to offer competitively priced products and capture a greater share of the global CGM market.

(2) Legislation

The medical equipment industry is strictly regulated and controlled by laws. In each country, medical devices must be registered with the respective national food and drug administration before they can be sold in the market and used. The registration process for medical devices involves submitting relevant product information, including the name of the product, classification, specifications, usages, structure, performance, and testing reports. Bionime is committed to upholding the quality of its products and quality systems, and conducts regular verifications on various laws and regulations, as well as quality systems, so that it can be ensured that the products and quality management systems meet all regulatory requirements.

With the rapid development of digital health and Software as a Medical Device (SaMD), software regulation has also become a key focus of global regulatory authorities. In addition to traditional safety and effectiveness requirements, legal requirements for personal data privacy and data security have become increasingly stringent across

countries. Compliance capabilities in “data security” have therefore become as important as product performance, forming an indispensable core competency for medical device companies. Bionime has incorporated international personal data protection standards into its product development and internal control processes to ensure that its products continue to comply with the latest information security and privacy requirements in various countries, thereby providing users with safe and reliable digital health solutions.

(3) The influence of Overall Management

According to estimates by several market research institutions, the global CGM market is expected to exceed US$13 billion in 2025, with a compound annual growth rate (CAGR) of more than 15%. This continued expansion is driving strong growth in the blood glucose monitoring market, and Bionime’s CGM products are well aligned with this market demand trend.

While pursuing corporate growth and maximizing shareholder value, the Company also emphasizes environmental protection, social responsibility, and corporate governance (ESG). Bionime is committed to fulfilling its corporate responsibilities and striving for long-term sustainable operations.We would like to thank our Shareholders, for your persistent efforts in upholding the strategic goal of the company, and to the shareholders, for your supports and encouragements. Looking ahead, through augmented hard-work and competitiveness, we relish the sustainable prospect of our business playing the international leading role in the industry of medical measurement devices. We shall not fail your expectation and concern.

Best Regards.

Chairman and General Manager: Huang, Chun-Mu

Accounting Manager: Chen, Ya-Wen

# II.Corporate Governance Report

## 1. Information of Directors, Supervisors, General Managers, Deputy General Managers, Assistant General Managers and other Departments and Branch Managers

### (1) Information of Directors

April 28,2026; Unit: share

| Title (Note 1) | Nationality or Place of Registration | Name | Gender Age (Note 2) | Elected Date | Term | Date First Elected (Note 3) | Shareholding when Elected | | Current Shareholding | | Spouse & Minor Children Current Shareholding | | Current Shareholding in the name of others | | Experience (Education) (Note4) | Current Positions at the Company and other Companies | Executives, Directors or Supervisors who are spouses or within two degrees of kinship | | | Remarks (Note5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | Shares | Ratio | Shares | Ratio | Shares | Ratio | Shares | Ratio | | | Title | Name | Relations | |
| Chairman | R.O.C | Huang, Chun-Mu | Male 61~70 years | June 17 2025 | 3 | April 14 2003 | 2,510,692 | 4.11% | 3,092,413 | 4.00% | 1,232,257 | 1.59% | 0 | 0% | ・General Manager of MS Tech.<br>・National Taipei University of Technology | Note 6 | - | - | - | - |
| Director | China | Tonghua Dongbao Pharmaceutical co., Ltd. | - | June 17 2025 | 3 | Feb. 5 2016 | 12,000,000 | 19.64% | 13,198,277 | 17.05% | 0 | 0.00% | 0 | 0% | - | - | - | - | - | - |
| | | Representative：Zhang,Wen Hai | Male 51~60 years | June 17 2025 | 3 | June 20 2019 | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0% | ・Deputy General Manager of Tonghua Dongbao<br>・Pharmaceutical CO. Chinese medicine program, Harbin University of Commerce | ・Director and Vice President of Tonghua Dongbao Pharmaceutical Co., Ltd.<br>・Legal representative and executive director of Shanghai Juyi Network Technology Co., Ltd. | - | - | - | - |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Representative：Fan,Pu | Male 41~50 years | Feb 10 2026 | 3 | June 20 2019 | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0% | · Vice President, Tonghua Dongbao Pharmaceutical Co., Ltd.<br>· Deputy General Manager and Chief Financial Officer, China Resources Biopharmaceutical Co., Ltd.<br>· Chief Financial Officer, Yuekang Pharmaceutical Group Co., Ltd.<br>· Master's Degree in Business Administration, Renmin University of China<br>· Major in Accounting, Renmin University of China | · Vice President, Tonghua Dongbao Pharmaceutical Co., Ltd.<br>· General Manager and Executive Director, Tianjin Runxin Enterprise Management Co., Ltd.<br>· Designated Representative of the Executive Partner, Tianjin Runhe Enterprise Management Partnership (Limited Partnership)<br>· Chairman, Benyuan Zhengyang Gene Technology Co., Ltd.<br>· Director, Dongbao International (Hong Kong) Co., Ltd. | - | - | - | - |
| Director | R.O.C | Hua Eng wire & cable co., ltd. | - | June 17 2025 | 3 | March 25 2010 | 7,004,900 | 11.47% | 7,704,384 | 9.95% | 0 | 0.00% | 0 | 0% | - | - | - | - | - | - |
| | | Representative：Liou, Xiu-Mei | Female 61~70 years | June 17 2025 | 3 | Feb. 1 20222 | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0% | · Vice President at Hua Eng Wire & Cable Co., Ltd<br>· Master of Accounting, Long Island University, New York, USA | Note 7 | - | - | - | - |
| Director | R.O.C | Yanben Investment Co., Ltd. | - | June 17 2025 | 3 | June 22 20222 | 1,500,000 | 2.46% | 1,845,938 | 2.38% | 0 | 0.00% | 0 | 0% | - | · Corporate Director at Advantech Co., Ltd.<br>· Corporate Director at Thuncloud Innovation Co., Ltd. | - | - | - | - |
| | | Representative：Liou,Ke-Chen | Male 71~80 years | June 17 2025 | 3 | June 22 20222 | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0% | · Founder and chairman of Advantedch Co.,Ltd<br>· Telecommunications Engineering,National Chiao Tung University | Note 8 | - | - | - | - |

| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Independent Director | R.O.C | Zeng,Hui-Jin | Female 61~70 years | June 17 2025 | 3 | June 22 20222 | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0% | ・Partner, Deputy Managing Partner, Chief Operating Officer, and Chief Strategy Officer, PricewaterhouseCoopers Taiwan<br>・Executive Master of Business Administration (EMBA), National Taiwan University–Fudan University Program<br>・Master of Accounting, National Chengchi University | Note 9 | - | - | - | - |
| Independent Director | R.O.C | Liu,Mei-An | Female 61~70 years | June 17 2025 | 3 | June 22 20222 | 96,171 | 0.16% | 118,350 | 0.15% | 0 | 0.00% | 0 | 0% | ・Executive Vice President of Fubon Financial Holding Venture Capital Co., Ltd.<br>・General Manager of Fubon Health Management Consulting Co., Ltd.<br>・General Manager of Fuyimed Health Management Consulting Co., Ltd.<br>・Vice President of Technology at Uni-President Life Sciences Co., Ltd.<br>・Executive Vice President of TSC BioSystems Co., Ltd.<br>・Ph.D. in Cell Biology from Harvard University, USA<br>・M.S. in Entomology from the University of Massachusetts, USA<br>・B.S. in Plant Pathology and Entomology from National Taiwan University | - | - | - | - | - |
| Independent Director | R.O.C | Chen, Rui-Xin | Male 71~80 years | June 17 2025 | 3 | June 22 2022 | 21,000 | 0.03% | 29,534 | 0.04% | 12,000 | 0.02% | 0 | 0% | ・Senior Examination Financial Personnel Legal Group Passed<br>・Former Deputy Director at the Trademark Division, Bureau of Standards, Metrology and Inspection, MOEA | - | - | - | - | - |

| | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Independent Director | R.O.C | Lai, Chun-Ling | Male 71~80 years | June 17 2025 | 3 | June 30 2023 | 272,000 | 0.45% | 299,160 | 0.39% | 0 | 0.00% | 0 | 0% | · Chairman of Thuncloud Inc.<br>· Founder and chairman of Thunder Tiger Corporation<br>· Chairman of TTBio Corporation.<br>· Graduated from the Department of Law, National Chung Hsing University | · Chairman of Thuncloud Inc.<br>· Chairman of Thuncloud Innovation Co., Ltd. | - | - | - | - |

April 19,2025; Unit: share

Note1：The corporate shareholders shall list the names of the corporate shareholder and the name of the representative of the corporate shareholder (if a representative, the names of the corporate shareholder shall be listed) separately and shall be stated in the following Table 1.

Note2：Please list the actual age and express it in a range, such as 41~50 years old or 51~60 years old.

Note3：If there is an interruption during the first elected term of the directors or supervisors, it shall be stated.

Note 4：The experience related to the current position, has held a position at the accounting firm or its affiliates before disclosure, the titles and responsibilities shall be stated.

Note 5：If the general manager or the equivalent (top management) are the chairman are the same person or spouses or the relative within the first degree of kinship, it shall disclosure the related information such as the cause, rationality, necessity and measures taken (such as adding the seats of independent directors, and requiring more than half of the directors not serving as employees or managers concurrently).。

Note 6：Huang,Chun-Mu , the Current Positions at the Company and other Companies： Chairman and General Manager of Bionime Corporation 、Corporate chairman of Bionime Inc、Corporate chairman of Bionime (Shenzhen)、Corporate chairman of Bionime (Pingtan) Corporate chairman of Bionime GmbH、Corporate chairman of Bionime USA Corp.、Director at Bionime(Malaysia) SDN BHD 、Director at Bionime Australia Pty Ltd 、Corporate director representative at Bonraybio Co., Ltd.

(1).The Chairman also concurrently serves as the general manager of the Company. It aims to improve the operation efficiency and the decision execution, and make the Board know the operation condition of the Company better. However, to enhance the independence of the Company, the Company already plans to recruit excellent talents externally and also train competent candidates internally.

(2). At present, the company has taken the following specific measures: (a) The knowledge, skills, literacy and overall competency of the current three independent directors shall be professional to perform the business and effectively play their supervisory functions. (b) More than half of the directors don't serve as employees or managers concurrently.

Note 7：Liou, Xiu-Mei, The Current Positions at the Company and other Companies：Vice President at Hua Eng Wire&Cable Co., Ltd., Director at China Ecotek Corporation, Director at Wafer Works Corp. Director at Co-Tech Development Corporation, Director at Savior Lifetec Corporation, Supervisor at Hua Ho Engineering Co., Ltd.

Note 8：Liou,Ke-Chen, currently concurrently serves in the following positions at the Company and other companies:

Chairman: Advantech Co., Ltd., Advantech Foundation, Ke Chen Investment Co., Ltd., Advantech Technology (China) Co., Ltd.

Director: Yanben Investment Co., Ltd., Advantech Investment Co., Ltd., Yancheng Investment Co., Ltd., Jia Yan Intelligent Connectivity Co., Ltd., Shanghai Advantech Huisheng Intelligent Technology Co., Ltd., Xi'an Advantech Software Co., Ltd., Advantech Technology Co., Ltd., Advantech Corporation, HK Advantech Technology Co., Limited, Advantech Automation Corp. (HK) Limited.

Supervisor: Chuan Fei Investment Co., Ltd.

Note 9：Zeng,Hui-Jin ,the Current Positions at the Company and other Companies：Independent Director of Delta Electronics, Inc., ASUSTeK Computer Inc., and Coretronic Corporation. Director of St. Shine Optical Co., Ltd., Onward Biotech Co., Ltd., and PanRock Biopharmaceutical Co., Ltd. Supervisor of Taiwan Bio-Manufacturing Corporation

Table 1: Major Shareholders of Institutional Shareholders

April 28, 2026

| Name of Institutional Shareholder (Note 1) | Major Shareholders (Note 2) |
|---|---|
| Hua Eng Wire & Cable Co., Ltd. | First Copper Technology Co., Ltd. (32.96%), Hua Hong Investment Co., Ltd. (7.39%)、Wang Yang, Bi-Er (5.24%)、Wang, Feng-Shu (2.46%)、Wang, Wen-Ling (2.20%) 、Wang, Hung-Jen (2.12%) 、Chen, Kun-Jung (0.80%) Wang, Tzu-Chia (0.73%) 、Meta Corporation (0.62%) 、Wang ,Wei-Chun (0.62%) |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | Dongbao Industrial Group Co., Ltd. (31.63%), Tianjin Zhenyi Equity Investment Partnership (Limited Partnership) (9.35%), Hong Kong Securities Clearing Company Limited (2.15%), Abu Dhabi Investment Authority (1.67%), Bank of China Co., Ltd. – China Merchants CSI Biomedicine Index Graded Securities Investment Fund (0.89%), Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Drug Industry ETF (0.73%), Li Yi-kui (0.58%), China Merchants Bank Co., Ltd. – Southern CSI 1000 Exchange-Traded Open-End Index Securities Investment Fund (0.55%), Tonghua Dongbao Pharmaceutical Co., Ltd. – 2025 Employee Stock Ownership Plan (0.47%), Bank of China Co., Ltd. – GF CSI Innovative Drug Industry ETF (0.42%). |
| Yanben Investment Co., Ltd. | Liou, Ke-Chen (18.77%) 、Advantech Foundation (10.08%) 、Chang, Mei-ling(5.08%) 、Liou, Wei-Chih(1%) |

Note 1: If the Director or Supervisor is the representative of a corporate shareholder, please fill in the name of the corporate shareholder.

Note 2: Please fill in the name of the major shareholder of the corporate shareholder (top 10 in shareholding) and the shareholding ratio. If the major shareholder is a corporate shareholder, please also fill in Table 2.

Table 2: Major shareholders of the major shareholders in Table 1 who are Institutional shareholders

April 28, 2026

| Name of Institutional Shareholder | Major Shareholder |
|---|---|
| First Copper Technology Co., Ltd. | Hua Eng Wire&Cable Co.,Ltd (39.44%) 、Wang,Yang,Bi-E (10.38%) Wang, Wen-Ling (1.82%) 、HSBC Custody Goldman Sachs International Investment Account (0.83%) 、Wang, Feng-Juan (0.67%) 、Wang, Feng-Shu( 0.43%) 、Standard Chartered Custody Mizuho Securities Co., Ltd. Investment Account (0.40%) 、Citibank Custody Barclays Capital SBL/PB Investment Account (0.28%) 、Wang, Feng-Qin (0.23%) 、Li-Hong Capital Co., Ltd. 0.23% |
| Huahong Investment Co., Ltd. | Hong Kong Gongsheng Industrial Company(79.79%) 、Wang, Wen-Ling( 3.19%) 、Wang, Feng-Juan( 3.19%) 、Wang, Feng-Shu (3.19%) 、Wang, Hong-Ren( 3.19%) 、Wang, Yu-Ting (2.13%) 、Wang, Yang Bi-E (1.60%) 、Wang, Wei-Chun(1.49%) 、Wang, Zi-Jia( 1.38%) 、Wang, Feng-Qin( 0.85%) |
| Meta Corporation | Huahong Investment Co., Ltd.(41.05%)、Wang, Wen-Ling(16.32%)、Wang, Feng-Juan (15.79%)、 Wang, Feng-Shu (15.79%)、 Wang, Hong-Ren (5.26%)、 Wang, Wei-Chun(2.63%)、 Wang, Zi-Jia(2.63%)、 Wang, Yu-Ting(0.53%) |

| | |
|---|---|
| Dongbao Industrial Group Co., Ltd. | Tonghua Shenghui Enterprise Management Center (Limited partnership) (35.91%)、Sao,Fu-Po (7.98%)、Cheng Jian-Chiu (7.00%)、Hsing,Cheng (7%)、Sun,Shiao-Ling (6.69%)、Cheng Cheng, Jian-Qiu (6.40%)、Hsu,Ning (6.35%)、Leng,Chun-Sheng (6.23%)、Wang,Jun-Ye(5.93%)、Li, Yi-Kui (4.47%)、Li Chia-Wei(3.20%)、Li, Chia- Hong (2.84%) |

Note 1: If the major shareholder in Table 1 is a corporate shareholder, please fill in its name.
Note 2: Please fill in the name of the corporate shareholder's major shareholder (top 10 in shareholding) and the shareholding ratio.
Note 3: For the institutional shareholder that is not a company, the names of shareholders and shareholding ratios shall be . disclosed above, namely, names of investors or donors and their capital contribution or donation ratios.

(a)Professional Qualifications and Independence Analysis of Directors:

| Name / Criteria | Meet one of the Following Professional Qualification Requirements, together with at Least Five Years Work Experience (Note1) | Independence Attribute (Note 2) | Number of holding concurrent independent director position in other public companies |
|---|---|---|---|
| Director<br>Huang,Chun-Mu | Mr. Huang is the founder of Bionime and has served in the Company since its establishment in 2003. Mr. Huang is the chairman and general manager of Bionime Corporation.<br>He does not constitute the circumstances defined in Article 30 of the Company Act. | An employees of the Bionime Corp. | None |
| Director<br>Yanben Investment Co., Ltd.<br>Representative：Liou,Ke-Chen | Yanben Investment Co., Ltd. Representative：Liou,Ke-Chen，Mr.Liou is the founder of Advantech Co.,Ltd.<br>He does not constitute the circumstances defined in Article 30 of the Company Act. | Not an employees of the Bionime Corp.or a subsidiaries | None |
| Director<br>Hua Eng wire&cable co.,ltd.<br>Representative：Liou,Xiu-Mei | Hua Eng wire&cable co.,ltd.<br>Representative：Liou,Xiu-Mei,She is the Vice President of Management Department at Hua Eng Wire & Cable Co., Ltd. She does not constitute the circumstances defined in Article 30 of the Company Act. | Not an employees of the Bionime Corp.or a subsidiaries | None |
| Director<br>Tonghua Dongbao Pharmaceutical co., ltd. Representative：Zhang,Wen Hai | Mr. Zhang serves as the deputy general manager of Sales in Tonghua Dongbao Pharmaceutical co., ltd. He has been designated as the representative of Tonghua Dongbao which is one of the directors of the Company since June 22, 2019.<br>He does not constitute the circumstances defined in Article 30 of the Company Act. | Not an employees of the Bionime Corp.or a subsidiaries | None |
| Director<br>Tonghua Dongbao Pharmaceutical co., ltd. Representative：Fan,Pu | Mr. Fan serves as the deputy general manager of Tonghua Dongbao Pharmaceutical co., ltd. He has been designated as the representative of Tonghua Dongbao which is one of the directors of the Company since Feb 10, 2026.<br>He does not constitute the circumstances defined in Article 30 of the Company Act. | Not an employees of the Bionime Corp.or a subsidiaries | None |

| | | | |
|---|---|---|---|
| Independent Director<br>Zeng,Hui-Jin | She was a partner and Vice President of PricewaterhouseCoopers Taiwan, Chief Operating Officer of the Audit Department, Chief Strategy Officer, and the convener of the company's audit committee, with expertise in accounting and taxation. Currently an advisory member of the Bio Taiwan Committee of the Executive Yuan.<br>She does not constitute the circumstances defined in Article 30 of the Company Act. | In the two years before the election and during the term of office, they have met the independence assessment conditions of the "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies". | 3 |
| Independent Director<br>Liu,Mei-An | Ph.D. in Cell Biology, Harvard University. He was the Executive Vice President of Fubon Financial Holding Venture Capital Co. and Head of Direct Investment Function of Fubon Financial Holding Investment Management Headquarter.<br>As the company's audit committee, with financial expertise.<br>She does not constitute the circumstances defined in Article 30 of the Company Act. | In the two years before the election and during the term of office, they have met the independence assessment conditions of the "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies". | None |
| Independent Director<br>Chen,Rui-Xin | He is a law graduate of Chung Hsing University, former Deputy Chief of Trademark Office of Central Bureau of Standards, MOEA, and former Director of Intellectual Property Office, MOEA. As the company's audit committee, with legal expertise.<br>He does not constitute the circumstances defined in Article 30 of the Company Act. | In the two years before the election and during the term of office, they have met the independence assessment conditions of the "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies". | None |
| Independent Director<br>Lai,Chun-Ling | He is Chairman of Thuncloud Inc. He was Founder and chairman of Thunder Tiger Corporation. As the company's audit committee ， He does not constitute the circumstances defined in Article 30 of the Company Act. | In the two years before the election and during the term of office, they have met the independence assessment conditions of the "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies". | None |

(b). Diversity and independence of the board of directors:

A. Member Composition Diversity Policy: In nominating and qualifying directors (including independent directors), the Board of Directors considers the professional background of the directors (including independent directors) and the knowledge, skills and qualities necessary to perform their duties. The Company has implemented a policy of diversifying the Board of Directors with the "Code of Corporate Governance Practices". The Board of Directors should have the following competencies: operational judgment, accounting and financial analysis, operational management, crisis management, industry knowledge, international market perspective, leadership, and decision-making ability.

B. Diversity objectives of the Board and implementation status

The Company currently has 9 board members (including 4 independent directors), of which 1 is an employee (11% of the total number of directors); The four independent directors are all new for this term.

The Company is also mindful of the gender equality of its board of directors, and currently there are three female directors among the nine directors (33% of the total number of directors). The Board of Directors is comprised of members with expertise in industrial management, technology research and development, marketing management, finance, accounting and taxation, and law, and are industry operators. With their diverse backgrounds in industry, academia and knowledge, the board members are able to provide professional advice from different perspectives, which is of great benefit to the Company's operational performance and management.

| Diversity management objectives | Achievement Status |
|---|---|
| It is advisable that the number of the director who concurrently serve as the managers of the Company should not exceed one-third of the board seats | Done |
| At least on female director | Done |
| The number of independent directors exceeds on third of the bord seats | Done |
| The independent directors shall not hold office for more than 3 terms. | Done |

| Diversification Item / Director Name | Gender | Nationality | Also an employee of the company | Years served as an independent director | Professional knowledge and skills | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | Industrial Management | Technology Research And Development | Marketing Management | Finance | Accounting And Taxation | Law |
| Huang,Chun-Mu | Male | R.O.C | V | | V | V | V | | | |
| Director Tonghua Dongbao Pharmaceutical co., ltd. Representative：Zhang,Wen Hai | Male | China | | | V | V | V | | | |
| Director Yanben Investment Co., Ltd. Representative：Fan,Pu | Male | China | | | | | | V | V | |
| Director Hua Eng wire&cable co.,ltd. Representative：Liou,Xiu-Mei | Female | R.O.C | | | | | | V | V | |
| Director Yanben Investment Co., Ltd. Representative：Liou,Ke-Chen | Male | R.O.C | | | V | V | V | | | |
| Zeng,Hui-Jin | Female | R.O.C | | 4 years | | | | V | V | |
| Liu,Mei-An | Female | R.O.C | | 4 years | | | | V | | |
| Chen,Rui-Xin | Male | R.O.C | | 4 years | | | | | | V |
| Lai,Chun-Ling | Male | R.O.C | | 3 years | V | V | V | | | |

(2) Information of General Managers, Deputy General Managers, Assistant General Managers and other Department and Branch Managers:

April 28, 2026; Unit: Share

| Title | Nationality | Name | Gender | Date Effective | Shareholding | | Spouse & Minor Children Shareholding | | Current Shareholding in the Name of others | | Experience (Education) | Current Positions at the Company and Other Companies | Executives, Directors or Supervisors who are spouses or within two degrees of kinship | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | Share | Ratio | Share | Ratio | Share | Ratio | | | Title | Name | Relations |
| Chairman and General Manager | R.O.C. | Huang, Chun-Mu | Male | July 9, 2010 | 3,092,413 | 4.00% | 1,232,257 | 1.59% | 0 | 0% | ・National Taipei University of Technology<br>・MS Tech General Manager | Note1 | - | - | - |
| Deputy General Managers of New Business Division | R.O.C. | Chen, Chieh-Shing | Male | May14, 2018 | 103,604 | 0.13% | 23,521 | 0.03% | 0 | 0% | ・National Chung Hsing University | - | - | - | - |
| Deputy General Managers of R&D Division | R.O.C. | Chen, Bi-Hsuan | Female | Feb.1, 2016 | 116,125 | 0.15% | 0 | 0% | 0 | 0% | ・Master of Biotechnology from National Cheng Kung University | Note2 | - | - | - |
| Deputy General Managers of IOT Technology Division | R.O.C. | Yeh, Zhi-Long | Male | Nov.7, 2018 | 61,000 | 0.08% | 0 | 0% | 0 | 0% | ・Department of Information Management at Chaoyang University of Technology | - | - | - | - |

| | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Governance Officer | R.O.C. | Huang, Shan-Pu | Male | Nov. 12, 2025 | 0 | 0.00% | 0 | 0% | 0 | 0% | ·Special Assistant of Bionime Corp.<br>·Finance Manager of Bao-Yuan CNC Co., Ltd.<br>·Accounting Manager of HIWIN Mikrosystem Corp.<br>·Department of Accounting, National Taiwan University | - | - | - | - |
| Financial Officer | R.O.C. | Huang, Chien-Yu | Female | Feb.8, 2024 | 32,842 | 0.04% | 0 | 00 | 0 | 0% | ·Manager of Bionime Corp<br>·Master of Business Administration in Enterprise Management at National Chung Hsing University | | | | |
| Accounting Officer | R.O.C. | Chen, Ya-Wen | Female | Feb.1, 2021 | 22,074 | 0.03% | 0 | 0.00 | 0 | 0% | ·Accounting Manager of Bionime Corp.<br>·Department of Accounting Information, National Taichung University of Science and Technology | - | - | - | - |



Note 1：Mr. Huang ,Chun-Mu the Current Positions at the Company and other Companies：Chairman and General Manager of Bionime Corporation、Corporate chairman of Bionime Inc、Corporate chairman of Bionime (Shenzhen)、Corporate chairman of Bionime (Pingtan) Corporate chairman of Bionime GmbH、Corporate chairman of Bionime USA Corp.、Director at Bionime(Malaysia) SDN BHD、Director at Bionime Australia Pty Ltd、Corporate director representative at Bonraybio Co., Ltd.

Note 2：Ms Chen, Bi-Hsuan the Current Positions at the Company and other Companies：Corporate director representative at Bionime(Malaysia) SDN BHD、Corporate director representative at Bionime Australia Pty Ltd.

(3). Remuneration for Directors (including Independent Directors), Supervisors, General Managers, Deputy General Managers

(a) Most Recent (2025) Traveling Expenses and Remuneration of the Directors

Unit: NT$ thousand

| Title | Name | Directors Compensation | | | | | | | | Ratio of Total Remuneration (A+B+C+D) to Net Income (%) (Note 10) | | Relevant remuneration received by directors who are also employees | | | | | | | | Ratio of total compensation (A+B+C+D+E+F+G) to net income (%)(Note 10) | | Compensation paid from an invested company other than the company's subsidiary(Note11) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Base Compensation（A）(Note2) | | Severance Payment（B） | | Directors Compensation(C)(Note 3) | | Business Execution Expenses(D)(Note 4) | | | | Salary, Bonuses and Allowances（E）(Note 5) | | Severance Payment（F） | | Employee Compensation（G）(Note 6) | | | | | | |
| | | | | | | | | | | | | | | | | The Company | | All companies in the consolidated financial statement (Note 7) | | | | |
| | | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | The Company | All companies in the consolidated financial statement (Note 7) | Cash | Stock | Cash | Stock | The Company | All companies in the consolidated financial statement (Note 7) | |
| Chairman | Huang,Chun-Mu | 0 | 0 | 0 | 0 | 0 | 0 | 320 | 320 | 320<br>-0.18% | 320<br>-0.18% | 3,099 | 3,099 | 0 | 0 | 0 | 0 | 0 | 0 | 3,419<br>-1.90% | 3,419<br>-1.90% | None |
| Director | Hua Eng Wire & Cable Co., Lt | 0 | 0 | 0 | 0 | 0 | 0 | 240 | 240 | 240<br>-0.13% | 240<br>-0.13% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 240<br>-0.13% | 240<br>-0.13% | None |
| | Hua Eng Wire & Cable Co., Lt Representative: Liou,Xiu-Mei | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 50 | 50<br>-0.03% | 50<br>-0.03% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50<br>-0.03% | 50<br>-0.03% | None |
| Director | Tonghua Dongbao Pharmaceutical Co., Ltd. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | None |
| | Tonghua Dongbao Pharmaceutical Co., Ltd Representative: Leng, Chun-Sheng (Dismissed on Feb. 10, 2026 ) | 0 | 0 | 0 | 0 | 0 | 0 | 310 | 310 | 310<br>-0.17% | 310<br>-0.17% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 310<br>-0.17% | 310<br>-0.17% | None |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Tonghua Dongbao Pharmaceutical Co., Ltd Representative: Fan,Pu (Appointed on Feb. 10, 2026 ) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | None |
| | Tonghua Dongbao Pharmaceutical Co., Ltd. Representative :Zhang,Wen-Hai | 0 | 0 | 0 | 0 | 0 | 0 | 310 | 310 | 310 -0.17% | 310 -0.17% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 310 -0.17% | 310 -0.17% | None |
| Director | Yanben Investment Co., Ltd. | 0 | 0 | 0 | 0 | 0 | 0 | 310 | 310 | 310 -0.17% | 310 -0.17% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 310 -0.17% | 310 -0.17% | None |
| | Yanben Investment Co., Ltd. Representative：Liou,Ke-Chen | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | None |
| Independent director | Zeng, Hui-Jin | 0 | 0 | 0 | 0 | 0 | 0 | 410 | 410 | 410 -0.23% | 410 -0.23% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 410 -0.23% | 410 -0.23% | None |
| Independent director | Liu,Mei-An | 0 | 0 | 0 | 0 | 0 | 0 | 410 | 410 | 410 -0.23% | 410 -0.23% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 410 -0.23% | 410 -0.23% | None |
| Independent director | Chen,Rui-Xin | 0 | 0 | 0 | 0 | 0 | 0 | 410 | 410 | 410 -0.23% | 410 -0.23% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 410 -0.23% | 410 -0.23% | None |
| Independent director | Lai,Chun-Ling | 0 | 0 | 0 | 0 | 0 | 0 | 410 | 410 | 410 -0.23% | 410 -0.23% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 410 -0.23% | 410 -0.23% | None |

1. Please explain the policy, system, criteria and structure of remuneration paid to independent directors, and describe the correlation with the amount of remuneration based on the factors such as responsibilities, risks, and time spent.

Explanation：Remuneration to the Company's directors is paid in accordance with the Company's Articles of Incorporation and the Company's "Regulations Governing Payment of Remuneration of Directors, Functional Committees ".

(a). Directors' remuneration: According to Article 28 of the Company's Articles of Incorporation, directors' remuneration is distributed based on the current year's profits, with no more than 3% of the annual profits. Submit to the Compensation Committee for review and the Board of Directors for resolution, and report to the Shareholders' Meeting.

(b). Attendance fees:

i) Directors (including independent directors): each director is entitled to a fixed monthly attendance fee of NT$20,000.

ii) Attendance at Board meetings: each director is entitled to an attendance fee of NT$10,000 per meeting, including attendance via video conference.

iii) Attendance at shareholders' meetings: each director is entitled to an attendance fee of NT$10,000 per meeting.

iv) Attendance at functional committee meetings: no additional remuneration is provided to members of functional committees; however, attendance fees equivalent to those for Board meetings shall apply.

2.The remuneration to all the directors served for all the companies within the consolidated financial statement (such as a consultant not an employee) in the most recent fiscal year: None.

* It shall separately disclose the related information about the directors (general directors rather than the independent directors) and the independent directors.

## Range of Remuneration

| Range of Remuneration | Names of Directors | | | |
|---|---|---|---|---|
| | Total of (A+B+C+D) | | Total of ( (A+B+C+D+E+F+G) | |
| | The Company (Note 9) | All Companies in the Consolidated Financial Statement (Note 10) I | The Company (Note 9) | All Companies in the Consolidated Financial Statement (Note 10) J |
| Under NT$1,000,000 | Huang,Chun-Mu,<br>Hua Eng Wire & Cable Co., Ltd,<br>Liou,Xiu-Mei,<br>Tonghua Dongbao Pharmaceutical Co., Ltd.,<br>Leng, Chun-Sheng,<br>Zhang,Wen-Hai,<br>Yanben Investment Co., Ltd.,<br>Liou,Ke-Chen,<br>Zeng,Hui- Jin,<br>Liu,Mei-An,<br>Chen,Rui-Xin,<br>Lai,Chun-Ling.<br>Fan,Pu | Huang,Chun-Mu,<br>Hua Eng Wire & Cable Co., Ltd,<br>Liou,Xiu-Mei,<br>Tonghua Dongbao Pharmaceutical Co., Ltd.,<br>Leng, Chun-Sheng,<br>Zhang,Wen-Hai,<br>Yanben Investment Co., Ltd.,<br>Liou,Ke-Chen,<br>Zeng,Hui- Jin,<br>Liu,Mei-An,<br>Chen,Rui-Xin,<br>Lai,Chun-Ling.<br>Fan,Pu | Hua Eng Wire & Cable Co., Ltd,<br>Liou,Xiu-Mei,<br>Tonghua Dongbao Pharmaceutical Co., Ltd.,<br>Leng, Chun-Sheng,<br>Zhang,Wen-Hai,<br>Yanben Investment Co., Ltd.,<br>Liou,Ke-Chen,<br>Zeng,Hui- Jin,<br>Liu,Mei-An,<br>Chen,Rui-Xin,<br>Lai,Chun-Ling.<br>Fan,Pu | Hua Eng Wire & Cable Co., Ltd,<br>Liou,Xiu-Mei,<br>Tonghua Dongbao Pharmaceutical Co., Ltd.,<br>Leng, Chun-Sheng,<br>Zhang,Wen-Hai,<br>Yanben Investment Co., Ltd.,<br>Liou,Ke-Chen,<br>Zeng,Hui- Jin,<br>Liu,Mei-An,<br>Chen,Rui-Xin,<br>Lai,Chun-Ling.<br>Fan,Pu |
| NT$1,000,000 (included)～NT$2,000,000(excluded) | | | | |
| NT$2,000,000 (included)～NT$3,500,000 (excluded) | | | Huang,Chun-Mu | Huang,Chun-Mu |
| NT$3,500,000 (included)～NT$5,000,000 (excluded) | | | | |
| NT$5,000,000 (included)～NT$10,000,000 (excluded) | | | | |
| NT$10,000,000(included)～NT$15,000,000 (excluded) | | | | |
| NT$15,000,000 (included)～NT$30,000,000(excluded) | | | | |
| NT$30,000,000 (included)～NT$50,000,000(excluded) | | | | |

| | | | | |
|---|---|---|---|---|
| NT$50,000,000 (included)～<br>NT$100,000,000(excluded) | | | | |
| Over NT$100,000,000 | | | | |
| Total | 13persons | 13 persons | 13 persons | 13 persons |

Note1: The Directors' names should be listed separately (if a corporate shareholder, the corporate name and the representative's name should be listed separately), and the payments should be consolidated for disclosure. The amount of cash payment is disclosed in a summary. If the director is also the general manager or deputy general manager, this table and the following table (Remunerations of the General Manager and Deputy General Manager; Range of Remuneration) shall be filled in.

Note2: The Director's remuneration for the most recent year (including salary, job allowances, Retirement Pension, various bonuses and incentives).

Note3: The latest amount of Director's remuneration as passed by the board of directors.

Note4: The latest annual business execution expenses of the Director (including transportation costs, special expenses, various subsidies, dormitory expenses, car expenses and other physical provisions). In case of the provision of expenses for housing, cars and other means of transportation or exclusive personal expenses, please disclose the nature and cost of the assets provided, the actual or fair market price of the rent, gasoline and other payments. If a driver is provided, please indicate the Company's relevant remuneration to the driver, but the amount should not be included in the remuneration.

Note5: The latest salary, job allowances, Retirement Pension, various bonuses, incentives, car expenses, special expenses, various subsidies, dormitory expenses, car expenses and other physical provisions for the Director's other jobs (including the positions of General Manager, Deputy General Manager, Manager and other positions). In case of the provision of expenses for housing, cars and other means of transportation or exclusive personal expenses, please disclose the nature and cost of the assets provided, the actual or fair market price of the rent, gasoline and other payments. If a driver is provided, please indicate the Company's relevant remuneration to the driver, but the amount should not be included in the remuneration. According to IFRS 2's recognition of remuneration in "Share-Based Payments", the remuneration shall include employee stock options, restricted-right employee shares and share subscription from participation in cash capital increase.

Note6: If a Director receives employee remuneration (including stock and cash) on his/her other job(s) (including the positions of General Manager, Deputy Manager, Manager and other positions) in the latest year, please disclose the amount of employee remuneration as passed by the board of directors in the latest year. If the amount cannot be estimated, it should be calculated based on the percentage of the actual amount distributed last year, and Appendix(Names of Managers and Distribution Details of Employee Remuneration Distribution)should be filled out.

Note7: The total remuneration paid by all the companies (including the Company) in the consolidated report to the Company's Director.

Note8: The total remuneration paid by the Company to each Director; the Director’s name should be disclosed in the respective tier.

Note9: The total remuneration paid by all the companies (including the Company) in the consolidated report to each of the Company's Directors should be disclosed, and the Director's names should be disclosed in the respective tier.

Note10: Net profit after tax refers to the net after-tax profit for the latest year. If the International Financial Reporting Standards have been adopted, then it is the net after-tax profit of the individual company or the respective financial statement.

Note11: a. In this field the amount of remuneration paid to the Director by the Company's re-invested businesses other than the subsidiaries should be clearly indicated.

b. If the Director receives remuneration from the Company's re-invested businesses other than the subsidiaries, such remuneration should be incorporated into column I of the Remuneration Tiers Table, and the name of the field should be changed to "All re-invested businesses".

c. Remuneration refers to the compensation, reward (including that for an employee, director or supervisor) and business execution expenses received by the Company's Director for acting as a director, supervisor or manager of the Company's re-invested businesses other than the subsidiaries.

* The contents of the remuneration disclosed in this table are different from those in the Income Tax Law. Therefore, this statement is for the purpose of disclosure but not for taxation.

(b).Most Recent (2025) Remunerations of the General Manager and Deputy General Manager (Including Independent Director):

Unit: NT$ thousand

| Title | Name | Salary (A) (Note 2) | | Severance Payment (B) | | Bonus and Special Fees (C) (Note 3) | | Employee Remuneration (D) (Note 4) | | | | The Sum of A, B, C and D as a percentage of After-tax Net Profit (%) (Note 6) | | Remuneration from Reinvested Business other than Subsidiaries (Note 7) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | The Company | Companies in the Consolidated Financial Statements (Note 5) | The Company | Companies in the Consolidated Financial Statements (Note 5) | The Company | Companies in the Consolidated Financial Statements (Note 5) | The Company | | Companies in the Consolidated Financial Statements (Note 5) | | The Company | Companies in the Consolidated Financial Statements (Note 5) | |
| | | | | | | | | Cash | Stock | Cash | Stock | | | |
| General Manager | Huang, Chun-Mu | 3,099 | 3,099 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,099<br>-1.72% | 3,099<br>-1.72% | None |
| Deputy General Manager | Chen, Chieh-Shing | 2,489 | 2,489 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,489<br>-1.38% | 2,489<br>-1.38% | None |
| | Chen, Bi-Hsuan | 2,498 | 2,498 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,498<br>-1.39% | 2,498<br>-1.39% | None |
| | Yeh, Zhi-Long | 2,317 | 2,317 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,317<br>-1.29% | 2,317<br>-1.29% | None |

Range of Remuneration

| Range of Remuneration (NT$) | Name of General Manager and Deputy General Manager | |
|---|---|---|
| | The Company (Note 6) | Companies in the Consolidated Financial Statements (Note 7)E |
| Under NT$1,000,000 | | |
| NT$1,000,000 (included)～NT$2,000,000(excluded) | | |
| NT$2,000,000 (included)～NT$3,500,000 (excluded) | Huang, Chun-Mu<br>Chen, Chieh-Shing<br>Chen, Bi-Hsuan<br>Yeh, Zhi-Long | Huang, Chun-Mu<br>Chen, Chieh-Shing<br>Chen, Bi-Hsuan<br>Yeh, Zhi-Long |
| NT$3,500,000 (included)～NT$5,000,000 (excluded) | | |
| NT$5,000,000 (included)～NT$10,000,000 (excluded) | | |
| NT$10,000,000(included)～NT$15,000,000 (excluded) | | |
| NT$15,000,000 (included)～NT$30,000,000(excluded) | | |
| NT$30,000,000 (included)～NT$50,000,000(excluded) | | |
| NT$50,000,000 (included)～NT$100,000,000(excluded) | | |
| Over NT$100,000,000 | | |
| Total | 4 persons | 4 persons |

Note1: The General Managers and Deputy General Managers' names should be listed separately, and the payments should be consolidated for disclosure. If the Directors are also General Managers or Deputy General Managers, this table and the table above (Traveling Expenses and Remuneration of the Directors; Range of Remuneration) shall be filled in.

Note2: The latest amount of the General Manager's and the Deputy General Managers' remunerations (including salary, job allowances and severance payment).

Note3: The latest annual business execution expenses of the General Manager and the Deputy General Managers (including transportation costs, special expenses, various subsidies, dormitory expenses, car expenses and other physical provisions). In case of the provision of expenses for housing, cars and other means of transportation or exclusive personal expenses, please disclose the nature and cost of the assets provided, the actual or fair market price of the rent, gasoline and other payments. If a driver is provided, please indicate the Company's relevant remuneration to the driver, but the amount should not be included in the remuneration. According to IFRS 2's recognition of remuneration in "Share-Based Payments", the remuneration shall also include employee stock options, restricted-right employee shares and share subscription from participation in cash capital increase.

Note4: The employee remuneration (including stock and cash) distributed to the General Manager or Deputy General Manager as passed by the board of directors in the latest year. If the amount cannot be estimated, it should be calculated based on the percentage of the actual amount distributed last year, and Appendix (Managers with Employee Remuneration Distribution Table) should be filled out. Net profit after tax refers to the net after-tax profit for the latest year. If the International Financial Reporting Standards have been adopted, then it is the net after-tax profit of the individual company or the respective financial statement.

Note5: The total remuneration paid by all the companies (including the Company) in the consolidated report to the Company's General Manager and Deputy General Managers.

Note6: The total remuneration paid by the Company to each General Manager and Deputy General Manager; the General Manager's and the Deputy General Managers' names are to be disclosed in the respective tiers.

Note7: The total remuneration paid by all the companies (including the Company) in the consolidated report to each of the Company's General Manager and Deputy General Managers should be disclosed, and the General Manager's and the Deputy General Managers' names should be disclosed in the respective tier.

Note8: Net profit after tax refers to the net after-tax profit for the latest year. If the International Financial Reporting Standards have been adopted, then it is the net after-tax profit of the individual company or the respective financial statement.

Note9: a. In this field the amount of remuneration paid to the General Manager or the Deputy General Managers by the Company's re-invested businesses other than the subsidiaries should be clearly indicated.

b. If the General Manager and Deputy General Managers receive remuneration from the Company's re-invested businesses other than the subsidiaries, such remuneration should be incorporated into column D of the Remuneration Tiers Table, and the name of the field should be changed to "All re-invested businesses".

c. Remuneration refers to the compensation, reward (including that for an employee, director or supervisor) and business execution expenses received by the Company's General Manager or Deputy General Manager for acting as a director, supervisor or manager of the Company's re-invested businesses other than the subsidiaries.

* The contents of the remuneration disclosed in this table are different from those in the Income Tax Law. Therefore, this statement is for the purpose of disclosure but not for taxation.

(c) The highest salaries of the top five executives of listed and over-the-counter companies in the most recent fiscal year (2025).

Unit: NT$ thousand

| Title | Name | Salary (A) (Note 2) | | Severance Payment (B) | | Bonus and Special Fees (C) (Note 3) | | Employee Remuneration (D) (Note 4) | | | | The Sum of A, B, C and D as a percentage of After-tax Net Profit (%) (Note 6) | | Remuneration from Reinvested Business other than Subsidiaries (Note 7) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | The Company | | Companies in the Consolidated Financial Statements (Note 5) | | | | |
| | | The Company | Companies in the Consolidated Financial Statements (Note 5) | The Company | Companies in the Consolidated Financial Statements (Note 5) | The Company | Companies in the Consolidated Financial Statements (Note 5) | Cash | Stock | Cash | Stock | The Company | Companies in the Consolidated Financial Statements (Note 5) | |
| General Manager | Huang, Chun-Mu | 3,099 | 3,099 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3,099<br>-1.72% | 3,099<br>-1.72% | None |
| Deputy General Manager | Chen, Chieh-Shing | 2,489 | 2,489 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,489<br>-1.38% | 2,489<br>-1.38% | None |
| | Chen, Bi-Hsuan | 2,498 | 2,498 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,498<br>-1.39% | 2,498<br>-1.39% | None |
| | Yeh, Zhi-Long | 2,317 | 2,317 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,317<br>-1.29% | 2,317<br>-1.29% | None |
| Associate Vice President | Tang, Wei (Note1) | 1,311 | 1,311 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,311<br>-0.73% | 1,311<br>-0.73% | None |

Note1: Associate Vice President Tang, Wei resigned and was discharged from office on October 31, 2025.

(d).Managers with Employee Remuneration Distribution

Unit: NT$ thousand; Date: April 28, 2026

| Title | Name | Stock Bonus | Cash Bonus | Total | Ratio of Total Amount to Net Income (%) |
|---|---|---|---|---|---|
| Chairman as well as General Manager | Huang,Chun-Mu | 0 | 0 | 0 | 0% |
| Deputy General Manager | Chen, Chieh-Shing | | | | |
| | Chen, Bi-Hsuan | | | | |
| | Yeh, Zhi-Long | | | | |
| Corporate Governance Officer | Huang, Shan-Pu | | | | |
| Financial Officer | Huang, Chien-Yu | | | | |
| Accounting Officer | Chen, Ya-Wen | | | | |

Note1:The names and titles should be listed separately, and the remuneration distribution may be consolidated for disclosure.

Note2:The latest amount of the manager's employee remuneration as passed by the board of directors (including shares and cash) in the latest year. If the amount cannot be estimated, it should be calculated based on the percentage of the actual amount distributed last year. Net profit after tax refers to the net after-tax profit for the latest year. If the International Financial Reporting Standards have been adopted, then it is the net after-tax profit of the individual company or the respective financial statement.

Note3:The definition of manager, as governed by the letter of the SFC on March 27, 2003 with a reference no. of Tai-Tsai-Cheng III 0920001301, is as follows:

(1) General Manager and equivalent.
(2) Deputy General manager and equivalent.
(3) Associate and equivalent.
(4) Head of financial department.
(5) Head of accounting department
(6) Other people who have the right to manage the company's affairs and are the company's authorized signatories.

Note4:If the Directors, General Managers and Deputy General Managers have received employee compensation (including stocks and cash), they shall fill in Table 1 (2) and this table.

(4). Analysis of the Proportion of the Total Remuneration, Directors, Supervisors, General Managers and Deputy General Managers of the Company Paid the Company and all Companies in the Consolidated Financial Statement to Net Profit After Tax in Individual Financial Statements of the Recent Two Years. Explanation of Remuneration Policies, Standards and Packages, the Procedure for Determining Remuneration, and its Linkage to Operating Performance and Future Risk Exposure:

(a) Analysis of the proportion of the total remuneration of directors, supervisors, general managers and deputy general managers of the Company paid the Company and all companies in the consolidated financial statements to net profit after tax in individual financial statements of the recent two years:

| Proportion of the Total Remuneration of Directors, Supervisors, General Managers and Deputy General Managers | 2024 | | 2025 | |
|---|---|---|---|---|
| | The Company | All Companies in the Consolidated Financial Statements | The Company | All Companies in the Consolidated Financial Statements |
| | (10.43)% | (10.43)% | (7.53)% | (7.53)% |

(b) Explanation of remuneration policies, standards and packages, the procedure for determining remunerations, and its linkage to operating performance:

A. Directors

Directors' remuneration: According to Article 28 of the Company's Articles of Association, directors' remuneration is distributed based on the current year's profits, with no more than 3% of the annual profits. The performance of the Company's Board of Directors as a whole, functional committee, and individual directors are evaluated once a year based on the "Regulation on the Performance Evaluation of the Board of Directors and the Functional Committee". The remuneration distribution proposal of each director is determined by taking into account their tenure, performance evaluation results, and operating performance of the Company. Before distributing the remuneration, the proposal shall be submitted to the Remuneration Committee and the Board for resolution, and shall also be submitted to the Shareholders' Meeting for reporting.

Since there was a pre-tax loss in 2025, the Board of Directors passed a resolution on March 11,2026 that employee remunerations and directors' remuneration will not be distributed.

The company has not issued other alterations in remuneration, except for the payment of the directors' attendance fees and the distribution of directors' remuneration which is based on the results of directors' performance evaluation.

B. General Managers and Deputy General Managers

Remuneration to general managers and deputy general managers includes wages, various bonuses, and employees' compensation, and the negotiated remuneration is considered the salary standard of same business; bonuses are highly related to the company's operating results and performance. Based on the company's OKR indicators each year (indicators include revenue, net profit, new products, management, etc.) and the manager's personal performance to determine remuneration proposal, the proposal is submitted to the board of directors for resolution after deliberation by the remuneration committee. The distribution standard for employee remuneration follows the company's articles of association and is issued after the resolution and approval of the board of directors.

(c) Linkage to Future Risk: The performance of the Company's important decisions refers the Company's profitability, so there is a positive correlation between the remuneration to directors, supervisors and managers.

3. Implementation of Corporate Governance

(1) Operation of the board meeting

(a) A total of 7 board meetings were held in 2025, and the attendance of Directors (including independent Directors) is as follows:

| Title | Name (Note 1) | Actual no. of Meetings Attended (B) | No. of Meetings with Entrusted Attendance | Actual Attendance Rate (%) 【B/A】 (Note 2) | Remarks |
|---|---|---|---|---|---|
| Chairman | Huang, Chun-Mu | 7 | 0 | 100% | Re-elected on June 17, 2025 |
| Director | Hua Eng Wire & Cable Co., Ltd. Representative: Liou, Xiu-Mei | 5 | 0 | 71% | Re-elected on June 17, 2025 |
| Director | Tonghua Dongbao Pharmaceutical Co., Ltd. Representative: Chang,Wen-Hai | 7 | 0 | 100% | Re-elected on June 17, 2025 |
| Director | Tonghua Dongbao Pharmaceutical co., ltd. Representative：Leng, Chun-Sheng | 7 | 0 | 100% | Re-elected on June 17, 2025 Dismissed on February 10, 2026 |
| Director | Yanben Investment Co., Ltd. Representative：Liou, Ke-Chen | 0 | 7 | 0% | Re-elected on June 17, 2025 |
| Independent Director | Zeng, Hui-Jin | 7 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Liu, Mei-An | 7 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Chen, Rui-Xin | 7 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Lai, Chun-Ling | 5 | 2 | 71% | Re-elected on June 17, 2025 |

Other matters to be recorded:

1. If any of the following circumstances occurs in the operation of the board meeting, please indicate the date of the board meeting, the session number, the contents of the resolution, the opinions of all independent directors and the Company's handling of the opinions of the independent directors:

   (1) Matters listed in Article 14-3 of the Securities Exchange Act.
   7 Board meetings were held in the year of 2025. The contents of the resolution are on pages 96 to 100 of the annual report. All independent directors had no objections to the matters listed in Article 14-3 of the Securities Exchange Act.

   (2) Other than the aforementioned matters, the board resolutions which independent

directors object to or have reservations about and there are records or written statements for them: None.

2. To avoid conflict of interest among directors, the Director's name, meeting content, and reason for avoiding conflict of interest and participation in the voting process must be properly recorded:

(1)2025/01/17 Proposal: Distribution of year-end bonus for managers for fiscal year 2024.

Resolution: Director Huang Chun-mu recused himself from discussion and voting due to his concurrent position as a manager. The resolution was passed unanimously by all other attending directors with no objection, following consultation by Acting Chairperson Liu Mei-an, who was elected by the attending directors.

(2)2025/03/13Proposal: Approval of the list of grantees for employee stock options under the 2025 employee stock option plan and the distribution details for managers.

Resolution: Director Huang Chun-mu recused himself from discussion and voting due to his concurrent position as a manager. The resolution was passed unanimously by all other attending directors with no objection, following consultation by Acting Chairperson Liu Mei-an, who was elected by the attending directors.

(3)2025/09/11Proposal: 2025 annual salary adjustment plan for managers.

Resolution: Director Huang Chun-mu recused himself from discussion and voting due to his concurrent position as a manager. The meeting was presided over by Acting Chairperson Liu Mei-an, a director designated by the Chairman, who consulted all other attending directors, and the resolution was passed unanimously with no objection.

(4) 2025/11/12 Proposal: Review of the number of shares eligible for subscription by managers under the 2025 cash capital increase employee share subscription plan.

Resolution: Director Huang Chun-mu recused himself from discussion and voting due to his concurrent position as a manager. The meeting was presided over by Acting Chairperson Liu Mei-an, a director designated by the Chairman, who consulted all other attending directors, and the resolution was passed unanimously with no objection.

3. The TWSE/GTSM Listed Companies shall disclose the evaluation cycles, evaluation periods, scope, method and content of the board of directors' self-evaluation by the board members of themselves or peers and fill in the attached Table 2 (2) Board of Directors' Evaluation Implementation Status.

4. The goals for strengthening the board's functions in the current and the previous year (e.g., establishment of an audit committee, promotion of information transparency, etc.):

(1) On Feb 5, 2026, the board of directors resolved to pass the 2025 board members, board and functional committee performance evaluation results.

(2) The Company had purchased the liability insurance for all directors, which have been filed as required.

(3) The company has established an audit committee. Its main responsibilities, in addition to complying with Article 14-5 of the Securities and Exchange Act, include auditing quarterly financial statements to ensure transparency in information disclosure.

Note 1: If a director or supervisor is a legal entity, please disclose the name of the corporate shareholder and of its representative.

Note 2: (1) If there is a director or supervisor leaving the company before the end of the year, please indicate the date of departure in Remarks field. The actual attendance rate (%) is calculated based on the number of board meetings held and the actual number of meetings attended during the tenure.

(2) If there is a director or supervisor election before the end of the year, please list both the new and the old directors and supervisors, and indicate in the Remarks field whether the director or supervisor is old, new or re-elected and the date of election. The actual attendance rate (%) is calculated based on the number of board meeting held and the actual number of meetings attended during the tenure.

## (b). Board of Directors' Evaluation Implementation Status

| Evaluation cycles (Note1) | Evaluation periods (Note2) | Evaluation scope (Note3) | Evaluation method (Note4) | Evaluation content (Note5) |
|---|---|---|---|---|
| Once a year | January 1, 2025 to December 31, 2025 | All Board of Directors' | Internal self-evaluation of the board of directors | Board performance evaluation items:<br>A. Participation in the operation of the company.<br>B. Improving the quality of decision-making of the board of directors.<br>C. Composition and structure of the board of directors.<br>D. Election and continuing education of the directors.<br>E. Internal control. |
| Once a year | January 1, 2025 to December 31, 2025 | Individual directors | Self-evaluation of the board of directors | Performance evaluation projects for individual directors:<br>A. Alignment of the goals and missions of the company.<br>B. Awareness of the duties of a director.<br>C. Participation in the operation of the company.<br>D. Management of internal relationship and communication.<br>E. The director's professionalism and continuing education.<br>F. Internal control. |
| Once a year | January 1, 2025 to December 31, 2025 | Audit Committee | Self-evaluation of the functional committee | Performance evaluation items for the functional committee:<br>A. Participation in the operation of the company.<br>B. Awareness of the duties of the functional committee. |

| | | | | |
|---|---|---|---|---|
| | January 1, 2025 to December 31, 2025 | Remuneration Committee | | C. Improving the quality of decision-making by functional committees<br>D. Composition and structure of the functional committee<br>E. Internal control. |

Evaluation results:

A. The overall results of the internal performance self-evaluation of the company's board of directors in 2025 were scored as 4.70 (The full score is 5), which means "excellent"

B. The overall results of self-evaluation of individual directors in 2025 were scored as 4.63 (The full score is 5), which means "excellent"

C. The overall results of the internal performance self-evaluation of the company's Audit Committee in 2025 were scored as 4.75 (The full score is 5), which means "excellent"

D. The overall results of the internal performance self-evaluation of the company's Remuneration Committee in 2025 were scored as 4.76 (The full score is 5), which means "excellent"

The conclusion: The company's board of directors is operating well as a whole.

(2) Information on the operation of the Audit Committee

A total of 5 Audit Committee meeting was held in 2025(A), and the attendance of Independent Director is as follows:

| Title | Name | Actual no. of Meetings Attended (B) | No. of Meetings with Entrusted Attendance | Actual Attendance Rate (%)【B/A】(Note ) | Remarks |
|---|---|---|---|---|---|
| Independent Director | Zeng,Hui-Jin | 5 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Liu,Mei-An | 5 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Chen,Rui-Xin | 5 | 0 | 100% | Re-elected on June 17, 2025 |
| Independent Director | Lai,Chun-Ling | 3 | 2 | 100% | Re-elected on June 17, 2025 |

Other matters to be recorded

1. If any of the following circumstances occurs in the operation of the Audit Committee meeting, please indicate the date of the Audit Committee meeting, the session number, the contents of the resolution, the opinions of all independent directors and the Company's handling of the opinions of the independent directors:
   (1) Matters listed in Article 14-5 of the Securities and Exchange Act => From Jan. 1, 2025 to December 31, 2025 Total five audit committee meetings were held, and all independent directors did not object to the matters listed in Article 14-5 of the Securities and Exchange Act and approved them.
   (2) Except for the aforementioned matters, other matters not approved by the Audit Committee and approved by two-thirds or more of all directors => None.
2. To avoid conflict of interest among Independent Directors, the Independent Director's name, meeting content, and reason for avoiding conflict of interest and participation in the voting process must be

properly recorded: None

3. Communication between the independent directors and the chief of internal audit and the accountant (should include the significant matters, methods and results of communication regarding the Company's financial and business status).

(1) The chief of the Company's internal audit regularly conducts audits operations, and reports audit results and their tracking status to the independent directors at the audit committee meetings held quarterly.

(2) The CPA attends the quarterly audit committee meetings to explain the process of reviewing the Company's financial statements, the scope of issues and the update of related regulations in the quarterly and annual financial reports, and discusses fully with the independent directors.

(3) The Company's CPA reports the results of the quarterly financial statement audits at the Audit Committee meetings and other communication matters required by the relevant laws and regulations, and the communication between the members of the Company's Audit Committee and the certified public accountant is good.

| Date | Nature | Significant item communicated with internal audit supervisor | Significant item communicated with the accountant | Communication Results |
|---|---|---|---|---|
| March 13, 2025 The 13th Meeting of the 1st Term | Audit Committee | 1.Audit Operations Execution and Communication.<br>2.Amendment to the Company's Internal Control System<br>3. The Company's "Internal Control System Statement for Fiscal Year 2024" | The accountants conducted a presentation and communication regarding the 2024 consolidated financial statements. | No Opinion |
| May 7, 2025 The 14th Meeting of the 1st Term | Audit Committee | Audit Operations Execution and Communication. | The accountants conducted a presentation and communication regarding the consolidated financial statements for the first quarter of 2025. | No Opinion |
| August 12, 2025 The 1st Meeting of the 2nd Term | Audit Committee | Audit Operations Execution and Communication. | The accountants conducted a presentation and communication regarding the consolidated financial statements for the second quarter of 2025. | No Opinion |
| Nov. 12, 2025 The 3rd Meeting of the 2nd Term | Audit Committee | 1.Audit Operations Execution and Communication.<br>2.Audit plan for 2025 | The accountants conducted a presentation and communication regarding the consolidated financial statements for the third quarter of 2025. | No Opinion |

Note: If there is any Independent Director leaving the Company before the end of the year, please indicate the date of departure in the Remarks field. The actual attendance rate (%) is calculated based on the number of board meetings held and the actual number of meetings attended during the tenure.

If there is a Independent Director election before the end of the year, please list both the new and the old supervisors, and indicate in the Remarks field whether the Independent Director is old, new or re-elected and the date of election. The actual attendance rate (%) is calculated based on the number of board meetings held and the actual number of meetings attended during the tenure.

3. The main powers and key tasks of the Audit Committee are as follows:
   (1) To establish or amend the internal control system in accordance with Article 14-1 of the Securities and Exchange Act.
   (2) To assess the effectiveness of the internal control system.
   (3) To establish or amend procedures for handling significant financial transactions involving the acquisition or disposal of assets, derivative transactions, lending of funds to others, or endorsement or guarantee of others, in accordance with Article 36-1 of the Securities and Exchange Act.
   (4) Matters involving the personal interests of directors.
   (5) Significant asset or derivative transactions.
   (6) Significant lending, endorsement, or guarantee of funds.
   (7) Issuance, offering, or private placement of equity securities.
   (8) Appointment, dismissal, or remuneration of certifying accountants.
   (9) Appointment and removal of the finance, accounting, or internal audit chiefs.
   (10) Annual financial reports signed or sealed by the Chairman, managers, and accounting chief.
   (11) Other significant matters stipulated by the company or regulatory authorities.

4. Audit Committee's performance in 2025:

| Audit Committee Date/Session | Motion content | Resolution situation | The Company's handling of committee members' opinions. |
|---|---|---|---|
| March 13, 2025 The 13th Meeting of the 1st Term | 1. Regarding the Company's 2024 Annual Report and Financial Statements.<br>2. Proposed Loss Offsetting Plan for the Company's 2024 Annual Results.<br>3. Plan for Cash Disbursement from Capital Reserves.<br>4. Proposed Amendments to Certain Articles of the Company's Articles of Association.<br>5. Scope of the Company's Frontline Employees.<br>6. Amendments to the Company's Internal Control System.<br>7. The Company's 2024 Internal Control System Statement.<br>8. Details of the Distribution of 2025 Employee Stock Option Certificates to Non-Managerial Employees. | After being consulted by the Chairman, all attending committee members passed the motion without objection. | The proposal was approved by the Board of Directors with the consent of all attending directors. |

| | | | |
|---|---|---|---|
| May 7, 2025<br>The 14th Meeting of the 1st Term | 1. Proposed financial statements for the first quarter of 2025, reviewed by the auditors.<br>2. The company regularly assesses the independence and competence of its certified public accountants.<br>3. Review of the certified public accountants' fees for 2025. | After being consulted by the Chairman, all attending committee members passed the motion without objection. | The proposal was approved by the Board of Directors with the consent of all attending directors. |
| August 12, 2025<br>The 1st Meeting of the 2nd Term | Audited financial statements for the Q2 2025. | | |
| September 11, 2025<br>The 2nd Meeting of 2nd Term | The Company plans to conduct a Capital Increase by Issuing New Shares for Cash in 2025. | | |
| November 12, 2025<br>The 3rd Meeting of 2nd Term | 1. Audited financial statements for the Q3 2025.<br>2. Audit plan for 2026. | | |

(3). The state of the Company's implementation of corporate governance, any departure of such implementation from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reason for any such departure:

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| 1. Does the Company establish and disclose the Corporate Governance Best-Practice Principles based on "Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies"? | ✓ | | The Company approved the establishment of the "Corporate Governance Best-Practice Principles" at the Board of Directors' Meeting on March 14,2024 and disclosed it on the company website. | No difference. |
| 2. Shareholding structure & shareholders' rights | | | (1)The Company has spokespersons, legal and shareholder personnel and other relevant departments to deal with shareholders' suggestions, disputes and other issues. | No difference. |
| (1) Has the company established an internal operating procedure to deal with shareholders' suggestions, doubts, disputes and litigations, and implement based on the procedure? | ✓ | | (2)With the management of dedicated personnel, the Company is able to keep track of the major shareholders and the relationship with them remains sound. | No difference. |
| (2) Does the company possess the list of its major shareholders as well as the ultimate owners of those shares? | ✓ | | (3)The Company has established relevant systems in the internal control system in accordance with the law. | No difference. |
| (3) Has the company established and implemented risk management and firewall mechanisms with its affiliates? | ✓ | | (4)The Company has established "Procedures for Handling Material Inside Information" in order to avoid improper disclosure of information. It is explicitly stated that insiders of | No difference. |
| (4) Has the Company established internal rules against insiders trading with | ✓ | | | |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| undisclosed information? | | | the Company are prohibited from using undisclosed information in the market to buy or sell securities. Regulatory measures are established to restrict insiders from trading stocks from the day they become aware of the financial report or relevant performance data. Directors are not allowed to trade stocks 30 days before the publication of the annual financial report, as well as during the closed period of 15 days before the publication of each quarterly financial report. At the beginning of the month of the closed period, emails are sent to remind insiders to pay attention and avoid accidentally violating this regulation. | |
| 3.Composition and Responsibilities of the Board of Directors<br>(1) Does the board of directors formulate a diversity policy, specific management objectives and implement it in terms of membership?<br>(2) Has the company voluntarily established other functional committees in addition to the Remuneration Committee and the Audit Committee? | ✓ | ✓ | (1) The Company has seven directors, including three independent directors, three of whom is a female. The professional background to the members covers business management, finance, accounting and law. The board members have a diverse background in industry, profession and knowledge, and provide professional advice from difference perspectives with their experiences, which shall greatly enhance the Company's business performance and management efficiency. The Company has established "Regulations of the Board of Directors" and | No difference.<br>It will be determined according the operation status and scale in the future. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| (3) Has the Company established methodology for evaluating the performance of its Board of Directors, on an annual basis, reported the result of performance evaluation to the Board as reference for remuneration paid to the directors and their nomination for succession?<br><br>(4) Does the Company regularly evaluate the independence of CPAs? | ✓<br><br>✓ | | "Regulations on the Election of Directors and Supervisors".<br>(2) Except for Compensation Committee, there are no other functional committees yet as there is currently no requirement.<br>(3) The Company has established a regulation on evaluating Board performance, and the evaluations are all conducted in form of surveys. The performance of the Board is evaluated by the meeting administrative office, which collects relevant data to assess the overall operations of the Board. The performance of individual members and functional committees is self-evaluated by each director and committee member. The results are submitted and approved at the Board Meeting on Feb 5, 2025, and are used as a reference for determining individual directors' salaries and remuneration. For details regarding the assessment methods and content, please refer to page 32 of the "Implementation Status of the Board's Assessment" section of the annual report.<br>(4) The Company evaluates the independence and suitability of its Certified Public Accountants (CPAs). In addition to requiring a "Declaration of Complete Independence" and "Audit Quality Indicators (AQIs)," CPAs are evaluated based on | No difference.<br><br>No difference. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| | | | the standards of Remark 1 and 13 AQI indicators. The evaluation results for the most recent year were approved by the Audit Committee on March 11, 2026 and were subsequently submitted to the Board of Directors on the same day for resolution. The evaluation of the independence and suitability of the accountants was approved. | |
| 4. Has the Company established adequate and competent corporate governance personnel, and assigned a corporate governance manager in charge of corporate governance affairs (including but not limited to provision of information required by directors and supervisors for business execution, by laws for matters relating to board meetings and shareholders' meetings, and information on corporate registration and amendment registration, as well as record minutes of board meetings and shareholders meetings, etc.)? | ✓ | | The company appoints the corporate governance officer who are responsible for related matters regarding corporate governance, including providing the directors and supervisors with required information to carry out their business, handling matters related to board of directors and shareholders according to the law, handling corporate registration and change of corporate registration related matters, taking the minutes of board meeting s and shareholders' meetings. The Company has set up "Standard Operating Procedures for Handling Directors' Requirements." | No difference. |
| 5. Has the Company established communication channels and dedicate | ✓ | | The Company's website has a stakeholder section, and dedicated personnel responds to | No difference. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| section for stakeholder (including but not limited to the shareholders, employees, clients and suppliers) on its website to respond to important issues of corporate social responsibility concerns? | | | important corporate social responsibility concerns. | |
| 6. Has the Company appointed a professional shareholder service agency to deal with shareholder affairs? | ✓ | | In 2008, the Company appointed Chinatrust Commercial Bank as the stock agency to handle shareholders' related affairs. | No difference. |
| 7. Disclosure of information<br>(1) Does the Company have a corporate website to disclose both financial standings and the status of corporate governance?<br>(2) Does the Company have other information disclosure channels (e.g. building an English website, appointing designated people to handle information on collection and disclosure, creating a spokesperson system, webcasting investor conferences)?<br>(3) Did the company announce and file its annual financial reports within 2 months from the end of the fiscal year? Did the company announce and file the financial | ✓<br>✓ | ✓ | (1) The Company has set up both Chinese and English websites to provide information related to financial business and corporate governance. The website: http://www.bionime.com.tw; Dedicated personnel is responsible for maintenance of the website and immediate updates are available for shareholders and interest parties.<br>(2) The Company has spokespersons and acting spokespersons according to the regulations. It has appointed dedicated personnel to collect company information and put onto MOPS on a regular basis.<br>(3) Except for the annual financial reports announced within 3 months after the end of the fiscal year, | No difference.<br>No difference.<br>It will be determined according the operation |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| reports for Q1, Q2 and Q3, as well as the operation status of each month before the due date? | | | the Company has announced and filed the financial reports for Q1, Q2 and Q3, as well as the operation status of each month before the due date. | status and scale in the future. |
| 8. Is there any other important information to facilitate a better understanding of the Company's corporate governance practices (e.g., including but not limited to employee rights, employee wellness, investor relations, supplier relations, rights of stakeholders, directors' and supervisors' training records, the implementation of risk management policies and risk evaluation measures, the implementation of customer relations policies, and purchasing insurance for directors and supervisors)? | ✓ | | (1) The status of directors and supervisors' further training: It has been disclosed in the "Corporate Governance Section of the MOPS".<br>(2)The Company has purchased Liability Insurance for Directors, Supervisors and Important Managers to strengthen the protection of shareholder's equity. | No difference. |
| 9. Please state the improvements made to the items in the corporate governance evaluation results issued by the Corporate Governance Center of the Taiwan Stock Exchange Co., Ltd., and indicate the enhancement and improvement measures for the items not yet improved (not applicable if not included as a company to be evaluated).<br>(1) Explanation of Improvements Based on the Most Recent Annual (2025) Corporate Governance Evaluation Results： | | | | |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |

| Evaluation Indicators for the 12th Term | Improved situation |
|---|---|
| Has the company's "Sustainability Report" been submitted to and approved by the Board of Directors? | The 2024 Sustainability Report was released after being approved by the Board of Directors on August 12, 2025. |
| Has the company disclosed its greenhouse gas Category 3 emissions and annual emissions for the past year? | Has been disclosed in the annual report. |
| Has the company developed an energy management plan and disclosed its implementation status on the company website, in its annual report or sustainability report? | Has been disclosed in the annual report and has obtained ISO 50001 certification. |
| Has the company developed a training and development plan to enhance employees' career skills, and has it disclosed the details and implementation status? | Has been disclosed in the annual report. |
| Has the company established a personal data protection policy, and disclosed its contents and implementation status? | Has been disclosed in the annual report. |
| Has the company established relevant policies and complaint procedures to protect the rights and interests of consumers or customers regarding issues such as customer health and safety, marketing, or labelling of its products and services? | Has been disclosed in the annual report. |

(2) Explanation of improvements made based on the most recently released Corporate Governance Evaluation results (2025), and priority enhancement items and measures for areas yet to be improved.

The company conducts corporate governance evaluation and self-evaluation in accordance with the regulations of the competent authority, and improves the corporate governance situation gradually to enhance the corporate governance image.

Note1：Assessment criteria of accountant’s independence

| Evaluation Item | Evaluation Result |
|---|---|
| 1.Does the CPA have a direct or indirect financial interest in Bionime. | ■YES □NO |
| 2.Does the CPA have a significant-close business relationship with Bionime. | ■YES □NO |
| 3. Is the CPA entering into potential employment negotiations with Bionime. | ■YES □NO |
| 4. The CPA has not had any monetary borrowings with the Company. | ■YES □NO |
| 5. The CPA has not received any gifts or presents of significant value (the value of which exceeds normal standards of social etiquette) from the Company, its directors or managers. | ■YES □NO |
| 6. The CPA has not provided audit services to the Company for seven consecutive years. | ■YES □NO |
| 7. The CPA does not hold any shares of the Company. | ■YES □NO |
| 8. The CPA, his or her spouse or dependent, and his or her audit team did not hold any position as a director, manager, or officer of the Company during the audit period or within the last two years that has significantly affected the audit case, and has determined that he or she will not hold any such position during the future audit period. | ■YES □NO |
| 9. Whether the CPA has complied with Accountants Code of Ethics Statement No. 18 on Independence and obtained a "Statement of Independence" from the CPA. | ■YES □NO |

(4) If the Company has a Remuneration Committee, Please Disclose its Composition, duties and Operation:

(a)Remuneration Committee Member Information

April 28 ,2026

| Title (Note 1) / Name \ Criteria | | Meet one of the Following Professional Qualification Requirements, together with at Least Five Years Work Experience(Note2) | Independence Attribute (Note3) | Concurrent members of the compensation and remuneration committees of other public offering companies (Number of companies) |
|---|---|---|---|---|
| Independent Director (Chairman) | Liu,Mei-An | Please refer to the information disclosed on directors and supervisors on page 12-13, 1. Professional Qualifications and Independence Analysis of Directors and Supervisors | | 0 |
| Independent Director | Zeng,Hui-Jin | | | 3 |
| Independent Director | Chen,Rui-Xin | | | 0 |
| Independent Director | Lai,Chun-Ling | | | 0 |

Note1: Please specify in the form the relevant working years, professional qualifications and experience, and independence of the members of the Compensation Committee. If they are independent directors, please refer to Table 1 Information of Directors and Supervisors (1) on page 00 for remarks. Please fill in the Title as an independent director or others (if one is an organizer, please add a note).

Note2: Professional qualifications and experience: please state the professional qualifications and experience of each compensation committee members.

Note3: Condition of independence: please state that the members of the Compensation Committee meet the conditions of independence, including but not limited to whether they, their spouse, or relatives within the second degree of kinship serve as directors, supervisors, or employees of the company or its affiliated companies; The number and proportion of the company's shares held by the person, spouse, relatives within the second degree of kinship (or in the name of another person); Whether one is a director, supervisor or employee of a company that has a specific relationship with the (Refer to Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of a Company Whose Stock is Listed on the Taiwan Stock Exchange or the Taipei Exchange, Article 6, Item 1, Subparagraphs 5 to 8); The amount of remuneration received for providing business, legal, financial, accounting and other services to the company or its affiliates in the last two years.

(b)Remuneration Committee Operation Status

A.The Company's Remuneration Committee is composed of four people.

B.Term of the 6th (current) committee members: from August 12, 2025 to June 16, 2028.The Remuneration Committee held 4 meetings (A), and the member qualifications and attendance are as follows:

| Title | Name | Actual No. of Meetings Attended (B) | No. of Meetings with Entrusted Attendance | Actual Attendance Rate (%) (B/A) | Remarks |
|---|---|---|---|---|---|
| Convener | Liu, Mei-An | 4 | 0 | 100% | Re-elected on August 12, 2025 |
| Member | Zeng, Hui-Jin | 4 | 0 | 100% | Re-elected on August 12, 2025 |
| Member | Chen, Rui-Xin | 4 | 0 | 100% | Re-elected on August 12, 2025 |
| Member | Lai, Chun-Ling | 3 | 0 | 100% | Re-elected on August 12, 2025 |

Other matters to be recorded:

1. If the board of directors did not adopt or amend the suggestion of the remuneration committee, please indicate the date and session number of the board meeting, the contents of the motion, the result of the resolution and the Company's handling of the suggestion of the remuneration committee (if the remuneration passed by the board is better than the suggestion of the remuneration committee, please state the difference and the reasons): None.
2. If any member had objections or reservations about the resolution of the remuneration committee and there is a record or a written statement please indicate the date and session number of the remuneration committee meeting, the contents of the motion, all the opinions of the members and how the opinions were handled: None.

Notes:

(1) If any remuneration committee member leaves the company before the end of the year, please state in the Remarks field the departure date, the actual attendance rate (%) calculated based on the number of remuneration committee meetings and the number of the actual meetings attended during the tenure.

(2) If there's a remuneration committee member election before the end of the year, please list both the new and the old members, and indicate in the Remarks field whether the member is old, new or re-elected and the date of election. The actual attendance rate (%) is calculated based on the number of remuneration committee meetings held and the atual number of meetings attended during the tenure.

(c) Main Powers and Key Tasks of the Remuneration Committee:

a. To periodically review the organizational procedures of the Remuneration Committee and propose amendments.

b. To establish and periodically review the performance evaluation standards, annual and long-term performance targets, and policies, systems, standards, and structures regarding remuneration for the Company's directors and managers.

c. To periodically evaluate the achievement of performance targets by the Company's directors and managers, and, based on the evaluation results obtained from the performance evaluation standards, to determine the content and amount of their individual remuneration.

(d) Content of motions, resolution results and the Company's handling of the opinion of the remuneration committee members in the most recent year：

| Remuneration committee meeting /date | Motion | Results of the resolutions | The Company's handling of the opinion of the remuneration committee members |
|---|---|---|---|
| The 8th meeting of the 5th remuneration committee held on January 17, 2025 | Proposal regarding the review of the 2024 year-end bonus distribution details for managers. | After the chairman consulted the opinion of committee members, the motion was approved upon the consent of all attending members. | Approved by the Board of Directors with the consent of all directors present. |
| The 9th meeting of the 5th remuneration committee held on March 13, 2025 | 1. Proposal regarding the allocation details of the 2025 employee stock option certificates to managers.<br>2. Proposal regarding the performance evaluation results of the Company's board members, Board of Directors, and functional committees for 2024. | | |
| The 1st meeting of the 6th remuneration committee held on Sep. 11, 2025 | Proposal for Annual Salary Adjustment for Managers in 2025 | | |
| The 2nd meeting of the 6th remuneration committee held on Nov. 12, 2025 | Regarding the proposal to review the number of shares that managers can subscribe to in employee stock options for the 2025 cash capital increase. | | |

(5). The implementation status of promoting sustainable development initiatives and the deviations from the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies and reasons.

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| 1. Does the company establish a management structure to implement the sustainable development initiatives and set up a dedicated (part-time) unit to implement, which shall be handled by senior management authorized by the board of directors, and the board of directors supervises the situation? | ✓ | | Under the President's Office, a Sustainable Development Office is set up, which is authorized by the Board of Directors to be handled by senior management. Regularly reports to the Board of Directors on a quarterly basis on the results of the implementation of sustainable development and future work plans, and the Board of Directors regularly receives reports from the management team on a quarterly basis to monitor the implementation of sustainable management issues and evaluate the implementation status.<br>In addition, the company has formulated "Management Procedures for Preventing Insider Trading", "Code of Ethical Conduct" and "Internal Control System", etc. With the continuous operation of various management systems and procedures, the company can immediately detect and respond to risks associated with the operating environment, employee safety, customers, suppliers, and various stakeholders. | No difference. |
| 2. Does the company proceed the risk assessments on environmental, social and corporate governance issues associated with company operations according to the principle of materiality, and formulate the relevant policies or | ✓ | | (1) Environmental protection: The company is committed to environmental restoration and energy conservation improvement in the factory area, and has formulated management strategies for "energy conservation and carbon reduction", "greenhouse gas reduction", and "reduction of water or other waste": | No difference. |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| strategies of risk management? (Note 2) | | | (a) Promote various energy-saving and carbon-reducing measures: including implementing paper reuse, garbage classification, turning off lights when leaving a room, and building energy-saving facilities to reduce greenhouse gas emissions and the impact on the natural environment.<br>(b) Greenhouse gas reduction measures: equipment is changed to high-efficiency and variable frequency regulation.<br>(c) Water-saving and other waste reuse measures: continue to invest in reducing process water consumption and using rainwater recycling to effectively reuse water resources.<br>(2) Social norms: The company's daily business follows legal regulations such as the Company Law and the Securities Exchange Act. All production activities and business behaviors require employees and suppliers to follow regulations. The company also promotes regulations in internal meetings or courses.<br>(3) Corporate governance: The company has established a code of conduct for integrity management, a code of ethics, operating procedures for integrity management, and behavioral guidelines as the basis for daily ethical behavior and business compliance by the company's management and employees. By regulating internal controls, authorization systems, functional division of labor, etc., it strengthens the company's operational efficiency and effectiveness, | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | protects asset security and compliance with laws and regulations, in order to implement the execution of corporate law. | |
| 3. Environmental issues<br>(1) Does the Company establish proper environmental management systems based on the characteristics of its businesses? | ✓ | | (1) The Company conducts EHS (Environment Health and Safety) promotion and auditing to all major suppliers, and conducts implementation on the employees' physical health examinations, occupational injury prevention, fire safety, environmental health, etc. Suppliers shall fully cooperate with requirements and improve to achieve the implementation of corporate social responsibility. | No difference. |
| (2) Is the Company committed to improving the efficiency in the use of resources, and the use of recycled materials with low environmental impact? | ✓ | | (2) The Company has a recycling area, which regularly recycles re-usable resources, and has also set up wastewater, rainwater and Condensate recycling for re-using. In addition, traditional lighting fixtures are continuously being improved to LED models, reducing power consumption. | No difference. |
| (3) Does the Company evaluate the current and future potential risks and opportunities brought by the climate change, and take measure to respond to the climate related issues? | ✓ | | (3) The Company assesses the current and future potential risks and opportunities of climate change on its business and adopts the following measures in response to climate-related issues: | No difference. |

| Evaluation item | Implementation status (Note1) | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | |
| | | | Key Risks and Opportunities | Countermeasures | |
| | | | Physical risks:<br>➢ High temperatures, typhoons, torrential rains, flooding, droughts, power shortages, and unannounced power outages may affect the stability of the factory area, production, water and electricity supply, and supply chain.<br>➢ The sustained high temperatures may increase electricity consumption, leading to increased heat hazards and occupational safety risks for outdoor workers.<br>➢ Due to the possibility of flooding in the factory area caused by typhoons and | ➢ The drainage system has adopted a one-operation-one-standby mechanism and is tested regularly to ensure stable operation of the equipment in emergency situations.<br>➢ Regular inspections and maintenance of emergency power supply equipment will be carried out to reduce the impact of power outages or power failures on production and operations.<br>➢ Wastewater generated during the production of rainwater and RO system will be recycled and reused, and the amount of recycled water | |

| Evaluation item | Implementation status (Note1) | | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | | |
| | | | heavy rains, water restrictions caused by droughts, and power shortages that may lead to production shutdowns.<br>➢ Extreme weather events may also affect the supply of raw materials, delivery times, and supply chain operations. | used will be increased.<br>➢ We will improve water recycling rates, strengthen energy use monitoring, and reduce water and electricity consumption risks.<br>➢ A mechanism for managing high-temperature operations, providing education and training, and responding to emergency medical emergencies will be implemented.<br>➢ We will establish outdoor high-temperature work indicators and corresponding protective measures to promote high-temperature outdoor work and climate change protection plans.<br>➢ Improvements will be made to the outdoor working | | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | environment and related hardware equipment to reduce heat hazards for outdoor workers.<br>➢ We will increase the safety stock level for raw materials and strengthen risk assessment of key suppliers.<br>➢ We will establish a supply chain climate adaptation plan and an emergency response mechanism to enhance supply chain resilience. | |

| Evaluation item | Implementation status (Note1) | | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | | |
| | | | Transition risks:<br>➢ Facing increasingly stringent domestic and international regulations on energy use, greenhouse gas emissions, information disclosure, energy efficiency, carbon reduction targets, carbon taxes, and carbon fees.<br>➢ The laws and regulations are gradually increasing the proportion of renewable energy use and setting carbon reduction targets and performance requirements.<br>➢ Enterprises need to gradually replace energy-consuming equipment and invest in renewable energy, green electricity purchases, low-carbon product | ➢ We will continue to implement energy conservation and carbon reduction measures to reduce electricity consumption, electricity costs, and greenhouse gas emissions.<br>➢ The factory's lighting equipment has been gradually replaced with energy-saving LED lamps to reduce electricity consumption for lighting.<br>➢ The air compressor has been changed from air-cooled to water-cooled, and waste heat has been recovered and reused to improve energy efficiency.<br>➢ A frequency converter has been added to the air | | |

| Evaluation item | Implementation status (Note1) | | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | | |
| | | | development, low-carbon processes, and carbon management.<br>➢ As the world moves toward net-zero carbon emissions, failure to transition in a timely manner could impact regulatory compliance, customer partnerships, and market competitiveness. | compressor to adjust the operating efficiency according to actual usage needs and reduce energy waste.<br>➢ The "ISO 50001 Energy Management System" is implemented to analyze energy consumption data, identify major energy-consuming equipment, and continuously promote improvement measures, thus enhancing efficiency and meeting regulatory and corporate carbon management requirements.<br>➢ A digital energy monitoring and early warning management system will be established, and an energy data analysis and early warning mechanism will be | | |

| Evaluation item | Implementation status (Note1) | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | |
| | | | | introduced.<br>➢ We will continue to promote low-carbon processes, energy management, and supply chain carbon management. | |
| | | | Opportunities:<br>➢ Improving the efficiency of energy and water resource use and reducing energy waste.<br>➢ Establishing digital energy monitoring and climate risk early warning management will improve the accuracy of energy management.<br>➢ By increasing water resource recycling rates and energy | ➢ We will promote water conservation, electricity conservation, and resource recycling.<br>➢ We will continue to increase the amount of recycled water used and the efficiency of water resource recycling.<br>➢ We will implement energy data analysis, digital monitoring, and early warning | |

| Evaluation item | Implementation status (Note1) | | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | | |
| | | | self-sufficiency, dependence on external resources is reduced.<br>➢ By focusing on low-carbon products, process innovation, and production automation, we aim to seize opportunities in the green healthcare market and sustainable supply chain collaborations.<br>➢ By coaching key suppliers to establish climate adaptation plans and incorporating climate adaptation capabilities into supplier management. | mechanisms to improve energy management efficiency.<br>➢ To promote process optimization, production automation, and the development of low-carbon products and low-carbon process technologies.<br>➢ We will utilize existing management tools to gradually establish a climate risk monitoring mechanism.<br>➢ We will guide suppliers to develop climate adaptation plans to enhance supply chain resilience.<br>➢ "Climate adaptation capability" has been incorporated into the annual assessment or performance evaluation criteria for | | |

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td>suppliers.</td><td></td></tr>
<tr><td>(4) Does the company calculate the greenhouse gases (GHG) emission, water consumption and total weight of wastes for the past two years, and formulated the strategies for energy conservation, carbon reduction, GHG emission reduction, water saving and management of other wastes?</td><td>✓</td><td></td><td>(4) There are statistics on greenhouse gas emissions, water consumption, waste water and total waste weight every year. The company also formulates energy saving, carbon reduction, greenhouse gas reduction, and water consumption policies to achieve the goal of reducing emissions by 1% per year. The solar power generation system on the top floor of the plant was completed in 2019, in response to the green energy saving policy.
<table>
<tr><th colspan="2">Our Daqing plant and Dawei plant</th><th>2024</th><th>2025</th></tr>
<tr><td colspan="2">Total water consumption (kilowatt hour)</td><td>29,526</td><td>31,324</td></tr>
<tr><td rowspan="3">Greenhouse Gas (Note)</td><td>Type 1: Common services (direct emissions)</td><td>315.8705 (tons) CO2 e</td><td>266.0702 (tons) CO2 e</td></tr>
<tr><td>Type 2: Electricity (indirect emissions) (kg CO2 e/kWh)</td><td>6,371.0596 (tons) CO2 e</td><td>5,787.3071 (tons) CO2 e</td></tr>
<tr><td>Type 3:Other (indirect emissions) (kg CO2</td><td>1,502.6039 (tons)</td><td>1,636.5799 (tons)</td></tr>
</table></td><td>No difference</td></tr>
</table>

<table>
<tr><th>Evaluation item</th><th>Implementation status (Note1)<br>Yes</th><th>No</th><th>Description (Note 2)</th><th>Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><td></td><td></td><td></td><td>
<table>
<tr><td></td><td>e/kWh)</td><td>CO2 e</td><td>CO2 e</td></tr>
<tr><td colspan="2">Waste (tons) - Non-hazardous waste</td><td>5.18</td><td>0.73</td></tr>
<tr><td colspan="2">Waste (tons) - Hazardous waste</td><td>55.01</td><td>41.24</td></tr>
<tr><td colspan="2">Wastewater (tons)</td><td>5,795</td><td>6,211</td></tr>
</table>
Note: The data for 2024 years has been verified by a third-party impartial unit (TUV).<br>
Our company implemented the ISO 50001 energy management system in 2025 and passed TÜV verification in November of the same year, with a certificate valid period ranging from November 24, 2025 to November 23, 2028. The operation of the above energy management system is expected to improve energy efficiency, reduce operating costs and carbon emissions, and achieve sustainable operation goals.</td><td></td></tr>
<tr><td>4. Social issues<br>(1) Has the Company formulated relevant management policies and procedures in accordance with relevant laws and regulations and international human rights conventions?</td><td>✓</td><td></td><td>(1) The Company’s implementation of human rights protection policies is as follows:<br>The Company complies with local applicable laws and international standards.<br>The Company and its subsidiaries abide by the relevant local laws and regulations of each operating site, support and respect relevant international labor human rights norms, including the ILO Tripartite Declaration of Principles and the United Nations Global Compact.</td><td>No difference</td></tr>
</table>

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td>
<table>
<tr><th>Human Rights Management Policy</th><th>Specific Solutions</th></tr>
<tr><td>Provide a safe and healthy work environment to help employees maintain physical and mental health and work-life balance</td><td>➢ Quality staff restaurant, balanced diet and good food.<br>➢ We promote the "Sunshine Workplace Program" to enable our management staff to create a good working atmosphere while pursuing organizational goals, so that all colleagues can work happily.<br>➢ Regular employee health checkups, from caring about the results to developing actions.<br>➢ Monthly on-site doctor visits to provide the most professional health consultation.</td></tr>
<tr><td>Prohibit forced labor and comply with local government</td><td>Implement a leave system to encourage colleagues to focus on work-life balance.</td></tr>
</table>
</td><td></td></tr>
</table>

| Evaluation item | Implementation status (Note1) | | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|---|
| | Yes | No | Description (Note 2) | | |
| | | | labor laws | | |
| | | | Promote a diverse and inclusive workplace; ensure equal employment and protection for vulnerable groups. | ➢ Develop diverse employment programs, including promoting employment opportunities for people with disabilities, indigenous people, those re-entering the workforce, and the middle-aged and elderly.<br>➢ Implement fair compensation and promotion policies to ensure that employees are not discriminated against or treated unequally based on race, gender, religion, age, or political affiliation. | |
| | | | Establish diverse communication and grievance mechanisms to promote opportunities for employees | ➢ Feedback and Communication Mailbox: This is a channel for colleagues to voice their opinions and complaints, managed by designated personnel. It aims to encourage colleagues to express various suggestions and serve as a reference for continuous improvement of company | |

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td>
<table>
<tr><td>to express their opinions.</td><td>policies.<br>➢ Labor-Management Meetings.</td></tr>
<tr><td>Eliminate inhumane treatment and maintain a safe and respectful workplace environment.</td><td>➢ Prohibit any unlawful infringement in the workplace.<br>➢ Promote sexual harassment prevention measures and complaint channels through multiple channels, prioritizing education and training for directors, managers, and supervisors at all levels.<br>➢ Supervisors at all levels and those involved in complaints will receive regular annual training, paying particular attention to the risks of sexual harassment in workplaces beyond the Company's control.</td></tr>
</table>
In 2025, human rights protection training was conducted for employees, totaling 3,421 training hours, with 3,165 participants completing the training. In the future, the Company will continue to pay attention to human rights protection issues and promote related education and training to raise awareness of human rights protection</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td>and reduce the possibility of related risks.<br><br><table><tr><th>Course Name</th><th>Total Attendance</th><th>Total Training Hours</th></tr><tr><td>【Newcomer Training】<br>Newcomer Education and Training</td><td>160</td><td>446</td></tr><tr><td>【Occupational safety and health】<br>Occupational safety and health education and training (including on-the-job training and retraining for operation supervisors)</td><td>43</td><td>281</td></tr><tr><td>【Occupational Safety and Health】<br>Safety Education and Training on Workplace Injury Prevention</td><td>1,810</td><td>1,180</td></tr><tr><td>【Occupational Safety and Health】<br>Emergency Response Drill Training</td><td>200</td><td>92</td></tr><tr><td>【Occupational Safety and Health】<br>First responder and occupational nursing related education and training</td><td>37</td><td>47</td></tr></table></td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td><table>
<tr><td>【Cybersecurity】Information Security Promotion</td><td>554</td><td>941</td></tr>
<tr><td>【Unlawful Infringement】Education and Training to Prevent Unlawful Infringement in the Workplace</td><td>125</td><td>37</td></tr>
<tr><td>【Corporate Governance】Essential Labor Theory for Business Managers: Starting with the Labor Standards Act and Common Labor Disputes</td><td>82</td><td>246</td></tr>
<tr><td>Education and training related to labor laws</td><td>154</td><td>151</td></tr>
<tr><td>Total</td><td>3,165</td><td>3,421</td></tr>
</table></td><td></td></tr>
<tr><td>(2) Does the Company formulate and implement reasonable policies of staff welfare (including compensation, vacation and other welfares), and reflect the operating performance or achievement in the compensation of the employees properly?</td><td>✓</td><td></td><td>(2)1. Employee benefit measures and remuneration policies are implemented in accordance with the Company's "Work Rules", "Payroll Cycle - Benefit Operations", "Payroll Cycle - Evaluation Operations" and "Performance Evaluation Management Regulations", The Company implements performance management through a performance evaluation system that does not differ by gender or age. Through performance management operations, the Company hopes to integrate the Company's overall operational objectives with the individual work goals of employees, which will serve as the basis for annual performance evaluation and feedback, as well as subsequent</td><td>No difference</td></tr>
</table>

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | employee training and development. In addition, the Company's Articles of Association stipulate that employees of the Company and its subsidiaries shall be compensated at a rate of not less than 3% of the Company's profit for the year. (Of this employee compensation amount, no less than 30% should be allocated to entry-level employees.)<br>2. Workplace Diversity Policy: Our company has a "Safety and Health Management Manual" and a "Workplace Sexual Harassment Prevention and Control Measures for Complaints and Discipline" document that are posted on bulletin boards and our internal website. We have a health room, a gym and a breastfeeding room in our factory and employ occupational safety personnel and workplace nurses to provide a dignified and safe workplace environment for our employees. We offer and provide disadvantaged positions, such as physically and mentally challenged, aboriginal, and secondary employment, to ensure employment diversity, fairness in remuneration and advancement opportunities, and that employees are not discriminated against, harassed, or treated unequally on the basis of race, gender, religion, age, political affiliation, or any other status protected by applicable laws and regulations. | |

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td><table>
<tr><th>Indicators</th><th>Percentage (%)</th><th>2026 Target (%)</th></tr>
<tr><td>Female as a percentage of total employees (%)</td><td>63.94</td><td>60</td></tr>
<tr><td>Female as a percentage of all supervisors (%)</td><td>25.61</td><td>34</td></tr>
<tr><td>Female as higher executives (%)</td><td>29.41</td><td>34</td></tr>
</table></td><td></td></tr>
<tr><td>(3) Does the Company provide employees with a safe and healthy working environment, with regular safety and health training?</td><td>✓</td><td></td><td>(1). In order to prevent the occurrence of occupational disasters, the Company spares no effort to improve the working environment to ensure the safety of employees (including all partners). Moreover, it has passed ISO 45001 occupational health and safety management system certification to provide a safe Working environment for the employees. The ISO 45001 certificate mentioned above is valid from November 17, 2023 to September 21, 2026.<br>(2). The Company provides employees with safety and health work relevant items as follows:<br>(a). Build diverse communication channels for employee suggestions and complaints.</td><td>No difference</td></tr>
</table>

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | (b). Schedule safety and health education and training courses annually (including unlawful infringement).<br>(c). Establish a machine and equipment safety optimization project to reduce machine risks.<br>(d). Establish a workplace safety and harmony project to identify and provide early warning of unlawful infringement.<br>(e). Strengthen contractor management and control of high-risk operations.<br>(f). Establish an online chemical management system.<br>(g). Establish a factory hazardous materials management process.<br>(h). Conduct plant-wide hazard identification and risk assessment annually.<br>(i). Develop diverse emergency response plans, including holding fire drills and workshops every six months.<br>(j). Occupational injury and disease statistics show no fatalities or serious occupational accidents.<br>(k). Promote the "Four Major Occupational Health Protection Plans". | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | (l). Implement on-site health consultation services, health publicity, health promotion activities, and special work-related health examinations.<br>(m). Carry out inspections in the operating environment every six months.<br>(n). Formulate "Appeal and Punishment Measures for Prevention and Control Measures of Sexual Harassment in the Workplace", provide complaint channels and keep the working environment in order<br>(o). Purchase accident and medical insurance for employees<br>(p). There was no fire incident in 2025. | |
| (4) Does the Company provide a safe and healthy working environment for employees and regularly carry out safety and health education for employees? | ✓ | | (4) The Company's talent cultivation strategy takes "function-oriented performance training", "class-specific training system" and "function-specific training academy" as the main projects, training and developing value chain management processes, inputting and connecting organizations as the strategic goal, and find out the functional gap and performance gap of human resources. Through systematic training course design, strengthen and upgrade staff's job functions to achieve organizational, departmental and personal performance. | No difference |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | We provide every colleague with a comprehensive education and training program: from 90-day training for new employees to progressive professional training for each unit. Through systematic unit training and irregular cross-departmental general education courses, we aim to improve the work efficiency and performance of our colleagues. The details of each training program, category and hours are as follows:<br>(a). General training: The Company pays attention to the details of its employees in the workplace, such as labor and workplace safety drills, the creation of a friendly workplace, the identification and avoidance of illegal infringements, and other general concepts or norms. We will provide sufficient publicity and education training to convey and create a safe, friendly and compliant employment environment.<br>(b). New employee experience training: From the beginning of work, each new employee will be assigned a dedicated counselor to lead and help the new employee to familiarize themselves with the work environment, strengthen their identification with the company, adapt to the company life and integrate into the company culture. Each department also arranges "New Employee Basic Training" courses to help new employees learn relevant professional knowledge for their work. | |

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Implementation status (Note1)</th><th rowspan="2">Deviations from “the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies” and Reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Description (Note 2)</th></tr>
<tr><td></td><td></td><td></td><td>(c). Professional training: The Company has always been committed to cultivating professional talents. To this end, each unit regularly organizes various professional trainings to achieve knowledge sharing and enhance work functions.<br>(d). Management training: The Company arranges managers at all levels to participate in management training to help them improve their management capabilities, and provide them with efficient management tools to more effectively manage the overall team and enhance cohesion and competitiveness.<br><br>
<table>
<tr><th rowspan="2">Employee Category</th><th rowspan="2">Total Training Hours</th><th colspan="2">General Training</th><th colspan="2">New Employee Training</th><th colspan="2">Professional / Functional Training</th><th colspan="2">Management Skills Training</th></tr>
<tr><th>Total Participants</th><th>Total Hours</th><th>Total Participants</th><th>Total Hours</th><th>Total Participants</th><th>Total Hours</th><th>Total Participants</th><th>Total Hours</th></tr>
<tr><td>Direct Employees</td><td>6,054</td><td>1,185</td><td>1,245</td><td>51</td><td>119</td><td>4,642</td><td>4,621</td><td>120</td><td>69</td></tr>
<tr><td>Indirect Employees</td><td>10,560</td><td>1,112</td><td>1,765</td><td>67</td><td>201</td><td>2,611</td><td>8,550</td><td>33</td><td>44</td></tr>
<tr><td>Management Personnel</td><td>1,730</td><td>154</td><td>306</td><td>2</td><td>6</td><td>366</td><td>1,331</td><td>71</td><td>87</td></tr>
<tr><td>Total</td><td>18,344</td><td>2,451</td><td>3,316</td><td>120</td><td>326</td><td>7,619</td><td>14,502</td><td>224</td><td>200</td></tr>
</table>
</td><td></td></tr>
</table>

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| (5) Does the Company follow regulations and international standards in the customer health, safety, customer privacy, marketing and labeling of its products and services, and set polices and appeal procedures for protection of consumer's rights and interests? | ✓ | | (1) The Company sets up a toll-free customer service hotline of 0800, which provides services including customer complaints, dispute resolution and after-sales service mechanism. Customer information is managed as confidential files in accordance with the "Personal Data Protection Act" and is strictly prohibited for non-relevant business personnel to access. The sales department also formulates a "Customer Complaints Handling Procedure" to directly carry out customer service, feedback reception and improvement operations. There is also a consumer contact mailbox where you can provide feedback or complaints via email to protect the rights and interests of customers.<br>Complaint hotline: 0800-371-688<br>Consumer contact email: info@bionime.com<br>(2) Product labeling is particularly important for protecting consumer rights and health. The Company's "Packaging Material Review Operation Standards" strictly abide by local government laws and regulations on medical device products to implement the control of product labeling by governments of various countries.<br>(3) The Company has passed the "ISO-13485 certification" to ensure that all operations in the entire life cycle of products from manufacturing, service to marketing activities meet quality, safety and standardization. In terms of information security management | No difference |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | and customer privacy protection, it has also passed the four international information security certifications of "ISO/IEC 27001:2022 (Information Security Management), ISO/IEC 27701:2019 (Privacy Information Management), ISO/IEC 27017:2015 (Cloud Service Information Security Management) and ISO/IEC 27018:2019 (Public Cloud Personal Data Protection)" by an impartial third-party certification unit, becoming the first full-scale blood glucose management manufacturer in Taiwan's biotechnology industry to have four "ISO Information Security Certifications". This once again proves that the Company has implemented information security and personal data protection management systems into its internal control, medical device software development, and customer service processes through the PDCA cycle, with the ultimate goal of providing users with a safer, more stable, and more attentive medical care experience. | |
| (6) Does the Company formulate the supplier management policies and require suppliers to follow relevant norms on environmental protection, occupational safety and health, or labor's human rights, and disclose the implementation? | ✓ | | (6) To implement sustainable supply chain management and mitigate operational risks, the Company has established the "Secure Supply Chain Management Procedures," "Supplier Management Procedures," and "Supplier Code of Conduct." Key issues, including occupational health and safety, labor and human rights, information and communication security, and privacy protection, have been incorporated into the supply chain management framework. Through | No difference |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | systematic management and periodic assessments, the Company ensures the effective implementation of these policies.<br>I. Supplier Management Policy<br>The Company's supplier management policy covers the following key areas:<br>1.Occupational Health and Safety Management<br>Suppliers are required to comply with applicable occupational health and safety regulations, establish safety management systems, implement hazard prevention measures and training programs, and ensure a safe working environment.<br>2.Labor and Human Rights Protection<br>Suppliers must comply with labor-related laws and regulations, prohibit child labor and forced labor, eliminate discriminatory practices, safeguard reasonable working hours and compensation, and establish employee grievance mechanisms.<br>3.Information Security Management<br>Suppliers are required to implement information security measures to ensure the confidentiality and integrity of the Company's trade secrets, technical information, and customer data, thereby preventing unauthorized access and data leakage.<br>4.Privacy and Personal Data Protection<br>Suppliers must comply with applicable personal data protection | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | laws and regulations and ensure that the collection, processing, and use of personal data are conducted in accordance with legal requirements.<br>II. Management Mechanisms and Implementation<br>1. Supplier Commitment and Contract Management<br>All new suppliers are required to sign a Supplier Code of Conduct Commitment Letter prior to contract execution. Existing key suppliers have also completed the signing process. As of the end of the current year, the signing coverage rate among key suppliers reached 100%.<br>2. Supplier Evaluation and Risk Management<br>A total of 100 key suppliers were included in the annual evaluation process, representing approximately 85% of the Company's annual procurement expenditure. On-site audits or document reviews were conducted for high-risk suppliers, with a total of 17 supplier assessments completed during the year.<br>The Company's supplier audit procedures include:<br>(1) Supplier Performance Evaluation<br>Supplier performance is evaluated monthly based on indicators such as incoming material acceptance rate, on-time delivery rate, abnormal issue response rate, and level of cooperation. Suppliers receiving a Grade C rating or | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | below are required to undergo improvement counseling and implement corrective action plans.<br>(2) Supplier Audits and Improvement Assistance<br>• If significant quality issues are identified during incoming inspections or production processes, suppliers are immediately notified to implement corrective and preventive actions. Where necessary, on-site audits and quality improvement guidance are conducted.<br>• Annual audit schedules are established for on-site supplier assessments. Suppliers that fail to achieve the required audit scores are issued nonconformance reports and required to submit corrective actions and improvement status reports within one month.<br>• Annual on-site sampling audits are conducted to assess compliance with AEO (Authorized Economic Operator) secure supply chain requirements.<br>• Annual on-site sampling audits are conducted for occupational safety and health evaluations.<br>• Monthly meetings and quality improvement guidance are provided to the three suppliers with the highest number of quality issues identified in the monthly quality reports. | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | 3. Corrective Action and Follow-up Mechanism<br>During the year, a total of 35 corrective actions, including deviation reports, were identified through audits and assessments. All suppliers were required to implement corrective measures within specified deadlines. By year-end, the completion rate of corrective actions reached 100%, and no material labor rights violations or information security incidents were reported.<br>4. Education, Communication, and Continuous Engagement<br>Through supplier meetings and written communications, the Company promotes sustainability policies and regulatory compliance requirements, including occupational health and safety, labor and human rights, information security, and privacy protection. These efforts strengthen supply chain partners' compliance awareness and risk management capabilities. | |
| 5. Does the Company, following internationally recognized guidelines, prepare and publish reports such as its corporate social responsibility report to disclose non-financial information of the Company? Does the Company obtain a third-party verification or assurance for such reports? | ✓ | | Our 2024 Sustainability Report was prepared in accordance with the GRI Guidelines (2021) issued by the Global Reporting Initiative (GRI) and disclosed information within the framework of the Sustainability Accounting Standards Board (SASB) Biotechnology and Healthcare Industry Indicators and the Task Force on Climate-related Financial Disclosures (TCFD). The report was reviewed by our management and is audited annually by our Audit Department. We have not yet obtained an assurance report from a third-party verification body, but will | No difference |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |
| | | | complete this process in accordance with the timeline stipulated by the competent authorities. | |
| 6. If the company has its own sustainable development principles based on "Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies", please describe the difference between its operation and the principles | ✓ | | With reference to the "Sustainable Development Best Practices for Listed Companies", the Board of Directors approved the establishment of the Company's "Sustainable Information Management Measures" on November 6, 2024, thus supervising and promoting the implementation of sustainable development strategies. The Company has reviewed and implemented the above-mentioned measures and made improvements accordingly, and no discrepancies have occurred so far. | No difference |
| 7. Other important information to help understand the operation of corporate social responsibility:<br>(1). Bromine is committed to promoting people's quality and healthy living, as well as to research and development of home health medical equipment that is trusted by everyone. Therefore, professional-grade medical equipment is equipped with a user-friendly operating interface, so that high-medical meters have a simple operating interface, and people can easily check their own health at home.IN addition, due to changes in people's diet and living styles in recent years, the age group of people who have high blood pressure, high blood sugar, and high cholesterol have tendency to decrease year by year. In order to implement the business philosophy of improving people's quality and healthy life, we cooperate with the health education department of major hospitals and distributors to educate the public to understand the relevant diseases and their correct health care concepts, so people have a better understanding of better health care for themselves and their families.<br>(2). In order to support local education to utilize students' knowledge, accumulate practical experience in the workplace, and enhance their competitiveness in the workplace, the Company actively cooperates with local senior secondary schools and colleges and universities to arrange for students to receive practical training in the workplace during their school years, so that their learning can be put to use. Through the K-12 Education Administration, MOE's "Industry-Academia Partnership Program", the National Chin-Yi University of Technology and The National Erh-lin Industrial and Commercial Vocational High School Education collaborated in 2025. National Chin-Yi University of Technology and National Chung Cheng | | | | |

| Evaluation item | Implementation status (Note1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description (Note 2) | |

University also provides summer internship opportunities for students, combining practical industrial experience and academic research resources to help professional and internship students experience the workplace early and give full play to their strengths, creating a win-win-win situation for enterprises, schools and students.

The following table summarizes the status of industry-academic cooperation for the year 2025：

| Type | Academic Institution | Number of People | Period |
|---|---|---|---|
| Corporate Internship | National Chin-Yi University of Technology | 1 | 2025.06.28~2029.06.30 |
| Building Education Cooperation | National Erh-lin Industrial and Commercial Vocational High School | 1 | 2025.05.19~2025.06.27 |

(3)Succession planning and operation of board members and key management personnel:(1)Regarding the succession planning of the Board of Directors, the Company plans to train senior managers to join the Board of Directors to familiarize them with the operation of the Board of Directors and the business of each unit of the Group, and to deepen their industrial experience through job rotation.(2)In addition to excellent professional and leadership skills, the successor of our key management should have values that are in line with our corporate culture, and should have sharp observation skills, good organizational skills, the ability to identify problems, and the ability to solve them. The cultivation of key management personnel covers management function strengthening, duty rotation and project experience, and systematically cultivates management personnel with timely and precise wisdom in decision-making and problem-solving abilities. In addition to cultivating management with growth-oriented values internally, we also recruit outstanding managers externally to strengthen the breadth and depth of the company's succession talent pool.

(4) For further information on our commitment to sustainable development, please refer to our Corporate Sustainability Report and website: https://www.bionime.com/zh-tw/tw-esg/

Note1: If "Yes" is selected under the Implementation Status, it shall explain the important policies, strategies, measures and implementations. If "No" is selected under the Implementation Status, it shall explain the reason and detail the plan to carry out the policies, strategies and measures in the future.

Note2: The Company has compiled a corporate social responsibility report, and the Description indicates the method of reviewing the CSR report and the replacement of index page.

Note3: The materiality principle refers to those related to environmental, social and corporate governance issues that have significant influence on the Company's investors and other interested parties.

Climate-related information for TWSE/TPEx Listed Companies

Implementation Status for the climate-related information

<table>
<tr><th>Item</th><th>Execution Status</th></tr>
<tr><td>1. Describe the board and management’s oversight and governance of climate related risks and opportunities.。</td><td>The General Manager's Office has established a "Sustainability Development Room" responsible for planning, coordinating, and promoting the Company's sustainable development. This Room invites department-level executives to serve as members of the "Sustainability Development Promotion Team," jointly promoting and implementing sustainability initiatives across three main areas: environmental sustainability, social welfare (including human rights), and corporate governance. The team regularly reports quarterly to the Board of Directors on the results of sustainability implementation and future work plans to ensure the practical implementation of related matters. The assessment and management of climate-related risks and opportunities are handled by the Sustainability Development Promotion Team. The Environmental Sustainability Team first identifies and discusses these risks, then formulates plans and response measures through internal discussions, and tracks the effectiveness of their implementation.</td></tr>
<tr><td>2. Describe how the identified climate risks and opportunities affect the company's business, strategy and finance (short term, medium term, long term).</td><td>Based on the Task Force on Climate-Related Financial Disclosures (TCFD), we assess climate risks and opportunities, systematically understand climate risks, opportunities and their financial impacts, effectively reduce risk factors and identify opportunities, and formulate corresponding measures.
<table>
<tr><th colspan="3">Short term: 1-3 years</th></tr>
<tr><th>Key Risks and Opportunities</th><th>Impact on business and finance</th><th>Countermeasures</th></tr>
<tr><td>Physical risks:<br>➢High temperatures increase electricity consumption, raising occupational safety risks for outdoor workers.<br>➢Typhoons and heavy rains may cause flooding in the factory area.<br>➢Drought may lead to water restrictions.</td><td>➢This may increase electricity and water consumption.<br>➢Flooding or water shortage in the factory area may affect production and operation.<br>➢Working in high temperatures may increase the risk of occupational accidents and medical complications.</td><td>➢The drainage system has adopted a one-operation-one-standby mechanism and is tested regularly to ensure stable operation of the equipment in emergency situations.<br>➢Wastewater generated during the production of rainwater and RO system will be recycled and reused, and the amount of recycled water used will be</td></tr>
</table></td></tr>
</table>

| | | | |
|---|---|---|---|
| | | | increased.<br>➢A mechanism for managing high-temperature operations, providing education and training, and responding to emergency medical emergencies will be implemented. |
| | Transition risks:<br>➢Businesses will face increasingly stringent domestic and international regulations on energy use and greenhouse gas emissions (such as information disclosure, energy efficiency and carbon reduction targets, carbon taxes and carbon fees), which will increase their operating costs. | ➢In response to regulatory compliance, carbon management, and energy use requirements, relevant resource inputs will be increased.<br>➢Resources need to be invested to promote energy conservation and carbon reduction measures. | ➢We will continue to implement energy conservation and carbon reduction measures to reduce electricity consumption, electricity costs, and greenhouse gas emissions.<br>➢The factory's lighting equipment has been gradually replaced with energy-saving LED lamps to reduce electricity consumption for lighting.<br>➢The air compressor has been changed from air-cooled to water-cooled, and waste heat has been recovered and reused to improve energy efficiency.<br>➢A frequency converter has been added to the air compressor to adjust the operating efficiency according to actual usage needs and reduce energy waste.<br>➢The "ISO 50001 Energy Management System" is |

| | | | |
|---|---|---|---|
| | | | implemented to analyze energy consumption data, identify major energy-consuming equipment, and continuously promote improvement measures, thus enhancing efficiency and meeting regulatory and corporate carbon management requirements. |
| | Opportunities:<br>➢ Improving the efficiency of energy and water resource use and reducing energy waste.<br>➢ Establishing a health protection and climate adaptation mechanism for outdoor workers. | ➢ This will reduce water and electricity costs and decrease energy waste.<br>➢ This will reduce the risk of occupational safety incidents and work stoppages, and improve operational stability. | ➢ We will promote water conservation, electricity conservation, and resource recycling.<br>➢ We will establish outdoor high-temperature work indicators and corresponding protective measures, as well as a high-temperature outdoor work and climate change protection plan. |

| Medium term: 3 to 5 years | | |
|---|---|---|
| Key Risks and Opportunities | Impact on business and finance | Countermeasures |
| Physical risks:<br>➢ If high temperatures and drought persist, and restrictions on electricity and water consumption continue to increase, this will not only increase the hazards for people working outdoors, but also affect production line operations. | ➢ This leads to a decrease in production capacity, which in turn affects overall operational performance.<br>➢ It may increase the heat hazards and occupational safety risks for outdoor workers.<br>➢ This may increase resource | ➢ Emergency power supply equipment will be inspected and maintained regularly.<br>➢ We will improve water recycling rates and strengthen monitoring of energy use.<br>➢ We will improve the outdoor |

| | | | |
|---|---|---|---|
| | ➢When a power outage causes a sudden, unannounced power failure, production operations will come to a standstill. | investment in emergency response, equipment maintenance, and operational recovery. | working environment and hardware equipment. |
| | Transition risks:<br>➢Energy-consuming equipment must be gradually replaced.<br>➢Develop low-carbon products and transform technologies<br>➢Relevant laws and regulations govern the proportion of renewable energy use, as well as domestic and international carbon (tax) fees, carbon reduction targets, and achievements. | ➢Implementing energy-consuming equipment replacement, renewable energy construction, or green electricity purchase will increase the resources invested.<br>➢Adjustments to electricity rates and the implementation of carbon taxes and fees will increase related expenditures. | ➢We will gradually replace high-energy-consuming equipment through the "ISO 50001 Energy Management System".<br>➢A digital energy monitoring and early warning management system will be established.<br>➢We will invest in the development of low-carbon products and process technologies. |
| | Opportunities:<br>➢Establish digital energy monitoring and early warning management.<br>➢Improve water resource recycling and energy self-sufficiency rates.<br>➢Improvement of environmental hardware facilities for outdoor workers.<br>➢Through process innovation, costs can be optimized, and there is an opportunity to enter the green healthcare market. | ➢It can improve the accuracy of energy management and reduce operating costs.<br>➢It can open up new revenue streams, enhance brand image, and increase opportunities to acquire international customers and sustainable supply chain partnerships. | ➢An energy data analysis and early warning mechanism will be implemented.<br>➢The use of recycled water will be increased.<br>➢We will promote process optimization and production automation. |

<table>
<tr><td></td><td>
<table>
<tr><th colspan="3">Long-term: 5 years or more</th></tr>
<tr><th>Key Risks and Opportunities</th><th>Impact on business and finance</th><th>Countermeasures</th></tr>
<tr><td>Physical risks:<br>➢When extreme climate events intensify, the risk of droughts and floods increases, which may in turn affect the operation of supply chains.</td><td>➢It can enhance supply chain stability and reduce fluctuations in raw material supply.<br>➢It is necessary to improve the control over delivery time and maintain stable production.<br>➢Supply chain management optimization is necessary to maintain customer trust and brand image.</td><td>➢The safety stock level for raw materials will be increased.<br>➢We will strengthen risk assessment of key suppliers.<br>➢A supply chain climate adaptation plan and an emergency response mechanism will be established.</td></tr>
<tr><td>Transition risks:<br>➢Moving towards the "net-zero carbon emissions target".</td><td>➢Invest in renewable energy, low-carbon processes, and carbon management resources to enhance sustainable operating capabilities.<br>➢Promote low-carbon transformation, enhance regulatory compliance, and create opportunities for customer cooperation.</td><td>➢We will set medium- and long-term carbon reduction targets and improve energy self-sufficiency.<br>➢We will continue to promote low-carbon processes, energy management, and supply chain carbon management.</td></tr>
<tr><td>Opportunities<br>➢It can establish a digital monitoring and climate risk early warning mechanism, as well as manage the climate adaptation plans of key suppliers.</td><td>➢Management tools should be used to gradually establish a climate risk monitoring mechanism.<br>➢Suppliers need to be guided to establish climate adaptation plans to enhance supply chain resilience.</td><td>➢"Climate adaptation capability" has been incorporated into the annual assessment or performance evaluation criteria for suppliers.</td></tr>
</table>
</td></tr>
<tr><td>3. Describe the financial impact of extreme climate events and transition actions.</td><td>Financial impact of extreme weather events:<br>➢Increased electricity and water consumption will raise operating costs for businesses.<br>➢To meet regulatory compliance, carbon management, and energy usage requirements, increased resource investment is needed.<br>➢Resources will need to be invested in promoting energy conservation and carbon reduction measures.</td></tr>
</table>

| | |
|---|---|
| | ➢ Increased resource investment is required for emergency response, equipment maintenance, and operational recovery.<br><br>Financial impact of the transformation initiative:<br>➢ With increasingly complete domestic and international regulations, and the gradual promotion of carbon tax and carbon fee systems, enterprises are expected to continue to increase their investment in areas such as replacing energy-consuming equipment, building renewable energy infrastructure, and purchasing green electricity.<br>➢ It may increase the investment of resources related to the development of low-carbon products and the procurement of low-carbon raw materials. |
| 4. Describe how climate risk identification, assessment, and management processes are integrated into an overall risk management system. | The "Sustainability Promotion Team" coordinates and plans climate change-related issues, referencing the Task Force on Climate-related Financial Disclosures (TCFD) framework to develop climate change risk assessments, response strategies, management systems, and action plans. The "Environmental Sustainability Team" is responsible for identifying and discussing these issues, and through internal discussions, formulating plans and response measures, and tracking their implementation. |
| 5. If scenario analysis is used to assess resilience to climate change risks, the scenarios, para meters, assumptions, analysis factors and main financial impacts used should be explained. | The Company has not yet used scenario analysis to assess resilience to climate change risks. |
| 6. If there is a transformation plan to manage climate related risks, describe the content of the plan, and | Our company has not yet established a complete overall climate risk scenario analysis model. At this stage, we mainly formulate response strategies and implementation measures for climate-related risks based on regulatory requirements and market trends, and in accordance with the regulations of competent authorities. Therefore, we have not yet formed an overall climate risk transformation plan. |

| | |
|---|---|
| the indicators and targets used to identify and manage physical risks and transformation risks. | |
| 7. If internal carbon pricing is used as a planning tool, the basis for setting the price should be stated. | Carbon pricing planning tools are not currently in use. |
| 8. If climate r elated goals are set, information such as the activities cove red, greenhouse gas emission scope, planning schedule, annual achievement progress, etc. should be explained I f carbon offsets or renewable energy certificates (RECs) are used to achieve relevant goals, should explain the source and quantity of carbon reduction credits or the quantity of renewable energy certificates (RECs) being redeemed. | Carbon pricing planning tools are not currently in use. |
| 9. Greenhouse gas inventory and assurance, and re | Our company began conducting greenhouse gas inventory checks at the parent company and through third-party external verifications starting in 2023. Our subsidiaries will complete their greenhouse gas inventory checks in 2027 |

| | |
|---|---|
| duction goals, strategies and specific action plans. (Also fill in the following 1-1 1-2) | and their third-party external verifications in 2029. |

**1-1 Recent Two-year GHG Inventory and Assurance Efforts**

1-1-1Green house Gas Inventory

| Specify the emissions(metric tons CO2e)、intensity(metric tonsCO2e/NT$ million) and data coverage for the greenhouse gases in the past two years. |
|---|
| The total carbon emissions for 2023 were 7,700.231 metric tons of CO2 equivalent (tCO2e), Emission intensity 3.83<br>The total carbon emissions for 2024 were 8,189.534 metric tons of CO2 equivalent (tCO2e), Emission intensity 3.77<br>The total carbon emissions for 2025 were 7,689.957 metric tons of CO2 equivalent (tCO2e), Emission intensity 3.55 |

1-1-2 Greenhouse Gas Assurance Efforts

| Explanation of the assured situation for the two most recent fiscal years as of the printing date of the annual report, including the scope of assurance, assurance institutions, assurance criteria and assurance opinions. | |
|---|---|
| We passed the "ISO 14064-1" external audits with the base years of 2023 and 2024 on June 9, 2024 and September 27, 2025, respectively. The relevant information is as follows: | |
| Certificate Holder： | BIONIME CORPORATION |
| Sites Subject to Verification and Validation: | ➢ Bionime Corporation – Daqing Plant<br>No. 100, Sec. 2, Daqing St., South Dist., Taichung City 40242, Taiwan (R.O.C.)<br>➢ Bionime Corporation – David Plant<br>No. 34, David Rd., Dali Dist., Taichung City 41259, Taiwan (R.O.C.) |
| Validation & Verification Site： | Including the sites according to annex |
| Validation & Verification Body： | TÜV Rheinland Taiwan Ltd. |
| Validation & Verification Standard： | ISO 14064-3:2019 |
| Base year： | - 2023 (2023.01.01~2023.12.31) |
| Validation & Verification year： | ●- 2023 (2023.01.01~2023.12.31)、2024(2024.01.01~2024.12.31) |

| | |
|---|---|
| Programme: | - Voluntary GHG scheme |
| Level of Assurance: | - Reasonable |
| Consolidation methodology: | - Operational Control |
| Materiality: | - 5% |
| Type of Greenhouse Gases: | - CO2, CH4, N2O, HFCs, PFCs, SF6, NF3 |
| Validation & Verification Scope: | Based on the information we have received and evaluated that:<br>- Global warming potential (GWP): IPCC 2021, AR6 - 2023 total carbon emission is 7,700.231 tonnes CO2 equivalent (tCO2e) /2024 total is 8,261.942(tCO2e)<br>- Category 1 Direct emission- 2023 :294.4033 (tCO2e) / 2024:270.7228 (tCO2e)<br>- Category 2 Indirect Imported energy emission-2023 : 5,895.5566 tCO2e/2024:6,371.0597 (tCO2e<br>- Category 3 Indirect Transportation emission-2023: 336.8650 tCO2e /2024:294.7949(tCO2e)<br>- Category 4 Indirect Products used by organization emission-2023: 1,173.4062 tCO2e /2024:1,325.3647(tCO2e)<br>- Category 5 Indirect Associated with the use of products from the organization emission is not quantified<br>- Category 6 Indirect Other sources emission is not quantified<br>- Data and information - Historical in nature: Category 1 / 2<br>- Historical in nature with scenario models: Category 3 / 4 |
| Validity： | This certificate only reviewed the emissions data of inventory year, this certificate is not for the management systems certification. |
| Verification Methods: | Site visits, personnel interviews, confirmation of operational practices and procedures, ownership assessment, review of data and information collection processes, tracing and sampling, control and estimation testing, analytical procedures between production and emissions, data recalculation, and document review. |
| Verification Opinion: | Reasonable Assurance |
| Modified Opinion: | i. Sufficient and appropriate evidence supports the material emissions, removals, or storage quantities.<br>ii. Appropriate criteria have been applied to material emissions, removals, or storage quantities.<br>iii. Where the verifier intends to rely on controls, the effectiveness of such controls has been evaluated. |

**1-2 Greenhous Gas Assurance Efforts**

| Explanation of the assured situation for the two most recent fiscal years as of the printing date of the annual report, including the scope of assurance, assurance institutions, assurance criteria, and assurance opinions. |
| --- |
| 1. Baseline Year and Data: The Company's baseline year for greenhouse gas reduction is set at 2023, with emissions of 7,700.231 (tCO2e) in 2023.<br>2. Reduction Target: The short-term (2023-2025) reduction target is set at a 1% reduction in greenhouse gas intensity.<br>3. Strategies and specific actions: Focusing on energy-saving improvements to the air compressor system and lighting equipment as the main measures for energy conservation and emission reduction, taking 2023 as an example, all lighting in the plant area, including T5 lamps and composite metal ceiling light bulbs, was replaced with LED types. Air compressor CDA02 was changed from an air-cooled to a water-cooled air compressor, and waste heat was extracted and used as return water for the air conditioning unit. In 2024, an inverter was installed on air compressor #5.<br>4. Status of carbon reduction targets achieved: The Company's carbon intensity decreased by 7.31% in 2025, compared to the baseline year of 2023. |

(6) Implementation of Integrity Management

Based on the concept of co-prosperity, the Company maintains friendly interaction and cooperation with suppliers and related stakeholders, and provides a good and effective communication channel and information transmission to establish long-term partnership and economic operation mode as the development direction.

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| 1. Setting business integrity policies and programs<br>(1) Does the Company have its regulations and publicly available documents addressing its corporate ethics principles and programs, and the commitment regarding implementation of such programs from the Board of Directors and the management team?<br>(2) Does the company establish appropriate preventive measures for the business activities prescribed in Paragraph 2, Article 7 of the "Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies" or any other such activities associated with high risk of unethical conduct?<br>(3) Does the Company formulate the operation procedures, guidelines, disciplinary and appeal system against unethical conduct? Does the Company implement and regularly review to revise them? | V<br>V<br>V | | (1) The Company has established the Code of Ethical Conduct approved by the board of directors. All directors, managers and all employees should be responsible for the compliance.<br>(2) The Company has established the Code of Ethical Conduct, Employee Code of Practice, and work rules, which clearly state that employees must not engage illegal interests with their job titles, and accept hospitality, gifts, rebates, embezzlement of public funds, or other illegal interests. It is expected to prevent unethical misconduct that may affect business or trade relations.<br>(3) The Company has established the Code of Ethical Conduct, and Employee Code of Practice, which clearly stipulate terms and guidelines regarding conflicts of interest, customer information confidentiality, business | No difference. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| | | | gifts, fair trading and competition. Through trainings and initiatives, the directors, managers and employees can truly understand and follow this concept. Any behavior against ethics and integrity, regardless of position levels, will be punished in accordance with the Work Rules. It also provides complaint channels for employees, so as to handle employees' opinions towards unfair and unreasonable treatment. | |
| 2. Implementation of integrity management<br>(1) Does the Company asses the integrity record of its business partner, and stipulate the terms of conduct on integrity in the contract with the business partner?<br><br>(2) Has the Company set up a dedicated (or concurrent) corporate integrity promotion unit under the board of directors which regularly reports to the board on its work?<br><br>(3) Has the Company formulated policies to prevent conflicts of interest, provided appropriate channels for statements and implemented them? | V<br><br>V<br><br>V | | (1) The Company conducts business activities in a fair and transparent manner, and stipulates that employees are responsible for protecting the Company's intellectual property and not disclosing any information that should not be disclosed or having connection with any dishonest manufacturers or customers. In case of any abnormal condition, it should be reported any time. Moreover, the terms of business integrity are included in the contract.<br><br>(2) In compliance with Company Law, Stock Exchange, Commercial Accounting Law, Political Donations Act, Anti-Corruption Act, Government Procurement Act, Public | No difference. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| (4) Has the Company established an effective accounting system and internal control system for the implementation of integrity management, which is checked by the internal auditing unit on a regular basis or audited by external auditors?<br><br>(5) Does the Company hold regular internal and external training on business integrity? | V<br><br>V | | Officer Conflict of Interest Avoidance Act, other relevant laws and regulations. As well as relevant internal regulation such as auditing and internal control, and considers the "Code of Integrity Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies" as the basis for implementing integrity management.<br><br>(3) The Company stipulates provisions to prevent conflicts of interest in the Code of Ethical Conduct, Management Regulations for Employees 'Code of Practice, labor contracts, and work rules, so as to provide employees with complete guidelines. It has an internal mailbox for suggestions and an external reporting mailbox to provide a smooth reporting and expressing channel.<br><br>(4) The Company has established an accounting system and internal control system to ensure the validity of the financial reporting process and internal control. The internal audit unit prepares the audit plan based on the risk assessment results, regularly performs audit | |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| | | | operations, and performs audits randomly upon demand. The audit results are also reported to the Board.<br><br>(5) It explains the Company's relevant regulations for the new recruits and request them to labor contracts. It also holds various internal meetings, conducts advocacy in various forms, and arranges trainings for new recruits at the first day when they come to work. Moreover, it organizes related internal educations and trainings (including courses on integrity management, regulatory compliance, intellectual property rights, business secrets, etc.) to illustrate the importance of integrity management.<br>(a). In 2025, we prepared education and training sessions for every newcomer to explain the code of conduct and work rules for employees for 1 hour each time, with a total of 212 participants.<br>(b). In 2025, we prepared education and training sessions for every newcomer to introduce "Intellectual Property Rights", which was | |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| | | | conducted for 0.5 hours each time, with a total of 52 participants.<br>(c). In 2025, we prepared education and training sessions for "Information Security and Business Secrets", which was held for colleagues in various departments, for 2 hours each time, with a total of 1,692 participants. | |
| 3. Operation of the Company Reporting System<br>(1) Has the Company set up specific reporting and reward systems and a convenient reporting channel, and does the Company assign appropriate personnel to investigate the person being reported?<br>(2) Has the Company established standard operating procedures for investigating complaints, and the subsequent measures taken after the investigation and ensuring that such complaints are handled in a confidential manner?<br>(3) Does the Company take measures to protect the reporter from improper treatment? | V<br>V<br>V | | (1) The opinions of employees can be reflected through multiple channels including management and human resources units, and shall be properly handled and communicated smoothly.<br>(2) The Company has a whistleblowing system and protects its employees from revenge by reporting their violations.<br>(3) The Company handles the reporting cases in a confidential manner to protect the whistleblower's identity. If the whistleblower is an employee, the Company guarantees that he will not be subject to improper treatment due to the reporting. | No difference. |
| 4. Strengthening of Information Disclosure<br>(1) Does the Company disclose the contents of its Code of Practice for Business Integrity and the effectiveness on its website and MOPS? | V | | The Company's performances of integrity management and adoption measures are disclosed on its website and annual reports. | No difference. |

| Evaluation Item | Implementation Status (Note 1) | | | Deviations from "the Corporate Social Responsibility Best-Practice Principles for TWSE/TPEx Listed Companies" and Reasons |
|---|---|---|---|---|
| | Yes | No | Description | |
| 5. If the Company has its own Corporate Governance Best Practice Principles in accordance with the "Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies", lease describe the difference between them:<br>The Company has not set up Corporate Governance Best Practice Principles but complies with the Company Law, Stock Exchange, Commercial Accounting Law, Political Donations Act, Anti-Corruption Act, Government Procurement Act, Public Officer Conflict of Interest Avoidance Act, other relevant laws and regulations and relevant internal regulation such as auditing and internal control, and considers the "Code of Integrity Corporate Governance Best Practice Principles for TWSE/TPEx Listed Companies" as the basis for implementing integrity management. | | | | |
| 6. Other important information that will help to understand the operation of the Company's integrity (eg. the Company reviews and amends its established code of conduct, etc.): the Company keeps a close eye on the developments of relevant norms of integrity management at home and abroad in order to review and improve the Company's integrity management policy to enhance the effectiveness. | | | | |

Note 1: Regardless of whether "Yes" or "No" is checked, it shall be specified in the Description field.

(7) Other significant information that will provide a better understanding of the state of the Company's implementation of corporate governance may also be disclosed: None.

(8) Implementation of the internal control system:

(a). Statement of Internal Control System (refer to p.101)

(b). If the CPA was engaged to conduct a Special Audit of Internal Control System, provide its audit report: None.

(9) Important resolutions of the shareholders' meeting and the board meetings during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report:

| Date / Meeting | Important Resolutions |
|---|---|
| June 17, 2025, Regular Shareholders' Meeting | ● Adoption of the 2024 Business Report and Financial Statements.<br>Implementation Status: Approved by resolution and duly completed in accordance with the resolutions of the shareholders' meeting.<br><br>●Adoption of the Proposal for 2024 Deficit Compensation.<br>Implementation Status: Approved by resolution and duly completed in accordance with the resolutions of the shareholders' meeting.<br><br>●Proposal to Amend Certain Articles of the Company's Articles of Incorporation.<br>Implementation Status: Approved by resolution, and the amendment registration was completed on August 8, 2025.<br><br>● Proposal for Capital Increase by Capital Surplus through Issuance of New Shares.<br>Implementation Status: Approved by resolution. The record date for share allocation was set on September 14, 2025, and the distribution date for the new shares was October 31, 2025.<br><br>● Proposal for the Comprehensive Re-election of Directors (Including Independent Directors)<br>Implementation Status: The re-election was completed, and the registration of changes to directors was completed on August 8, 2025.<br><br>● Proposal for Release of the Non-Compete Restrictions on Newly Elected Directors. |

| Date ／ Meeting | Important Resolutions |
| --- | --- |
| | Implementation Status: Approved by resolution, and the concurrent positions held by directors were reported to and approved by the shareholders' meeting. |
| January 17, 2025 Board of Directors | ●Approved the 2025 operating plan.<br>●Approved the proposal to distribute 2024 managerial year-end bonuses.<br>●Approved the proposal to issue new shares upon exercise of employee stock options and to set a base date for the capital increase.<br>●Approved the bank financing application proposal. |
| March 13, 2025 Board of Directors | ●Approval of the 2025 Employee Stock Option Certificate Issuance List and Manager Distribution Details.<br>●Approval of the 2024 Annual Report and Financial Statements.<br>●Approval of the 2024 Loss Offset Proposal.<br>●Approval of the Issuance of New Shares from Capital Surplus<br>●Approval of the Definition of the Scope of the Company's Frontline Employees and Amendments to the Company's "Articles of Association".<br>●Amendments to the Company's Internal Control System.<br>●Approval of the Complete Re-election of the 11th Board of Directors (including Independent Directors).<br>●Approval of the Convening of the Company's 2025 Annual General Meeting of Shareholders.<br>●Approval of the Announcement of the Acceptance of Nominations for Directors (including Independent Directors) for the 2025 Annual General Meeting of Shareholders.<br>●Approval of the handling of matters related to the right of shareholders to propose resolutions at the Company's 2025 Annual Regular Meeting of Shareholders.<br>●Approval of the Performance Evaluation Results of the Company's 2024 Board Members, Board of Directors, and Functional Committees.<br>●Approval of the Company's 2024 Internal Control System Statement.<br>●Approved the bank financing application proposal. |
| May 7, 2025 Board of Directors | ●Approved the audited financial statements for the first quarter of 2024.<br>●Approved matters related to the issuance of new shares through |

| Date ／ Meeting | Important Resolutions |
| --- | --- |
| | capital reserve conversion.<br>●Approved the nomination and review of the list of candidates for directors (including independent directors).<br>●Approval of the lifting of non-compete restrictions on newly appointed directors.<br>●Approval of the convening of the Company's 2025 Annual Regular Meeting of Shareholders (with new grounds for convening).<br>●Approval of the exercise of employee stock options for the issuance of new shares and the determination of the base date for the capital increase.<br>●Approval of the Company's periodic assessment of the independence and competence of the auditors.<br>●Approval of the review of the auditors' expenses for 2025. |
| June 17, 2025<br>Board of Directors | ●The proposal to elect a new chairman of the 11th Board of Directors of the Company was passed. |
| August 12, 2025<br>Board of Directors | ●Approval of the Company's audited financial statements for the second quarter of 2025.<br>●Approval of the Company's 2024 Annual "Sustainability Report".<br>●Approval of the Appointment of the Company's 6th Remuneration Committee.<br>●Approval of the Exercise of Employee Stock Option Certificates for the Issuance of New Shares and the Setting of the Capital Increase Benchmark Date.<br>●The Chairman is authorized to set the ex-rights date for the Company's capital reserve capitalization in 2025.<br>●Approved the bank financing application proposal. |
| September 11,2025<br>Board of Directors | ●Approved the Company's proposal for a cash capital increase and issuance of new shares in 2025.<br>●Approved the 2025 annual salary adjustment plan for managers. |
| September 12,2025<br>Board of Directors | ●Approval of the Auditor's Review of the Company's Third Quarter 2025 Financial Statements.<br>●Approval of the 2026 Audit Plan.<br>●Approval of the Review of the Number of Shares Eligible for Managers to Subscribe for in the 2025 Cash Capital Increase Employee Stock Option Plan<br>●Approval of the proposal to change the Company's management<br>●Approval of the proposal "Employee Stock Option Exercise for |

| Date ／ Meeting | Important Resolutions |
| --- | --- |
| | Subscription of New Shares and Determination of Capital Increase Base Date".<br>●Approved the bank financing application proposal. |
| February 5, 2026<br>Board of Directors | ●Approved the 2026 Operating Plan.<br>●Approved the 2025 Managerial Bonus Distribution Plan.<br>●Approved the 2025 Performance Evaluation Results of the Company's Board Members, Board of Directors, and Functional Committees.<br>●Approved that overdue accounts receivable are not loans in nature.<br>●Approval of the scope of the company's frontline employees, including the definition and periodic assessment.<br>●Approval of the proposal of "Employee Stock Option Exercise for Subscription of New Shares and Determination of Capital Increase Base Date".<br>●Approved the bank financing application proposal. |
| March 11, 2026<br>Board of Directors | ●Approved the proposal for the Company's 2025 Annual Report and Financial Statements.<br>●Approved the 2025 Loss Offset Proposal.<br>●Approved the proposal to lift the non-compete restrictions on the Company's directors.<br>●Approved the proposal to convene the Company's 2026 Annual Regular Meeting of Shareholders.<br>●Approved the handling of matters related to the right of shareholders to propose resolutions at the Company's 2026 Annual Regular Meeting of Shareholders.<br>●Approved the proposal to change the auditor in accordance with the business restructuring of KPMG (Taiwan).<br>●Approved the Company's periodic assessment of the independence and competence of the auditors.<br>●Approved the review of the auditors' expenses for 2026.<br>●Approved the Company's "2025 Internal Control System Statement".<br>●Approved the bank financing application proposal. |
| May 13, 2026<br>Board of Directors | ●Approval of the Company's audited financial statements for the first quarter of 2026.<br>●Approval of managerial appointments and promotions. |

| Date ／ Meeting | Important Resolutions |
| --- | --- |
| | ●Approval of the proposal of "Employee Stock Option Exercise for Subscription of New Shares and Determination of Capital Increase Base Date".<br>●Approved the bank financing application proposal. |

(10) Where, during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report, a director or supervisor has expressed a dissenting opinion with respect to a resolution approved by the board of directors, and said dissenting opinion has been recorded or prepared as a written declaration, disclose the principal content thereof: None.

# BIONIME Corporation
# Statement of Internal Control System

Date: March 11, 2026

The internal control system from January 1 to December 31, 2025, according to the result of self-assessment is thus stated as follows:

1. The Company acknowledges that the implementation and maintenance of internal control system is the responsibility of Board of Directors and management, and the Company has established such system. The internal capital system is aimed to reasonably assure that the goals such as the effectiveness and the efficiency of operations (including profitability, performance and protection of assets), the reliability of financial reporting and the compliance of applicable law and regulations are achieved.
2. An internal control system has inherent limitations. No matter how perfectly designed, an effective internal control system can provide only reason assurance of accomplishing its three state objectives above. Moreover, the effectiveness of an internal control system may be subject to changes due to extenuating circumstances beyond our control. Nevertheless, our internal control system contains self-monitoring mechanisms, and the Company takes immediate remedial actions in response to any identified deficiencies.
3. The Company evaluate the design and operating effectiveness of its internal control system Control Systems by Public Companies (herein below, the Regulations). The criteria adopted by the Regulations identify five key components of managerial internal control: i. control environment, ii. risk assessment, iii. control activities, iv. information and communication, and v. monitoring activities.
4. The Company has evaluated the design and operating effectiveness of its internal control system according to the aforesaid Regulations.
5. Based on the findings of such evolution, the Company believes that, on December 31, 2025, it has maintained, in all material respects, an effective internal control system (that includes the supervision and management of our subsidiaries), to provide reasonable assurance over our operational effectiveness and efficiency, reliability, timeliness transparency of reporting, and compliance with applicable rulings, laws and regulations.
6. This Statement is an integral part of the Company's annual report for the year 2024 and prospectus, and will be made public. Any falsehood, concealment, or other illegality in the content made public will entail legal liability under Articles 20, 32, 171 and 174 of the Securities and Exchange Law.
7. This statement was approved by the board of directors in the meetings held on March 11, 2026, with none of the nine attending directors expressing dissenting opinions, and the remainder all affirming the content of this Statement.

BIONIME Corporation
Chairman: Huang, Chun-Mu
General Manager: Huang, Chun-Mu

4. Information on CPA Profession Fees

## Information on CPA Profession Fees

Unit: NT$ thousand

| Accounting Firm | CPA Name | Audit period | Audit fee | Non-audit fee | Total | Remarks |
|---|---|---|---|---|---|---|
| KPMG | Chen, Yen- Hui | 2025.01.01 ~2025.12.31 | 3,000 | 1,005 | 4,005 | •TP Report NT$570 thousand.<br>•Tax Certification NT$250 thousand.<br>•Business Registration NT$125 thousand.<br>•Review Opinion on the Case of Capital Reserve Transfer to Capital Increase: NT$60 thousand. |
| | Kuo, Shyh-Huar | | | | | |

Please specify the content of non-audit public services: (such as tax visa, assurance or other financial advisory services)

Note: If there is any change of accountants or accounting firm this year, please list the audit period separately, explain the reason of the change in the remarks column, and disclose the audit and non-audit fees paid in sequence. The non-audit fees should be noted and should explain its service content.

(1) If there is a change of the accounting firm, and in the year of the change the audit fee is lower than that in the previous year, please disclose the audit fees before and after the change and the reasons: None.

(2) If the audit fee is reduced more than 15% compared with the previous year the reduction in the amount of audit fees, the proportions, and reason (s) there for shall be disclosed: There is no reduction in the audit fees.

5. Change of Accountants:

(1)Regarding the former accountant

<table>
<tr><td>Change Date</td><td colspan="4">March 2026</td></tr>
<tr><td>Reasons and explanations for replacement</td><td colspan="4">In line with internal business adjustments at the accounting firm, effective from the first quarter of 2026, the Company’s financial reporting auditors will be changed from Ms. Chen, Yen-Hui and Ms. Kuo,Shyh-Huar to Ms. Chen, Yen- Hui and Ms. Chien,Szu-chuan.</td></tr>
<tr><td rowspan="3">Explain the reason why the appointor or accountant terminated or refused the appointment.</td><td>Party<br>Condition</td><td colspan="2">Accountant</td><td>Appointor</td></tr>
<tr><td>The appointment was terminated voluntarily.</td><td colspan="2">Not applicable.</td><td>Not applicable.</td></tr>
<tr><td>No longer accepting (continuing) appointments.</td><td colspan="2">Not applicable.</td><td>Not applicable.</td></tr>
<tr><td>Comments and reasons for the most recent audit reports issued within the last two years, excluding unqualified opinions.</td><td colspan="4">None.</td></tr>
<tr><td rowspan="7">Are there any disagreements with the issuer?</td><td rowspan="5">Yes.</td><td></td><td colspan="2">Accounting principles or practices</td></tr>
<tr><td></td><td colspan="2">Disclosure of financial reports.</td></tr>
<tr><td></td><td colspan="2">Scope or steps of the verification</td></tr>
<tr><td></td><td colspan="2">Others</td></tr>
<tr><td></td><td colspan="2"></td></tr>
<tr><td>None.</td><td colspan="3">✓</td></tr>
<tr><td colspan="4">Explanation</td></tr>
<tr><td>Other matters to be disclosed (sub-items 1.4 to 1.7 of Section 6 of Article 10 of this Guideline that should be disclosed).</td><td colspan="4">None.</td></tr>
</table>

(2) Regarding the successor accountant

| Firm name | KPMG in Taiwan |
|---|---|
| Accountant name | Chen, Yen- Hui and Kuo, Shyh-Huar |
| Date of appointment | March 2026 |
| Consultation on accounting treatment or accounting principles for specific transactions and possible opinions on financial reports prior to appointment, and the results thereof. | N/A |
| Written opinion of the successor accountant on matters in which the successor accountant disagrees with the previous accountant | N/A |

6.The Employment of the Company's Chairman, General Manager, Financial or Accounting Manager with the Auditing CPA Firm or its Affiliated Businesses in the Past Year, Name, Title as well as Serving Period of the Accounting Firm or its Affiliate shall be Disclosed: None.

7. Any Transfer of Equity Interests and/or Pledge of or Change in Equity Interests by a Director, Supervisor, Managerial Officer; or Shareholder with a Stake of More than 10 Percent during the Most Recent Fiscal Year or during the Current Fiscal Year up to the Date of Publication of the Annual Report:

(1) For information regarding changes in shareholding, please visit the MOPS Public Information Observation Station (https://mops.twse.com.tw), select "Single Company," then "Shareholding Changes/Securities Issuance," then "Share Transfer Information Inquiry," and finally "Post-Event Reporting Form for Insider Shareholding Changes" (Company Code: 4737) to inquire.

(2) Information on equity transfer: None.

(3) Information on equity pledge:

| Name | Reasons for pledge changes | Date | Counterparty | Counterparty's relationship with company directors, supervisors, managers and shareholders who hold more than 10% of the shares | Shareholding ratio | Share | Pledge ratio | Pledge (redemption) amount |
|---|---|---|---|---|---|---|---|---|
| Huang,Chun-Mu | pledge | 2026/1/19 | First Commercial Bank, Dali Branch | - | 4.00% | 1,000,000 | 71.14% | - |
| Lai, Chun-Ling | pledge | 2025/1/15 | Cathay United Bank Taichung Branch | - | 0.39% | 48,000 | 90.25% | - |

8. Relationship Information, if among the Company's 10 Largest Shareholders any one is a Related Party or a Relative within the Second Degree of Kinship of another:

April 28 ,2026

| Name | Shareholding | | Spouse & Minor Children Current Shareholding | | Current Shareholding in the Name of others | | Relationships among the Top Ten Shareholders, anyone who is a Related Party, Spouse, or Second-Degree Kinship of another: Name and Relation | | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| | Share | % | Share | % | Share | % | Title (Name) | Relation | |
| Tonghua Dongbao Pharmaceutical Co., Ltd. Representative: Lee, Jia-Hong | 13,198,277 | 17.05% | - | - | - | - | - | - | - |
| Hua Eng Wire & Cable Co., Ltd. Representative: Wang, Ho-Jen | 7,704,384 | 9.95% | - | - | - | - | - | - | - |
| China Trust Commercial Bank is entrusted with safekeeping of the World Tree Global Fund SPC - Valhalla Fund SP. | 5,100,000 | 6.59% | - | - | - | - | - | - | - |
| Huang, Chun-Mu | 3,092,413 | 4.00% | 1,232,257 | 1.59% | - | - | Shi,Jin-Xiu, Huang,Xiu-Qin Shi,Cui-E | Husband and wife, Siblings, In-law | - |
| Bank SinoPac is entrusted with safekeeping of the investment account of FAMPETUAL Investments Sdn Bhd. | 2,065,000 | 2.67% | - | - | - | - | Lee,Zheng-Hong | Lee,Zheng-Hong is the person in charge of the investment account of FAMPETUAL Investment Sdn Bhd, entrusted by Bank SinoPac. | |
| Yanben Investment Co., Ltd. Representative：Chang, Mei-Ling | 1,845,938 | 2.38% | - | - | - | - | - | - | - |
| Shi,Cui-E | 1,728,000 | 2.23% | - | - | - | - | Shi, Jin-Xiu, Huang,Chun-Mu | Sisters, In-law | - |
| Lee ,Zheng-Hong | 1,659,000 | 2.14% | 600,000 | 0.78% | 2,065,000 | 2.67% | Bank SinoPac is entrusted with safekeeping of the investment account of FAMPETUAL Investments Sdn Bhd. | Lee,Zheng-Hong is the person in charge of the investment account of FAMPETUAL Investment Sdn Bhd, entrusted by Bank SinoPac. | - |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Shi,Jin-Xiu | 1,232,257 | 1.59% | 3,092,413 | 4.00% | - | - | Huang,Chun-Mu Shi,Cui-E, Huang,Xiu-Qin | Husband and wife, Sisters, In-law | - |
| Huang,Xiu-Qin | 1,202,696 | 1.55% | - | - | - | - | Huang,Chun-Mu Shi, Jin-Xiu | Siblings, In-law | - |

Note 1: The top ten shareholders shall be listed, and the corporate shareholders shall list the names of the corporate shareholder and the name of the representative of the corporate shareholder separately.

Note 2: The shareholding ratio refers to the calculation of the shareholding ratio in the name of the shareholder, spouse, minor children or shareholding in the name of others.

Note 3: The shareholders listed in the previous disclosure, including corporate shareholders and natural persons, shall disclose the relationship between them.

9. The Total Number of Shares and Total Equity Stake Held in any Single Enterprise by the Company, its Directors and Supervisors, Managers, and any Companies Controlled either Directly or Indirectly by the Company:

March 31, 2026; Unit: thousand shares; %

| Investee Company | Investment by the Company | | Investment by Directors, Supervisors, Managers, and Enterprises Directly or Indirectly Controlled | | Comprehensive Investment | |
|---|---|---|---|---|---|---|
| | Number of Shares | Shareholding Percentage | Number of Shares | Shareholding Percentage | Number of Shares | Shareholding Percentage |
| Bionime Incorporated(B.V.I) | 3.09 | 100.00 | - | - | 3.09 | 100.00 |
| Bionime (Shenzhen) Co., Ltd | - | 100.00 | - | - | - | 100.00 |
| Bionime GmbH | - | 100.00 | - | - | - | 100.00 |
| Bionime USA Corp. | 1,115 | 100.00 | - | - | 1,115 | 100.00 |
| Bionime Australia Pty Ltd | - | 100.00 | - | - | - | 100.00 |
| Bionime (Pingtan) Co., Ltd. | - | 100.00 | - | - | - | 100.00 |
| Bionime(Malaysia) SDN BHD | - | 65.09 | - | - | - | 65.09 |

Note: Refers to investments accounted for using the equity method.

# III. Capital Overview

## 1. Capital and Shares

### (1) Source of capital

Unit: NT$ thousand; 1000 shares

| Year/ Month | Par Value | Approved Capital | | Paid-in Capital | | Remarks | | |
|---|---|---|---|---|---|---|---|---|
| | | Shares | Amount | Shares | Amount | Source of Capital | Capital Increased by Assets other than Cash | Others |
| 2003/4 | 10 | 750 | 7,500 | 750 | 7,500 | Capital at establishment 7,500 | None | Note 1 |
| 2003/6 | 10 | 1,500 | 15,000 | 1,500 | 15,000 | Capital increase 7,500 by cash | None | Note 2 |
| 2003/11 | 10 | 4,500 | 45,000 | 4,500 | 45,000 | Capital increase 30,000 by cash | None | Note 3 |
| 2004/7 | 10 | 11,000 | 110,000 | 9,000 | 90,000 | Capital increase 45,000 by cash | None | Note 4 |
| 2005/1 | 30 | 11,000 | 110,000 | 10,000 | 100,000 | Capital increase 10,000 by cash | None | Note 5 |
| 2005/3 | 30 | 15,000 | 150,000 | 11,000 | 110,000 | Capital increase 10,000 by cash | None | Note 6 |
| 2005/7 | 15 | 15,000 | 150,000 | 12,000 | 120,000 | Capital increase 10,000 by cash | None | Note 7 |
| 2005/9 | 30 | 15,000 | 150,000 | 13,500 | 135,000 | Capital increase 15,000 by cash | None | Note 8 |
| 2006/4 | 31.5 | 50,000 | 500,000 | 16,500 | 165,000 | Capital increase 20,000 by cash | Capital increase 31,500 by creditor's right | Note 9 |
| 2006/4 | 31.5 | 50,000 | 500,000 | 18,500 | 185,000 | Capital increase20,000 by cash | None | Note 10 |
| 2007/4 | 31.5 | 50,000 | 500,000 | 21,500 | 215,000 | Capital increase 30,000 by cash | None | Note 11 |
| 2007/10 | 10/15 | 50,000 | 500,000 | 21,935 | 219,350 | Employee stock option certificates4,350 | None | Note 12 |
| 2008/5 | 39 | 50,000 | 500,000 | 26,189 | 261,898 | Capital increase 17,548 by capital surplus Capital increase 25,500 by cash | None | Note 13 |
| 2008/8 | 10 | 50,000 | 500,000 | 26,345 | 263,447 | Employee stock option certificates NT$1,549 thousand | None | Note 14 |
| 2008/9 | 15 | 50,000 | 500,000 | 26,556 | 265,563 | Employee stock option certificates 2,116 | None | Note 15 |
| 2008/12 | 64 | 50,000 | 500,000 | 27,884 | 278,844 | Capital increase 13,281 by cash | None | Note 16 |
| 2009/8 | 10/ 11.9 | 50,000 | 500,000 | 35,236 | 352,356 | Capital increase 71,641 by earnings Employee stock option certificates | None | Note 17 |

| Year/ Month | Par Value | Approved Capital | | Paid-in Capital | | Remarks | | |
|---|---|---|---|---|---|---|---|---|
| | | Shares | Amount | Shares | Amount | Source of Capital | Capital Increased by Assets other than Cash | Others |
| | | | | | | 1,871 | | |
| 2010/1 | 14.4 | 50,000 | 500,000 | 36,236 | 362,356 | Employee stock option certificates 10,000 | None | Note 18 |
| 2010/12 | 95 | 50,000 | 500,000 | 39,952 | 399,516 | Capital increase NT$37,160 thousand by cash | None | Note 19 |
| 2011/8 | 10 | 50,000 | 500,000 | 43,947 | 439,468 | Capital increase NT$39,952 thousand by capital surplus | None | Note 20 |
| 2014/12 | 38 | 70,000 | 700,000 | 51,447 | 514,468 | Capital increase NT$75,000 thousand by cash | None | Note 21 |
| 2015/12 | 95 | 70,000 | 700,000 | 63,447 | 634,468 | Capital increase NT$120,000 thousand by private placement | None | Note 22 |
| 2017/8 | 10 | 70,000 | 700,000 | 59,447 | 594,468 | Capital increase NT$40,000 by treasury stock | None | Note 23 |
| 2019.7 | 10 | 100,000 | 1,000,000 | 59,501 | 595,008 | Employee stock option certificates NT$540 | None | Note 24 |
| 2019.11 | 47.7 | 100,000 | 1,000,000 | 59,670 | 596,698 | Employee stock option certificates NT$1,690 | None | Note 25 |
| 2020.2 | 47.7 | 100,000 | 1,000,000 | 60,536 | 605,358 | Employee stock option certificates NT$8,660 | None | Note 26 |
| 2020.6 | 47.7<br>49.4 | 100,000 | 1,000,000 | 61,522 | 615,218 | Employee stock option certificates NT$9,860 | None | Note 27 |
| 2020.11 | 46.4<br>48 | 100,000 | 1,000,000 | 61,756 | 617,558 | Employee stock option certificates NT$2,340 | None | Note 28 |
| 2021.3 | 46.4<br>48 | 100,000 | 1,000,000 | 61,963 | 619,633 | Employee stock option certificates NT$2,075 | None | Note 29 |
| 2021.7 | 48 | 100,000 | 1,000,000 | 62,195 | 621,953 | Employee stock option certificates NT$2,320 | None | Note 30 |
| 2021.10 | 48 | 100,000 | 1,000,000 | 62,236 | 622,358 | Employee stock option certificates NT$405 | None | Note 31 |
| 2021.12 | 48<br>46.6 | 100,000 | 1,000,000 | 62,289 | 622,888 | Employee stock option certificates NT$530 | None | Note 32 |
| 2022.05 | 46.6<br>56.7 | 100,000 | 1,000,000 | 60,580 | 605,810 | Employee stock optioncertificate NT$2,922 Capital increase NT$20,000 by | None | Note 33 |

| Year/ Month | Par Value | Approved Capital | | Paid-in Capital | | Remarks | | |
|---|---|---|---|---|---|---|---|---|
| | | Shares | Amount | Shares | Amount | Source of Capital | Capital Increased by Assets other than Cash | Others |
| | | | | | | treasury stock | | |
| 2022.06 | 56.7 | 100,000 | 1,000,000 | 60,602 | 606,022 | Employee stock option certificates NT$212 | None | Note 34 |
| 2022.09 | 56.7 | 100,000 | 1,000,000 | 60,624 | 606,240 | Employee stock option certificates NT$218 | None | Note 35 |
| 2022.12 | 56.7<br>55.1 | 100,000 | 1,000,000 | 60,687 | 606,870 | Employee stock option certificates NT$630 | None | Note 36 |
| 2023.05 | 55.1 | 100,000 | 1,000,000 | 60,749 | 607,488 | Employee stock option certificates NT$618 | None | Note 37 |
| 2023.07 | 55.1 | 100,000 | 1,000,000 | 60,802 | 608,022 | Employee stock option certificates NT$534 | None | Note 38 |
| 2023.12 | 55.1<br>53.6 | 100,000 | 1,000,000 | 60,820 | 608,202 | Employee stock option certificates NT$180 | None | Note 39 |
| 2024.04 | 53.6 | 100,000 | 1,000,000 | 60,942 | 609,424 | Employee stock option certificates NT$1,222 | None | Note 40 |
| 2024.07 | 53.6 | 100,000 | 1,000,000 | 61,015 | 610,146 | Employee stock option certificates NT$722 | None | Note 41 |
| 2024.12 | 53.6<br>52.1 | 100,000 | 1,000,000 | 61,039 | 610,388 | Employee stock option certificates NT$242 | None | Note 42 |
| 2025.03 | 52.1 | 100,000 | 1,000,000 | 61,073 | 610,732 | Employee stock option certificates NT$344 | None | Note 43 |
| 2025.06 | 52.1 | 100,000 | 1,000,000 | 61,088 | 610,884 | Employee stock option certificates NT$152 | None | Note 44 |
| 20025.10 | 52.1 | 100,000 | 1,000,000 | 67,221 | 672,215 | Employee stock option certificates NT$254<br>Capital Increase by Capital Surplus NT$61,077 | None | Note 45 |
| 2025.12 | 52.1<br>47.4 | 100,000 | 1,000,000 | 67,273 | 672,727 | Employee stock option certificates NT$512 | None | Note 46 |
| 2026.04 | 47.4<br>50 | 100,000 | 1,000,000 | 77,285 | 772,852 | Employee stock option certificates NT$126<br>Capital increase NT$100,000 by cash | None | Note 47 |

Note 1: The capital increase was approved by Ministry of Economic Affairs on April 14, 2003 No. 09231929030.

Note 2: The capital increase was approved by Ministry of Economic Affairs on June 19, 2003 No. 09232227670.

Note 3: The capital increase was approved by Ministry of Economic Affairs on November 27, 2003 No. 09233029400.

Note 4: The capital increase was approved by Ministry of Economic Affairs on August 26, 2004 No. 09332627270.

Note 5: The capital increase was approved by Ministry of Economic Affairs on February 25, 2005 No. 09431721640.

Note 6: The capital increase was approved by Ministry of Economic Affairs on May 13, 2005 No. 09432106330.

Note 7: The capital increase was approved by Ministry of Economic Affairs on September 16, 2005 No. 09432834870.

Note 8: The capital increase was approved by Ministry of Economic Affairs on October 5, 2005 No. 09432935950.

Note 9: The capital increase was approved by Ministry of Economic Affairs on May 5, 2006 No. 09532127100.

Note 10: The capital increase was approved by Ministry of Economic Affairs on May 17, 2006 No. 09532182970.

Note 11: The capital increase was approved by Ministry of Economic Affairs on May 14, 2007 No. 09632110580.

Note 12: The capital increase was approved by Ministry of Economic Affairs on October 22, 2007 No. 09632934410.

Note 13: The capital increase was approved by Ministry of Economic Affairs on June 20, 2008 No. 09732462450.

Note 14: The capital increase was approved by Ministry of Economic Affairs on August 8, 2008 No. 09732815110.

Note 15: The capital increase was approved by Ministry of Economic Affairs on October 22, 2008 No. 09733293140.

Note 16: The capital increase was approved by Ministry of Economic Affairs on January 6, 2009 No. 09831508980.

Note 17: The capital increase was approved by Ministry of Economic Affairs on September 10, 2009 No. 09833037820.

Note 18: The capital increase was approved by Ministry of Economic Affairs on February 22, 2010 No. 09931699410.

Note 19: The capital increase was approved by Ministry of Economic Affairs on January 4, 2011 No. 10031506780.

Note 20: The capital increase was approved by Ministry of Economic Affairs on August 25, 2011 No. 10032427660.

Note 21: The capital increase was approved by Ministry of Economic Affairs on January 8, 2015 No. 10301266680.

Note 22: The capital increase was approved by Ministry of Economic Affairs on January 12, 2016 No. 10401278900.

Note 23: The capital increase was approved by Ministry of Economic Affairs on August 29, 2017 No. 10601121050.

Note 24: The capital increase was approved by Ministry of Economic Affairs on July 22, 2019 No. 10801090630.

Note 25: The capital increase was approved by Ministry of Economic Affairs on November 28, 2019 No. 108011721120.

Note 26: The capital increase was approved by Ministry of Economic Affairs on February 14, 2020 No. 10901014580.

Note 27: The capital increase was approved by Ministry of Economic Affairs on June 9, 2020 No. 10901095090.

Note 28: The capital increase was approved by Ministry of Economic Affairs on Nov. 17, 2020 No. 10901204940.

Note 29: The capital increase was approved by Ministry of Economic Affairs on March. 9, 2021 No. 11001036530.

Note 30: The capital increase was approved by Ministry of Economic Affairs on July. 14, 2021 No. 11001117870.

Note 31: The capital increase was approved by Ministry of Economic Affairs on October. 1, 2021 No. 11001170820.

Note 32: The capital increase was approved by Ministry of Economic Affairs on December. 30, 2021 No. 11001222170.

Note 33: The capital increase was approved by Ministry of Economic Affairs on May. 17, 2022 No. 11101083910.

Note 34: The capital increase was approved by Ministry of Economic Affairs on June. 13, 2022 No. 11101092240

Note 35: The capital increase was approved by Ministry of Economic Affairs on Nov. 14, 2022 No. 11101173000.

Note 36: The capital increase was approved by Ministry of Economic Affairs on December. 16, 2022 No. 11101236530

Note 37: The capital increase was approved by Ministry of Economic Affairs on May. 24, 2023 No. 11230084940

Note 38: The capital increase was approved by Ministry of Economic Affairs on July. 17, 2023 No. 11230136120

Note 39: The capital increase was approved by Ministry of Economic Affairs on December. 20, 2023 No. 11230234730

Note 40: The capital increase was approved by Ministry of Economic Affairs on March. 29, 2024 No. 11330039100

Note 41: The capital increase was approved by Ministry of Economic Affairs on July. 17, 2024 No. 11330116730

Note 42: The capital increase was approved by Ministry of Economic Affairs on December. 23, 2024 No. 11330214710

Note 43: The capital increase was approved by Ministry of Economic Affairs on April 7, 2025 No. 11430040240

Note 44: The capital increase was approved by Ministry of Economic Affairs on June 6, 2025 No. 11430074330

Note 45: The capital increase was approved by Ministry of Economic Affairs on Oct.14, 2025 No. 11430159430

Note 46: The capital increase was approved by Ministry of Economic Affairs on Dec.22, 2025 No. 11430198130

Note 47: The capital increase was approved by Ministry of Economic Affairs on April 7, 2026 No. 11530024630

April 28,2026 Unit: thousand shares

| Type of Stock | Approved Capital | | | Remarks |
|---|---|---|---|---|
| | Issued Shares | Un-issued Shares | Total | |
| Common stock | 77,398 | 22,602 | 100,000 | |

(2) Major Shareholders

List all shareholders with a stake of five percent or greater, or the names of the top ten shareholders, specifying the number or shares and stake held by each shareholder on the list

April 28,2026; Unit: Share

| Shares / Name of Major Shareholders | Shareholding | Percentage |
|---|---|---|
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 13,198,277 | 17.05% |
| Hua Eng Wire & Cable Co., Ltd. | 7,704,384 | 9.95% |
| China Trust Commercial Bank is entrusted with safekeeping of the World Tree Global Fund SPC - Valhalla Fund SP. | 5,100,000 | 6.59% |
| Huang,Chun-Mu | 3,092,413 | 4.00% |
| Bank SinoPac is entrusted with safekeeping of the investment account of FAMPETUAL Investments Sdn Bhd. | 2,065,000 | 2.67% |
| Yanben Investment Co., Ltd. | 1,845,938 | 2.38% |
| Shi,Cui-E | 1,728,000 | 2.23% |
| Lee,Zheng-Hong | 1,659,000 | 2.14% |
| Shi,Jin-Xiu | 1,232,257 | 1.59% |
| Huang,Xiu-Qin | 1,202,696 | 1.55% |

(3) Dividend Policy and Implementation Status

(a)Dividend Policy:

The Company's dividend policy is based on current and future investment environment, capital needs, capital budget and changes in internal and external environment, as well as taking into account the interests of shareholders, balanced dividends and the long-term plans of the Company. The Company is in technology industry which is at growing stage.

(b)Implementation Status

On March 13, 2025, the Board of Directors resolved on the dividend distribution for 2024: a portion of the capital reserve of NT$61,076,590 will be

used to issue 6,107,659 new shares with a par value of NT$10 per share. According to the shareholders' holdings recorded in the shareholder list on the ex-rights base date, 100 shares will be allocated free of charge for every 1,000 shares. This is proposed for resolution at the Shareholders' Meeting on June 17, 2025.

(c) If a significant change in the dividend policy is expected, this should be stated:

There are no significant changes in the Company's dividend policy.

(4) Effect upon business performance and earnings per share of any stock dividend distribution proposed or adopted this year:

Not applicable as the Company has no public financial forecast information.

(5) Compensation of employees, directors, and supervisors

(a).Ratio or scope of compensation for employees, directors, and supervisors, as set forth in the Company's Article of Incorporation:

Article 28 of the Company's Article of Incorporation: The Company shall distribute the compensation of employees at a rate not less than 3% of the profitability of the current year and shall distribute the compensation of directors and supervisor at a rate not higher than 3% of the profitability of the current year. It shall make up the Company's accumulated losses if any. The Company shall deduct the benefits of the employees' compensation and the compensation of the directors and supervisors from the current year's pre-tax benefits.

(b).The estimated amount of compensation for employees, directors, and supervisors for the current period.

A.Since there was a pre-tax loss in 2025, employee remunerations and directors' remuneration will not be distributed.

B.The actual distribution amount is consistent with the estimated provision.

(c).Distribution of compensation approved by the board of directors:

A. Amount of employee compensation and director and supervisor remuneration distributed in cash or stock. If there is a difference from the estimated amount for the recognized expense, the difference, reason and treatment should be disclosed:

On March 11, 2026, the Board of Directors resolved not to pay remuneration to employees and directors.

B. The percentage of employee compensation distributed in the form of stocks to the total net profit after tax and total employee compensation for the current period: This is not the case.

(d). The distribution of compensation for employees, directors, and supervisors in the previous fiscal year:

Since no employee or director remuneration was paid in 2024, there is no difference between the actual distribution amount and the estimated amount.

(6) In accordance with the provisions of Article 28-2 “Regulations Governing Share Repurchase by Exchange-Listed and OTC-Listed Companies”. The implementation of the Company’s share repurchase is as follows: None.

2. Corporate Bonds: None.

3. Preferred Shares: None.

4. Global Depository Receipts (GDR): None.

5. Employee Stock Warrants:

(1)The employee stock option certificate of the Company that has no expired:

April 28, 2026

| Types of Employ Stock Option Certificates (Note 2) | 2019 Employ Stock Option Certificates | 2024 Employ Stock Option Certificates | |
|---|---|---|---|
| Date of Effective Registration from the Competent Authority | Effective date of declaration: August 12, 2019 Total shares:2,930,000 | Effective date of declaration: April 14,2023 Total shares:5,000,000 | |
| Issuing (handling) Date (Note 4) | November 5,2019 | April 9,2024 | March 14,2025 |
| Numbers of Units Issued | 2,930,000 | 3,500,000 | 1,500,000 |
| Number of units still available | 0 | 0 | 0 |
| Ratio of Subscribable Shares to Total Issued Shares | 3.79% | 4.53% | 1.94% |
| Subscription Period | 10years | 7years | 7years |
| Exercise Method (Note 3) | By issuing new shares | By issuing new shares | By issuing new shares |
| Period and Ratio in which Subscription is Restricted (%) | Maturity of 2 years: 20%<br>Maturity of 3 years: 20%<br>Maturity of 4 years: 20%<br>Maturity of 5 years: 20%<br>Maturity of 6 years: 20% | Maturity of 2 years: 20%<br>Maturity of 3 years: 20%<br>Maturity of 4 years: 20%<br>Maturity of 5 years: 20%<br>Maturity of 6 years: 20% | Maturity of 2 years: 20%<br>Maturity of 3 years: 20%<br>Maturity of 4 years: 20%<br>Maturity of 5 years: 20%<br>Maturity of 6 years: 20% |
| Number of Shares that have been Obtained through Exercise of Subscription Rights | 835,800 | 19,000 | - |
| NT$ Amount of the Shares Subscribed | 44,731,260 | 1,160,900 | - |
| Number of Shares that have not been Subscribed | 1,043,800 | 2,840,000 | 1,271,000 |
| Subscription Price per Share of the Unsubscribed Shares | NTD 46.9 | NTD 61.1 | NTD 56.9 |
| Ratio of the Number of Unsubscribed Shares to Total Issued Share | 1.35% | 3.67% | 1.64% |
| Effect on Shareholders' Equity | Little impact on the dilution of the original common stockholders' equity | Little impact on the dilution of the original common stockholders' equity | Little impact on the dilution of the original common stockholders' equity |

Note 1:The description of the status of employee stock warrants includes public placement and private placement of employee stock warrants. Public placement of employee stock warrants in the process of handling refers to effective by this meeting. Private placement of employee stock warrants in the process of handling refers to the approval made by the board meeting.

Note 2: The number of fields depends on the actual number of adjustments.

Note 3: It shall list the issued shares or new shares.

Note 4: If the issuing (handling) date is different, it shall be listed separately.

Note 5: If private placement, it shall be marked in a noticeable method.

(2) Names and subscription status of managerial officers who have obtained employee stock warrants and of employees who rank among the top ten in terms of the number of shares to which they have subscription rights through employee stock warrants acquired, cumulative to the date of publication of the annual report:

April 30, 2026

| | Title (Note 1) | Name | Number of Shares Subscribed | Ratio of Total Issued Shares to Number of Shares Subscribed (Note4) | Subscribed (Note2) | | | | Unsubscribed (Note 2) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | Number of Shares Subscribed | Price of Shares Subscribed (Note 5) | Amount of Shares Subscribed | Ratio of Total Issued Shares to Number of Shares Subscribed (Note4) | Number of Shares Subscribed | Price of Shares Subscribed (Note 6) | Amount of Shares Subscribed | Ratio of Total Issued Shares to Number of Shares Subscribed (Note4) |
| Managerial Officers | CEO | Huang, Chun-Mu | 586,000<br>858,000<br>153,000 | 0.76%<br>1.11%<br>0.20% | 94,200<br>0<br>0 | 56.7<br>55.1<br>53.6<br>46.9<br>(Note5) | 5,166,220<br>0<br>0 | 0.12%<br>0%<br>0% | 491,800<br>858,000<br>153,000 | 46.9<br>61.1<br>56.9 | 23,065,420<br>52,423,800<br>8,705,700 | 0.64%<br>1.11%<br>0.20% |
| | Deputy General Managers | Chen, Bi-Hsuan | | | | | | | | | | |
| | | Chen, Chieh-Shing | | | | | | | | | | |
| | | Yeh, Zhi-Long | | | | | | | | | | |
| | Corporate Governance Officer | Huang, Shan-Pu | | | | | | | | | | |
| | Finance Manager | Huang, Chein-Yu | | | | | | | | | | |
| | Accounting Manager | Chen, Ya-Wen | | | | | | | | | | |
| Employee (Note 3) | Employee | Huang, Li-Gang | 393,000<br>492,000<br>230,000 | 0.51%<br>0.64%<br>0.30% | 141,200<br>0<br>0 | 56.7<br>55.1<br>53.6<br>52.1<br>46.9<br>(Note5) | 7,586,840<br>0<br>0 | 0.18%<br>0%<br>0% | 251,800<br>497,000<br>230,000 | 46.9<br>61.1<br>56.9 | 11,809,420<br>30,366,700<br>13,087,000 | 0.33%<br>0.64%<br>0.30% |
| | | Lu,Cheng-Wei | | | | | | | | | | |
| | | Chen, Chi-Hao | | | | | | | | | | |
| | | Chang, Kuan-Lin | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Liu, Ting-Yu | | | | | | | | | | |
| | | Jiang,Hung-Wen | | | | | | | | | | |
| | | Huang, Ta-Yu | | | | | | | | | | |
| | | Chen,Chien-Hao | | | | | | | | | | |
| | | Lu, Kuan-Yu | | | | | | | | | | |
| | | Ho,Yi-Ting | | | | | | | | | | |

Note 1: Including managerial officers and employees (those who have been resigned or deceased shall be stated) shall disclose individual names and titles, but may be aggregated to disclose their acquisition and subscription status.

Note 2: The number of fields depends on the actual number of adjustments.

Note 3: Employees obtained employee stock warrants that rank among the top ten refers to the employees other than managerial officers.

Note 4: The total number of issued shares refers to the number of shares listed in the Ministry of Economic Affairs' change of registration information.

Note 5:The employee stock warrants that have been subscribed shall disclose the price at the time of the subscription.

(1) Employee stock options issued in 2019:

The initial exercise price was NT$56.7. The exercise price was adjusted to NT$55.1 effective July 28, 2022 due to cash dividend distribution, to NT$53.6 effective July 30, 2023 due to cash dividend distribution, to NT$52.1 effective August 5, 2024 due to cash dividend distribution, to NT$47.4 effective September 15, 2025 due to stock dividend distribution, and further adjusted to NT$46.9 effective January 16, 2026 due to cash capital increase.

(2) Employee stock options issued in 2024:

The initial exercise price was NT$70. The exercise price was adjusted to NT$68 effective August 5, 2024 due to cash dividend distribution, to NT$61.8 effective September 15, 2025 due to stock dividend distribution, and to NT$61.1 effective January 16, 2026 due to cash capital increase.

(3) Employee stock options issued in 2025:

The initial exercise price was NT$63.3. The exercise price was adjusted to NT$57.6 effective September 15, 2025 due to stock dividend distribution, and to NT$56.9 effective January 16, 2026 due to cash capital increase.

Note 6:The employee stock warrants that have not been subscribed shall disclose the adjustedsubscription price which is calculated according to the issuance method.

## 6. New Restricted Employee Shares: None

## 7. Issuance of New Shares for Acquisition or Exchange of other Companies' Shares: None

8. This refers to situations where prior to the implementation of the investment plan, previous issuances or private placements of securities have not yet been completed, or have been completed within the last three years but the planned returns have not yet materialized.

Implementation Status of the 2025 Cash Capital Increase Project:

(1) Total funds required for this project: NT$550,000,000.

(2) Source of funds: Issuance of 10,000 ordinary shares at a par value of NT$10 per share and an issue price of NT$50 per share, raising a total of NT$500,000,000.

(3) The project and its implementation schedule are as follows:

Unit: NT$1,000

| Project item | Scheduled completion date | Total funds required | Scheduled Fund Utilization Progress |
|---|---|---|---|
| | | | Q1 2026 |
| Repay bank loans. | Q1 2026 | 550,000 | 550,000 |
| Total | | 550,000 | 550,000 |

(4) Assessment of the progress of fund execution and expected benefits

The cash capital increase was completed in the first quarter of 2026, with a total amount of NT$550,000 raised. All funds have been used to repay bank loans, effectively saving on interest expenses, improving the financial structure, reducing dependence on banks, increasing cash flow flexibility, and mitigating operational risk. Based on the projected interest rate on the repaid bank loans, the Company expects to save NT$9,610,000 in interest expenses in 2026 and NT$10,483,000 annually from 2027 onwards. The actual benefits achieved are not significantly different from the projected benefits.

(5) Handling of Insufficient Funds Raised

Given that this cash capital increase was underwritten by the underwriters or subscribed by specific individuals, all the shares issued in this capital increase were sold. However, the actual issue price was adjusted due to market changes, resulting in insufficient funds raised. The shortfall was covered by the Company's own funds.

# IV. Operational Highlights

1. Business Activities

(1) Scopes of the business

(a). Main contents of operating business of the Company

The business contents as stated in the Company's Articles of Association are as follows:

1).F108031 Medical Equipment Wholesale Industry (limited to the Republic of China Industry Standard Classification 4565 Watches and Glasses Wholesale Industry, 4571 Pharmaceutical and Medical Supplies Wholesale Industry and 4649 other Machinery and Equipment Wholesale Industry) .

2).IG01010 Biotechnology Service Industry (limited to the Republic of China Industry Standard Classification 7210 Natural and Engineering Science Research Service Industry).

3).F113030 Precision Instrument Wholesale Industry (limited to the Republic of China Industry Standard Classification 4564 Household Photographic Equipment and Optical Products Wholesale Industry and 4649 other Machinery and Equipment Wholesale Industry).

4).CF01011 Medical Equipment Manufacturing Industry (limited to the Republic of China Industry Standard Classification 2760 Radiation and Electronic Medical Equipment Manufacturing, 3321 Glasses Manufacturing and 3329 other Medical Equipment and Supplies Manufacturing).

5).CC01101 Telecom Control RF Equipment Manufacturing (limited to the Republic of China Industry Standard Classification 2721 Telephone and Mobile Phone Manufacturing, 2729 Other Communication Equipment Manufacturing, 2751 Measurement, Navigation and Control Equipment Manufacturing and 2760 Radiation and Electronic Medical Equipment Manufacturing).

6).F401021 Telecom Control RF Equipment Input Industry (limited to the Republic of China Industry Standard Classification 4642 Electronic Equipment and its Components Wholesale Industry).

7).F399040 Retail business without a store (limited to the Republic of China's Industry Standard Classifications 4871 e-shopping and mail order industries, and other unclassified retailing without a store 4879; except for pharmacies, drug stores, chemist stores, or live animal retails).

8).F203010 food & beverage retailing (limited to the Republic of China Industry Standard Classification 4711 Food and Beverage-based General Merchandise Retailing and 4729 Other Food and Beverage, Tobacco

Products Retailing; Excluding Pharmacy, Drugstore or Retail Sale of Live Animals)

9). CB01010 Mechanical Equipment Manufacturing (limited to the Republic of China Industry Standard Classification 2531 Boiler, Metal Tank, and Pressure Containers Manufacturing, 2911 Metallurgical Machinery Manufacturing, 2919 Other Metal Processing Machinery and Equipment Manufacturing, 2921 Agricultural and Forestry Machinery and Equipment Manufacturing, 2922 Mining and Construction Machinery and Equipment Manufacturing, 2923 Food, Beverage, and Tobacco Production Machinery and Equipment Manufacturing, 2924 Textile, Clothing, and Leather Production Machinery and Equipment Manufacturing 2925 Woodworking Machinery and Equipment Manufacturing, 2926 Chemical Processing Machinery and Equipment Manufacturing, excluding equipment and parts of Isotope Separation Machine, 2927 Rubber and Plastic Processing Machinery and Equipment Manufacturing, 2929 Other Unclassified Special-Purpose Machinery and Equipment Manufacturing, excluding the Production of Firearms and Weapons, Gun Repairs, Ammunitions, and Fire Controls, 2931 Engine and Turbine Manufacturing, excluding Hydraulic Turbines and Water Wheels with a power exceeding 10,000 kW and Reaction Engines (Except Turbojets), and 2935 Conveying Machinery and Equipment Manufacturing)

10). CC01990 Other Electrical Engineering and Electronic Machinery Equipment Manufacturing (limited to the Republic of China Industry Standard Classification 2699 Other Unclassified Electronic Parts and Components Manufacturing, 2832 Wiring Equipment Manufacturing, 2929 Other Unclassified Special-Purpose Machinery and Equipment Manufacturing, and 2939 Other General-Purpose Machinery and Equipment Manufacturing, excluding the Production of Firearms and Weapons, Gun Repairs, Ammunitions, and Fire Control)

11). F113010 Wholesale of Machinery (limited to the Republic of China Industry Standard Classification 4643 Wholesale of Agricultural and Industrial Machinery and Equipment)

12). F113990 Wholesale of Othe Machinery and Tools (limited to the Republic of China Industry Standard Classification 4649 Wholesale of Other Machinery and Tool)

13). F119010 Wholesale of Electronic Materials (limited to the Republic of China Industry Standard Classification 4642 Wholesale of Electronic Equipment and Parts and Component)

14). E604010 Machinery Installation (limited to the Republic of China Industry Standard Classification 3400 Repair and Installation of Industrial Machinery and Equipment)

15).JE01010 Rental and Leasing (limited to the Republic of China Industry Standard Classification 7711 Rental and Leasing of Construction Machinery and Equipment, 7712 Rental and Leasing of Agricultural and Other Industrial Machinery and Equipment, 7713 Rental and Leasing of Office Machinery and Equipment, 7719 Rental and Leasing of Other Machinery and Equipment, excluding Rental and Leasing of Telecommunication Equipment, Medical Machinery and Equipment, and Electrical Equipment, 7729 Rental and Leasing of Other Transport Equipment, and 7731 Renting and Leasing of Sports and Recreational Goods)

(b).The sales proportion of the main products of the business

Unit: NT$ Thousand

| Item | 2025 | |
|---|---|---|
| | Amount | Percentage |
| Blood glucose meter | 224,849 | 12% |
| Blood glucose test strips | 1,128,815 | 61% |
| Others | 484,924 | 27% |
| Total | 1,838,588 | 100% |

(c). Existing main products (services)

Blood glucose meter.

Blood glucose test strips.

(d). New products (services) development projects

Development of a new generation of continuous blood glucose (CGM) monitoring system, AID (Automated Insulin Delivery,) and CGM with insulin pumps.

(2) Industry Overview

(a). Current Status and Development of the Industry

1). Current status and development of industry

The primary drivers of growth in the global medical device industry are changing demographics, increasing demand for chronic disease management, and continuous advancements in medical technology. As countries around the world gradually enter aging societies, the prevalence of diabetes, cardiovascular disease, and other chronic diseases is increasing. Consequently, healthcare needs are expanding from acute treatment to early diagnosis, disease prevention, long-term monitoring, and health management. The latest UN population data indicates that the proportion of the global population aged 65 and over is projected to rise from approximately 10% currently to nearly 16% by 2050. This demonstrates that

the aging trend will continue to drive demand for diagnostic, chronic disease monitoring, home care equipment, and smart healthcare solutions, representing a crucial supporting factor for the long-term development of the global medical device industry.

Meanwhile, the medical device industry has evolved towards integration with smart technology, data-driven approaches, and telemedicine in recent years. The introduction of artificial intelligence (AI), cloud computing, the Internet of Things (IoT), and smart sensing technologies into medical applications is transforming medical devices from single-function devices into integrated health management systems that combine physiological data collection, analysis, care tracking, and clinical decision support.

A research report by Fortune Business Insights estimates that the global medical device market will be worth approximately US$572.3 billion in 2025, growing to US$605 billion in 2026, and reaching approximately US$1.03 trillion in 2034, with a compound annual growth rate (CAGR) of approximately 6.9% from 2026 to 2034. Regionally, North America is the world's largest medical device market, accounting for nearly 40% of the market share, primarily benefiting from its well-developed healthcare infrastructure, comprehensive insurance reimbursement system, and advanced medical technologies. The Asia-Pacific market, driven by its large population, increased healthcare spending, economic growth, and rising demand for chronic disease care, is expected to be one of the most important growth regions in the global medical device market.

In terms of the development situation of Taiwan's medical device industry, limited by the size of the domestic market, major manufacturers in the line primarily export their products. Therefore, their revenue performance is closely related to international market booming, changes in product mix, and the global medical supply chain. According to data from the Ministry of Economic Affairs' Industrial Development Agency, the Industrial Technology Research Institute's International Business Laboratory (IEK), and ITIS's industry review, the total output value of Taiwan's medical device industry reached NT$153.5 billion in 2024, and is projected to reach approximately NT$156.8 billion in 2025. This indicates that the overall industry has maintained a stable development trend, supported by the recovery of conventional medical supplies and export demand.

Overall, the global medical device market has long-term growth potential, and the industry continues to move towards integration with smart technology, data-driven processes, continuous monitoring, and remote care. Taiwanese manufacturers already possess a strong industrial foundation in precision manufacturing, medical electronics, sensing technology, and ICT

integration. If they continue to focus on strengthening smart diagnostics, chronic disease monitoring, and international market presence, they will enhance their competitiveness in the global medical device supply chain and secure a significant position in the future.

2). Current Status and Development of the Blood Glucose Monitoring Device Market

Diabetes is now one of the world's leading chronic diseases. With an aging population, increasing prevalence of chronic diseases, and rising demand for blood glucose management, blood glucose monitoring devices have become an important tool for diabetes care and long-term health management. According to the 11$^{th}$ edition of the International Diabetes Federation's (IDF) “Diabetes Atlas”, approximately 589 million adults aged 20 to 79 worldwide had symptoms of diabetes in 2024, or about one in nine adults. This number is projected to increase to approximately 853 million by 2050, demonstrating the long-term growth potential of global demand for blood glucose monitoring.

Traditionally, blood glucose monitoring primarily uses finger-prick blood glucose monitoring (BGM), which have long been the basic tool for daily blood glucose management for diabetic patients due to their widespread use, ease of operation, and relatively low cost. However, BGM only provides a single blood glucose value, limiting the measurement frequency and making it difficult to fully represent the trends in daytime and nighttime blood glucose fluctuations. With advancements in sensing technology, data analysis, and digital healthcare applications, continuous glucose monitoring (CGM) systems now offer more real-time and continuous blood glucose trend information and are gradually replacing BGM as a key tool in diabetes management.

Regarding monitoring operation, CGM involves inserting a soft needle under the skin to continuously monitor the glucose concentration in the interstitial fluid and transmit the data to a mobile phone, receiver, or healthcare platform, allowing users and medical personnel to monitor blood glucose changes in real time. Compared to traditional blood glucose monitoring methods, CGM provides more complete blood glucose data and uses indicators such as Time in Range (TIR) as a reference for blood glucose management, demonstrating significant effectiveness in preventing the risks of hypoglycemia and hyperglycemia and improving blood glucose management.

Fortune Business Insights also pointed out that the global blood glucose monitoring system market size was approximately US$18.03 billion in 2025, and is projected to grow from US$18.93 billion in 2026 to US$32.59 billion in

2034, with a CAGR of approximately 7.0% during the forecast period. According to data from Grand View Research, the global CGM market size was approximately US$13.38 billion in 2025, with a CAGR of approximately 15.1% from 2026 to 2033, higher than the overall blood glucose monitoring system market growth rate. The faster growth rate of CGM reflects that the blood glucose monitoring industry is trending towards continuous monitoring, real-time data tracking, and digital health management, moving away from single-point measurement.

Looking at the domestic market, the “Taiwan Diabetes Yearbook 2024” noted that the number of people with type 2 diabetes in Taiwan has exceeded 2.4 million, and these patients constitute the majority of the overall diabetes population. This indicates that the scale of the diabetes population in Taiwan is considerable, and the demand for blood glucose monitoring products is expected to be stable and long-term. Currently, the blood glucose monitoring market in Taiwan is still dominated by BGM (Browser Glucose Monitoring). However, with the rapid development of sensing technology and digital healthcare, CGM (Continuous Glucose Monitoring) will eventually become the mainstream tool for diabetes management.

Since 2017, Taiwan's National Health Insurance system has included CGM (Continuous Glucose Medication) in the reimbursement coverage for some diabetes patients, primarily applicable to specific groups with type 1 diabetes. From November 2023, the National Health Insurance Administration further relaxed the relevant reimbursement conditions, including patients with gestational diabetes and those pregnant with type 2 diabetes who require insulin therapy, to strengthen blood glucose management during pregnancy. However, patients with type 2 diabetes, who currently constitute the largest group, are not yet fully covered by National Health Insurance. Most patients still need to pay out of pocket for CGM devices, resulting in a relatively limited adoption rate of CGM among the overall diabetes population in Taiwan.

Looking ahead, with the continued increase in the diabetic population, the development of precision medicine and digital health management, coupled with future health insurance reimbursement for CGM, and improved clinical physician recommendations and patient education to enhance awareness, the penetration rate of CGM in the domestic market will be boosted. Overall, the domestic blood glucose monitoring market has significant development potential and a strong opportunity to gradually shift from a BGM-based monitoring model towards integrated CGM and smart healthcare applications.

(b). Upstream, midstream and downstream industry linkages




The Company operates in the blood glucose monitoring equipment industry as follows: Upstream includes suppliers of biochemical reagents, sensing materials, plastic consumables, electronic components, precision molds, packaging materials, and related testing equipment. Midstream involves the research, development, manufacturing, assembly, testing, and quality management of products such as blood glucose meters, blood glucose test strips, and continuous blood glucose monitoring systems. Downstream encompasses domestic and international medical device importers and exporters, distributors, medical institutions, pharmacy chains, medical device stores, mass-market channels, and end-users.

Given that blood glucose monitoring products involve biochemical materials, electronic signal processing, precision manufacturing, and medical regulatory requirements, high standards are placed on the quality of raw materials, process stability, and product consistency. In particular, the quality of testing reagents, sensing materials, and key components directly affects product accuracy and safety. Thus, the quality management, delivery stability, and long-term partnerships with upstream suppliers are crucial foundations for product manufacturing and market supply.

The Company operates its blood glucose meters, blood glucose test strips, and related products under its own brand, and independently develops and maintains domestic and international sales channels. This allows for a high degree of integration and flexibility between R&D, manufacturing, and market development. Meanwhile, leveraging its quality system management, long-term distribution partnerships, and product portfolio advantages, the Company is able to continuously enhance its operational flexibility and market responsiveness across different national regulations, market demands, and distribution channels.

(c).Development trends of products

While traditional blood glucose measurement primarily uses blood glucose monitoring (BGM), which is cost-effective and widely available, it only provides a single blood glucose reading and is insufficient for a comprehensive understanding of blood glucose fluctuations, however. With diabetes care increasingly moving towards precision, continuity, and data-driven approaches, the application of blood glucose monitoring (CGM) can provide real-time data on blood glucose trends, assisting patients and healthcare professionals in managing diet, exercise, medication, and lifestyle. This represents a growing trend in blood glucose management.

1).CGM becomes an important tool in diabetes management.

Clinical studies have now confirmed that CGM effectively improves glycemic control and reduces the risk of complications, making it an important tool in diabetes management. Medical institutions and clinical guidelines also recommend that diabetic patients use CGM for glycemic monitoring, further highlighting its growing importance in the diabetes care system. Significantly, CGM has integrated insulin pumps, automated infusion systems, and digital management platforms, forming a data-driven glycemic management model that facilitates timely and accurate treatment decisions.

2).CGM application group is expanding.

Related trends show that the user base for CGM has gradually expanded from traditional type 1 and type 2 diabetes patients in recent years to include prediabetes, metabolic health management, and weight control. Furthermore, with the rapid global adoption of GLP-1 inhibitors, more and more users are using CGM to understand the relationship between diet, exercise, metabolic changes, and blood glucose levels. This has also extended the application of CGM to the fields of health management and preventive medicine, driving continued growth in the CGM market demand.

3).Integration of CGM system with AI technology

In terms of application systems, with the continuous development of data analysis technology and algorithms, the functionality of the applications accompanying CGM is also constantly being improved. In addition to providing real-time blood glucose level displays, this system can further analyze blood glucose trend changes and predict blood glucose fluctuations through algorithms, providing predictive alerts for high and low blood glucose levels and enabling corresponding measures. Some applications are incorporating artificial intelligence technology to analyze users' blood glucose data, dietary records, and lifestyles, providing dietary advice and health education information for effective blood glucose management.

In terms of technological integration, the blood glucose data collected by CGM can be connected to smart wearable devices, allowing users to view blood glucose information in real time on different devices, improving ease of use. In addition, related data can be shared with medical institutions through remote care platforms, enabling medical personnel to simultaneously monitor patients' blood glucose changes, thereby strengthening diabetes care management and remote health monitoring capabilities.

4). Increased competition in the CGM market

While CGM technology is maturing and market demand continues to grow, competition in the global CGM market is also intensifying. The international market is dominated by a few large medical device manufacturers, but more counterparts and related players are now vying for control of blood glucose monitoring technology and product development, expanding the market landscape accordingly. As the competitive environment continues to evolve, manufacturers are constantly improving product accuracy, such as extending sensor lifespan, optimizing product convenience, and reducing manufacturing costs. This has transformed the CGM market from a purely technological competition to a comprehensive competition encompassing technology, cost, and product integration capabilities.

(d) Product Competition

Abbott, Dexcom, and Medtronic, three major international medical device manufacturers, still dominate the global CGM (Continuous Glucose Monitoring) market for the time being. Statistics from Mordor Intelligence show that these three companies are projected to account for up to 98.28% of global CGM shipments by 2025, demonstrating the highly concentrated and competitive nature of the market. As the focus of the blood glucose monitoring industry gradually shifts towards CGM, the competitive emphasis has expanded from single product specifications to accuracy, wearing days,

data transmission stability, manufacturing costs, patent portfolio, regulatory approval, mass production capabilities, and integration with applications such as insulin pumps and automated infusion systems. In the future, manufacturers must consider product performance, quality systems, cost control, intellectual property rights, and market expansion capabilities to cope with fierce international competition.

(3)Technology and R&D Overview

1). Technology level and R&D status of operating business

BIONIME CORPORATION's R&D team, inspired by its own laboratory-grade YSI 2300 instrument, has developed unique embedded precious metal electrode-sensing test strips for in vitro diagnostic testing. Based on this platform, the Company has developed test strips for blood glucose, blood ketones, uric acid, and cholesterol. These differ from electrochemical blood glucose monitorings sold by other major international manufacturers, whose test strips are mostly manufactured using carbon printing and lamination methods. The Company's patented structural technology enables the implementation of nano-scale precious metal electrodes in disposable test strip structures with a low-cost structure and process, improving test strip accuracy.

Our company designs and develops fully automated test strip equipment in-house, and utilizes computer-aided testing of precious metal electrodes to enhance product reliability, thereby saving labor time and increasing production capacity. Our products have consistently received positive feedback from SCI journal articles and international conference papers, demonstrating the significant competitive advantage. Furthermore, their measurement accuracy and long-term stability, as demonstrated in relevant clinical studies published in international journals, have garnered high praise from international researchers, securing a certain position among our peers in the blood glucose meter and test strip industry.

The technological development of continuous glucose monitoring (CGM) products has shifted from an early focus on real-time glucose monitoring to a focus on extending wearability, improving measurement accuracy and signal stability, optimizing algorithms and alert logic, and enhancing integration with automated insulin delivery systems (AIDs) and digital health platforms. The recent continuous rollout of next-generation products by major international players is evidence of this. For example, Dexcom received the US FDA clearance for its G7 15-day system in 2025, and Medtronic received FDA approval for Simplera Sync with the MiniMed 780G system in 2025, respectively. Not to mention that FDA approved the

first OTC CGM in 2024, and Abbott also obtained clearance for two OTC CGM systems, Lingo and Libre Rio, in the same year. Overall, CGM product development has expanded from competition on single sensor hardware to comprehensive competition encompassing sensing technology, software algorithms, platform integration, regulatory compliance, and application scenarios.

The first challenge for manufacturers developing CGM products is avoiding patent infringement, especially given that the top three international CGM companies (Abbott, Dexcom, and Medtronic) have filed over 5,000 patents globally and continued to do so in recent years. Thanks to our company's continuous efforts in developing its own Continuous Glucose Monitoring (CGM) system, we have successfully obtained multiple patents. This not only breaks through the patent defenses of many competitors but also lays the foundation for a significant presence in the international market. In response to the continued development of blood glucose meter applications and blood glucose management platform technologies, our company has developed the CGM application that includes the integration of important observation indicators such as TIR and AGP. This allows users and healthcare professionals to quickly understand changes in blood glucose levels and use them as a reference for adjusting diet and medication.

BIONIME CORPORATION focuses on the research and development of related products and technology platforms, primarily in the areas of home medical devices, in-vitro diagnostics, smart medical devices, and digital health integration. Its recent annual R&D strategy emphasizes the following:

(1) Improving the accuracy, stability, convenience, and overall user experience of existing products.

(2) Strengthening hardware and software integration, data connectivity, and digital health application capabilities.

(3) Optimizing key materials, process conditions, and mass production technologies to improve yield and reduce costs.

(4) Developing new products that meet market demands to expand the product portfolio and target markets.

(5) Continuously advancing verification, certification, and design change processes in accordance with regulatory requirements and product lifecycle management.

2). R&D personnel and their academic qualifications/experience

Unit: People

| Year / Academic qualifications | 2023 | 2024 | 2025 |
|---|---|---|---|
| Ph. D. | 6 | 5 | 3 |
| Master | 54 | 53 | 55 |
| University | 101 | 83 | 111 |
| College | 7 | 3 | 13 |
| General and vocational high school | 9 | 3 | 6 |
| Total | 177 | 147 | 188 |

3). R&D expenses invested in the most recent five fiscal years

Unit: NT$ Thousand

| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| R&D Expense | 187,860 | 201,977 | 242,338 | 322,326 | 354,755 |
| Operating revenue | 1,849,924 | 2,210,589 | 1,755,567 | 1,933,746 | 1,838,588 |
| Percentage of operating revenue for the fiscal year (%) | 10.16 | 9.14 | 13.80 | 16.67 | 19.29 |

4). Technology or product development accomplishments

| Year of patent application | Technology or product development accomplishments |
|---|---|
| Jul-2020 | Obtained the US invention patent (US 12193809) for "Physiological Signal Sensor Device" in 2025 |
| Jul-2020 | Obtained the EU invention patent (EP 3771412) for "Physiological Signal Sensor Device" in 2025 |
| Jul-2020 | Obtained the US invention patent (US 12478328) for "Physiological Signal Sensor Device" in 2025 |
| Jul-2020 | Obtained the U.S. patent (US 12403260) for "Implantable Device for Biosensors and Implantation Method Thereof" in 2025. |
| Jul-2020 | Obtained the U.S. patent (US 12343172) for "Anti-misimplantation needle structure for implantable devices" in 2025. |
| Jul-2020 | Obtain the EU invention patent (EP 3771451) for "A container for carrying a sensor and a method for operating the container thereon" in 2025. |
| Aug-2020 | Obtained a China invention patent (CN 3104329) for "Micro-biosensor and its measurement method" in 2025 |
| Aug-2020 | Obtained the EU invention patent (EP 3771399) for "Physiological Signal Sensor Device" in 2025 |
| Aug-2020 | Obtained the U.S. patent (US 12427253) for "Implantable Device for Biosensors |

| Year of patent application | Technology or product development accomplishments |
|---|---|
| | and Implantation Method Thereof" in 2025. |
| Aug-2020 | Obtained the EU invention patent (EP 3771427) for "Needle implantation module and implantation device with needle implantation module" in 2025. |
| Aug-2020 | Obtained the U.S. patent (US 12364418) for "Method for Manufacturing an Implantable Micro Biosensor" in 2025. |
| Aug-2020 | Obtained a China invention patent (CN 112294324B) for "Method for reducing measurement interference in miniature biosensors" in 2025. |
| Aug-2020 | Obtained a China invention patent (CN 112294316) for "Physiological Signal Sensor Device" in 2025. |
| Aug-2020 | Obtained a China invention patent (CN 112294315) for "Physiological Signal Sensor Device" in 2025. |
| Dec-2020 | Obtained a China invention patent (CN 113131557) for "Charging device and charging method for physiological signal sensor" in 2025. |
| Dec-2020 | Obtained a China invention patent (CN 113131558) for "Charging device and charging method for physiological signal sensor" in 2025. |
| Dec-2020 | Obtained a China invention patent (CN 113131555) for "Charging device and charging method for physiological signal sensor" in 2025. |
| Dec-2020 | Obtained a China invention patent (CN 113131559) for "Charging device and charging method for physiological signal sensor" in 2025. |
| Jan-2021 | Obtained a Korean invention patent (KR10-2759259) for "Physiological Signal Sensor Device" in 2025 |
| Oct-2021 | Obtained a China invention patent (CN 114343624) for "Needle implantation structure and implantation device" in 2025. |
| Dec-2021 | Obtained the U.S. design patent (US D1063953) for "Graphical User Interface for Screen" in 2025. |
| Dec-2021 | Obtained the U.S. design patent (US D1063953) for "Graphical User Interface for Screen" in 2025. |
| Dec-2021 | Obtained the US design patent for a "medical monitoring device" (USD 1080880) in 2025. |
| Apr-2022 | Obtained the US design patent (US D1082013) for an "analyte measuring device" in 2025. |
| Jul-2022 | Obtained an Australian invention patent (AU 2022313382) for "Miniature Biosensor and Sensing Structure" in 2025. |
| Aug-2022 | Obtained the EU invention patent (EP 3851041) for "Moisture-proof component for preventing physiological signal sensor from getting wet" in 2025. |
| Sep-2022 | Obtained a Korean invention patent (KR 102883859) for "Patch, Patch System and Patch Application Method" in 2025. |
| Jan-2023 | Obtained the EU invention patent (EP 4186423) for "Implantable micro biosensor and its operation method" in 2025. |
| Feb-2023 | Obtained the US design patent (USD 1083112) for a "physiological signal monitoring patch" in 2025. |
| Feb-2023 | Obtained the US design patent (USD 1083109) for a "physiological signal monitoring patch" in 2025. |
| Feb-2023 | Obtained the US design patent (USD 1080881) for a "physiological signal |

| Year of patent application | Technology or product development accomplishments |
|---|---|
| | monitoring patch" in 2025. |
| Jul-2023 | Obtained the US invention patent (US 12490921) for "Physiological Signal Sensor Device" in 2025 |
| Aug-2023 | Obtained the US design patent (USD 1072732) for "part of the charging dock" in 2025. |
| Aug-2023 | Obtained the U.S. patent (US 102750872) for a "physiological signal monitoring system that can be installed quickly" in 2025. |
| Dec-2023 | Obtained the U.S. patent (US 12303669) for "Implantable Device for Biosensors and Implantation Method Thereof" in 2025. |
| Feb-2023 | Obtained a Canadian invention patent (CA 3230184) for a "physiological signal monitoring device" in 2025. |
| Mar-2023 | Obtained a Taiwan design patent (TW D238160) for "Graphical User Interface for Mobile Device Screens" in 2025. |
| Mar-2023 | Obtained a Taiwan design patent (TW D239449) for "Graphical User Interface for Mobile Device Screens" in 2025. |
| Mar-2023 | Obtained a Taiwan design patent (TW D239448) for "Graphical User Interface for Mobile Device Screens" in 2025. |
| Mar-2023 | Obtained a Taiwan design patent (TW D240550) for a "Carrying Case for Continuous Glucose Monitoring Systems" in 2025. |
| Apr-2024 | Obtained the Korean invention patent (KR 10-2769690) for "Physiological Signal Sensor Device" in 2025 |
| Nov-2024 | Obtained Taiwan invention patent (TW D239391) for "Physiological Signal Sensor Device" in 2025 |
| Nov-2024 | Obtained Taiwan invention patent (TW D239392) for "Physiological Signal Sensor Device" in 2025 |

5). The Company's intellectual property management plan and its implementation in the year.

A. Intellectual property management plan linked to operational objectives:

(i). To protect the results of advanced technology, the Company has formulated an "Intellectual Property Strategy" that combines operational objectives with research and development resources to create value through intellectual property rights, strengthen competitive advantages, and promote profits. To this end, the Company encourages employees to innovate and transform their efforts in patent applications into rewards, safeguard the Company's intellectual property rights, and promote the application and protection of proposals such as patents and trade secrets.

(ii). Implementation of the Company's 2025"Intellectual Property Management Plan": The Board of Directors completed the report on November 12, 2025, and implemented the protection and management of the Company's intellectual property rights. Thanks to the full recognition of the Board of Directors, the Company has been able to enhance its intellectual property strategy and protection to a more complete level.

B. Trade secret management and education and training:

(i). Completed "Trade Secret Awareness and Education Training" (external lawyer instruction) in 2025, with a total of 229 participants.

(ii). Completed "Information Security, Personal Data and Trade Secret Protection Awareness (DL)" in 2025, with a total of 40 participants.

(iii). Completed "Basic Training in Intellectual Property Management System" in 2025, with a total of 63 participants.

(iv). Completed "Trade Secret Awareness and Education Training" in 2025, with a total of 853 participants.

C. The Company’s TIPS Intellectual Property Management System was primarily implemented as follows in 2025:

1).In 2020, the Company updated the intellectual property management system to include trade secret management and confidential document protection mechanisms to strengthen the protection of its intellectual property. The Company also conducted trade secret protection education and training every year to enhance its awareness and cognition of intellectual property protection.

2). In 2020, in response to the Company's main CGM product, it adopted a strategy of giving equal weight to both internal and external aspects of CGM IP management. Internally, the Company emphasized self-patent development and IP management, while externally, the Company engaged legal professionals to ensure the freedom to operate (FTO) of the technology to avoid infringement risks.

- Internal IP Policy
  i. To respect the intellectual property rights of competitors and avoid infringing on others' patent rights.
  ii. To develop the Company's own technology and apply for its own patent protection.
  iii. To use the TIPS management system to manage IP risks in R&D and design and avoid infringement.

➢ External IP Policy

i. Collaborating with external law firms to enhance IP management skills.

ii. Collaborating with reputable law firms to ensure the quality of patent applications.

iii. Before the product is launched, an external law firm is commissioned to conduct an FTO (Freedom to Operate) analysis to ensure the free operation of the Company's products.

D. Intellectual property list and achievements:

(i). Patents: By the end of 2025, the Company has filed a total of 702 patent applications worldwide (covering major markets such as the United States, the European Union, China, Japan, South Korea, the United Kingdom, Germany, Canada, Australia and Taiwan), of which 475 have been approved. In addition, the number of CGM patent applications totaled 501, of which 317 were approved.

(ii). Trademark: As of December 31, 2025, CGM trademarks have been registered in 34 countries, including Taiwan, China, the European Union (including 27 member states), Japan, Saudi Arabia, Iran, Mexico, and India, United Kingdom, Malaysia.

(4) Long-term and short-term business development plans

1.Short-term business development plans of the Company

(1)Marketing strategies

①Taiwan Market

A.To promote the launch of CGM products and market education: In conjunction with the launch of our CGM products, we will continue to strengthen market promotion and medical professional education, including cooperation with medical institutions, professional forums and health education activities, to improve the market's understanding of the value of CGM technology and products and gradually increase product penetration.

B.To expand the user base for CGM products: In addition to existing diabetic patients, we will continue to explore application opportunities for CGM products in areas such as health management, exercise and metabolic health. Through blood glucose data analysis, we will help users understand the relationship between diet, exercise and blood glucose changes, and gradually expand the user base for our products.

C.To enhance brand marketing and market visibility: We will continue to invest in brand marketing resources, and enhance the market awareness of the "RIGHTEST" brand in the field of blood glucose monitoring through diversified media promotion and digital marketing, while deepening our relationships with existing customers and partners.

D.To deepen patient and community engagement: We will collaborate with patient groups, medical institutions, and health promotion organizations to promote health education and public welfare activities, thereby enhancing brand trust and user loyalty.

②International market

A. To strengthen international brand and digital marketing platform: We will integrate and optimize the content of corporate and brand official websites to establish a unified international brand image and digital marketing platform, thereby strengthening global market information dissemination and brand communication capabilities.

B. To expand global distribution and cooperation channels: We will continue to deepen our existing international distribution system and actively explore emerging markets to enhance the visibility and sales opportunities of our products in major regional markets.

C. To participate in international exhibitions and professional exchanges: We will enhance the brand's exposure in the global market and expand our potential partners and customers by participating in international medical device exhibitions and professional conferences.

(2)Research and development (R&D) aspect

We will continue to invest in the research and development of continuous glucose monitoring system products and technologies. Short-term R&D mainly includes improving sensor performance, optimizing signal algorithms, improving wearability, enhancing data display and warning functions, and verifying and establishing technical documentation in accordance with regulatory requirements, as follows:

A. Process optimizations will be implemented to improve sensor accuracy during the initial implantation phase.

B. Algorithms will be calibrated and optimized for different user scenarios to enhance post-calibration accuracy.

C. Disposable transmitters will be introduced, and the pairing process will be simplified for a more optimized user experience.

(3) Production aspect

A. Introduce automation equipment and MES system to save costs and increase production efficiency.

B. Maintain close partnership with domestic and foreign suppliers to ensure product delivery.

C. Strictly implement the quality policy of designing and manufacturing world-class quality and high accuracy glucose testers and strips at low cost to achieve the quality goal of 99.9% product yield.

D. Actively adopt advanced manufacturing process, expand R&D for highly accurate biotechnology detecting instruments, and expand market share with its technology and cost advantages

(4) Operational and financial aspects

A. Introduce KPI and OKR management systems, clearly define the objectives and more active long-term development goals of each department. Through organizational cooperation and competition, it further enhances the overall execution of the Company and strengthens the operating efficiency and effectiveness.

B. Increase capital by cash at the appropriate time and make proper use of financial leverage to issue bonds or apply for bank loans based on the capital requirements of the Company's business development and R&D technology improvement without affecting the profitability.

2.Long-term business development plans

(1) Sales and marketing aspects

①Taiwan Market

A. To deepen the professional positioning of the "RIGHTEST" brand: With blood glucose monitoring technology as the core, we will continue to strengthen the professional image of the "RIGHTEST" brand in the field of diabetes management, and build long-term brand value through product innovation, digital services and customer relationship management.

B. To develop an integrated blood glucose management platform: We will continue to develop an integrated blood glucose management platform, mainly combining BGM, CGM and related applications to provide a complete range of services from personal blood glucose monitoring and care from family and friends to remote medical care, thereby forming a user-centric blood glucose management ecosystem.

C. To deepen the cooperation model in medical care: We will establish long-term cooperative relationships with medical institutions and care

units to jointly promote the application of CGM in clinical care and chronic disease management, and enhance the overall value of blood glucose management services.

②International market

A. Expanding the global market through the CDMO business model: We will establish strategic partnerships with international medical device manufacturers through the Contract Development and Manufacturing Organization (CDMO) model, thereby expanding product applications and market coverage.

B. Promoting the integration of CGM with related medical devices: Due to the continuous development of diabetes treatment technologies, the integration of CGM with insulin pumps to form automated insulin delivery systems (AIDs) has become a popular trend in the industry. In view of this, the Company will continue to monitor related technological developments and assess the feasibility of integrating CGM with medical devices to improve the convenience of blood glucose management and expand clinical applications.

C. Expanding diversified international sales channels: We will continue to expand our global sales channels, including our distribution network and e-commerce platforms, with a particular focus on increasing product market coverage in major markets such as the Americas, Europe, and Asia.

(2) R&D aspect

The Company plans to develop technologies related to long-lasting sensing, signal quality improvement, hardware and software integration, and the expansion of digital health applications in order to establish long-term technological barriers and a foundation for growth. The main research and development priorities are as follows:

A. Capable of predicting the risk of hypoglycemia and hyperglycemia 20 to 30 minutes or longer in advance and providing actionable countermeasures.

B. Utilizing AI technology to link blood glucose fluctuations with "meals, exercise, sleep, and lifestyle" to create event attribution and behavioral recommendations.

C. Actively cultivating R&D talent to build a strong R&D team, while ensuring knowledge sharing and experience transfer to improve R&D efficiency and effectiveness.

(3). Production aspect:

A. Establish a lean supply chain and operating procedures in response to the changes in the medium and long-term market structure and corporate strategy.

B. More than 90% of the production line is automated to improve efficiency, product quality and profit.

(4). Operational and financial aspects:

A. Actively develop globally, develop international talents, and continue to expand the scale of operations to become a world-class company.

B. To secure stable global cost of capital as financial support for the Company's rapid business expansion, thereby reducing operating costs and mitigating operational risks.

2. Market and Sales Overview

(1)Market analysis

(a). Sales regions of main products

Unit: NT$ Thousand

| Year / Region | 2024 | | 2025 | |
|---|---|---|---|---|
| | Amount | Percentage (%) | Amount | Percentage (%) |
| Europe | 431,235 | 23% | 388,279 | 21% |
| Asia | 566,217 | 29% | 577,894 | 31% |
| America | 179,688 | 9% | 146,111 | 8% |
| Others | 756,606 | 39% | 726,304 | 40% |
| Total | 1,933,746 | 100% | 1,838,588 | 100% |

(b). Product market share

Our blood glucose meters and test strips are now sold in over 100 countries worldwide, and we hold approximately 15% market share in the Taiwan blood glucose monitoring market. Over the years, we have established our own brand "RIGHTEST" and a global distribution network, accumulating a solid market foundation in the blood glucose monitoring market.

Following the certification of its CGM products, the Company will expand into the CGM market based on its existing BGM distribution system. It will also collaborate with companies that have sales channels for blood glucose monitoring products but lack CGM R&D capabilities, jointly expanding the market through a CDMO (Contract Development and Manufacturing Organization) model. By adopting diversified business strategies including distribution, brand cooperation, and CDMO mentioned above, the Company aims to gradually expand its CGM market presence and increase its global market share in blood glucose monitoring products in the future.

(c). The future supply and demand situation and growth of the market

A research report by Mordor Intelligence indicates that the global CGM market was valued at approximately US$13.13 billion in 2025 and is projected to exceed US$24 billion by 2030, with a compound annual growth rate (CAGR) of approximately 12.9% from 2025 to 2030. The United States remains the world's largest CGM market, with a market size of approximately US$5.6 billion in 2024, and is expected to continue its rapid growth, reaching US$11.6 billion by 2030.

The use of CGM in diabetes management has been increasing in recent years, gradually expanding from being mainly used for patients with type 1 diabetes to patients with type 2 diabetes and those on insulin therapy, leading to a continuous increase in the importance of CGM in clinical care. Furthermore, with increased awareness of health management and metabolic health, some users are beginning to use CGM to observe the correlation between diet, exercise, lifestyle, and blood glucose changes, which is also a significant reason for the growth of CGM applications in the health monitoring field. On the other hand, GLP-1 drugs are experiencing rapid growth in the weight management and diabetes treatment markets. This is because users use CGM to observe blood glucose responses and understand metabolic changes, creating a certain complementarity between CGM and metabolic health management. With the continued

increase in demand for related treatments and health management, the future prospects of the CGM market are optimistic.

(d). Competitive Niches

① Possesses a complete blood glucose monitoring product line and technology integration capabilities

Our core advantage in BGM is achieved through years of accumulated high-precision test strip platform, ranking among the top in international commercially available blood glucose meters in terms of accuracy, with ±10% accuracy being a benchmark. The test strips feature embedded gold electrodes, a short-path transmission design, and automatic code correction; these design features directly contribute to accuracy, consistency, and ease of use. Our company possesses integrated technical capabilities from R&D to production, with a product portfolio covering both BGM and CGM to meet the blood glucose management needs in different scenarios. In particular, our end-to-end integrated manufacturing capabilities effectively reduce errors at each stage, further improving the accuracy of blood glucose testing.

It is worth mentioning that our company' CGM has an innovative sensor structure, a self-manufacturing rate of over 99%, technology spanning more than 80 fields, and more than 480 global patents. The manufacturing process of CGM involves more than 200 steps, with the core sensor involving more than 100 biochemical processes. It is equipped with 139 self-developed automated machines and 126 AOI inspection machines, and uses CIM/MES for real-time monitoring to achieve sensor yield, quality consistency and cost optimization. Currently, clinical trials in Taiwan and Europe meet the requirements of the US FDA's iCGM special control regulations. If we successfully obtain medical device approval in Europe this year, we will be able to enter the major CGM markets in Europe and other countries. Meanwhile, our company will continuously improve quality, yield, processes, and costs, and integrate the supply chain to enhance the technology of our partners and the company's overall competitiveness in the market.

② A digital ecosystem centered on diabetes management.

The Company has established its own IoT technology team, with a dedicated IoT department actively developing a digital health platform. It is responsible for connecting various products, including blood glucose monitoring instruments for home or professional use, software application platforms (such as BGM App, CGM App, Partner App, and blood glucose management systems), to establish a health management

ecosystem centered on diabetic patients. This allows blood glucose monitoring to go beyond simply measuring data and provide comprehensive blood glucose management services.

③ International market channels and brand foundation

The Company markets its products under the "RIGHTEST" brand in over 100 countries worldwide and has established a complete international distribution system. Through collaboration with global distribution partners, brand image management and promotion at international exhibitions, and global market cooperation, the company aims to rapidly expand into various regional markets and enhance brand visibility.

(e). Development outlook - favorable and unfavorable factors

| Item | Favorable factors |
|---|---|
| Global population aging and increased awareness of disease prevention | As the global population ages and the prevalence of chronic diseases continues to rise, the number of patients with diabetes, cardiovascular disease, and other metabolic-related diseases is increasing year by year, leading to a surge in demand for blood glucose monitoring and chronic disease management devices. Furthermore, in recent years, healthcare systems worldwide have placed increasing emphasis on the long-term management and preventative medicine of chronic diseases, resulting in a growing application of blood glucose monitoring devices in clinical care and home health management. |
| Government policy incentives and promotion | Given the increasing evidence from clinical research and the relaxation of medical insurance policies in various countries, the use of CGM in diabetes management is gradually increasing, and the coverage has expanded from type 1 diabetes patients to type 2 diabetes patients, resulting in a significant expansion of the CGM market demand. |
| The Development of Smart Healthcare Technology | With the widespread increase in health management awareness and the advancement of data technology, blood glucose monitoring devices have gradually transformed from simple measurement tools into important platforms integrating health data and care services. This is primarily achieved through the integration of mobile applications, remote care platforms, and health management systems, allowing blood glucose monitoring data to provide patients, medical personnel, and caregivers with more timely and comprehensive health information, thus improving the efficiency of blood glucose management. Furthermore, thanks to the rapid development of the metabolic health and weight management market in recent years, the demand for blood glucose monitoring products has become increasingly strong, laying the foundation for future growth in the blood glucose monitoring industry. |

| Item | Unfavorable factors | Countermeasures |
| --- | --- | --- |
| Market competitors are mostly large international companies, requiring significant investment in research and development. | The global CGM market is currently dominated by large international medical device manufacturers. As CGM technology matures, many companies are investing heavily in the research and development of related monitoring products, further intensifying and diversifying market competition. Driven by international manufacturers with advantages in technology, brand, and market size, competition regarding product performance, price, and market distribution is expected to intensify in the future. | Faced with this market environment, the Company not only continues to invest in technological research and development and product innovation, but also enhances product quality and cost competitiveness through patent layout, process optimization and automated production, so as to strengthen the Company's competitive advantage in the international market and remain invincible. |
| The high dependence on exports makes the Company vulnerable to fluctuations in the overall business environment and exchange rates. | As the Company's products are sold globally, with its main revenue source relying on exports, its overall operating performance is susceptible to fluctuations in international demand and exchange rates. Uncertainties in the global economic environment, such as geopolitical tensions, climate change, and extreme weather events, will affect supply chain stability and market demand, making the company more vulnerable to challenges from external environmental volatility. | We will actively adopt a variety of countermeasures, including strengthening the exchange rate hedging awareness of our financial staff and collaborating with financial institutions to analyze exchange rate trends as a reference for hedging operations. Simultaneously, we will strive to use sales revenue in the same currency to cover procurement expenditures, achieving an automatic hedging effect. In terms of operational strategy, the Company will continue to promote innovation and R&D and cost optimization, and strengthen brand management and regulatory compliance to reduce the negative impact of external uncertainties on operations. Furthermore, we will strengthen our long-term competitiveness in the international market through sustainable operations and ESG strategies. |

| Item | Unfavorable factors | Countermeasures |
| --- | --- | --- |
| Medical device regulations are stringent and clinical validation costs are high. | Because medical device products must meet the stringent regulatory reviews and clinical validation requirements of various countries, the related market launch process typically involves lengthy and costly investments, posing a significant challenge to companies in product development and market promotion. To address the varying regulatory requirements of different countries, the company not only continuously strengthens its quality management system and regulatory compliance capabilities but also implements high-standard quality control during product research and development and manufacturing. Furthermore, it accumulates relevant data through clinical trials and product validation to ensure that products meet the market launch requirements of various countries. | The Company will continuously monitor global medical device regulatory trends, mitigate regulatory risks and accelerate product launches through a comprehensive regulatory strategy and quality management mechanism. |
| The requirements for software verification and cybersecurity in medical device regulations continue to increase. | Given that CGM are connected medical devices comprising sensors, transmitters, applications, and cloud servers, the US FDA, in its updated medical device cybersecurity guidance in February 2026, requires manufacturers to submit information related to cybersecurity design, labeling, and documentation before market launch, emphasizing the need for marketed devices to be sufficiently resilient to cyber threats. For CGM, this means that regulatory costs will significantly increase if the product is to be used for data sharing, remote care, algorithm updates, or AI insights. | The design and development documentation should incorporate secure-by-design, SBOM, threat modeling, OTA update mechanisms, logs, and post-market monitoring into the product architecture from the very beginning. |

| Item | Unfavorable factors | Countermeasures |
| --- | --- | --- |
| High patent and litigation risks | CGM technology spans sensing chemistry, electrode structure, packaging, adhesion, communication, algorithms, and data platforms, and boasts a high patent density. If found to have infringed on a third party's intellectual property rights, businesses may face substantial damages, licensing fees, injunctions, and even disruptions to manufacturing and sales. Conversely, if a business's own patent protection is insufficient, it may also be overtaken and bypassed by competitors. | Our company has long been engaged in patent strategy. This involves conducting FTO (freedom to operate) searches, design avoidance, core patent strategy, and cross-domain patent portfolios in the early stages of R&D, rather than waiting until the product is about to be launched. |

(2) Important use and production process of main products

(a). Important use of main products

| Name of product | Important uses and functions |
|---|---|
| Blood glucose meter | The main function of the Company's blood glucose meter is to measure the glucose concentration in the blood (referred to as blood glucose concentration) of users quickly and accurately. It provides a complete information to the users and the medical personnel, and further control the blood glucose changes in the body by measuring the level of blood glucose. |
| Blood glucose test strips | In addition to the blood glucose meter, it needs to pair with the blood glucose test strip in order it can measure the blood glucose concentration normally and correctly. Blood glucose test strip looks like a thin piece, and usually has an enzyme in biochemical sensor, such as glucose oxidase (GOD) in the blood area.<br>This type of enzyme substance plays an important role in the blood glucose test strip by generating a specific biochemical reaction with blood glucose, and further generating a current that can be measured by the blood glucose meter, and thereby converting to the concentration value that can be interpreted by user. |
| Continuous Glucose Monitoring System | The Continuous Glucose Monitoring System (CGM) can continuously monitor the user's interstitial fluid glucose concentration, helping the user observe glucose trends and potentially replacing fingertip blood sampling for blood glucose measurement. It also assists in the detection of hyperglycemia and hypoglycemia events and serves as a reference for acute and long-term treatment. When judging CGM results, it should be based on both the trend of glucose changes and continuous readings. |

(b). Production process

A.Blood glucose meter

The blood glucose meter is an electronic product, which is divided into the following major production processes:

1)PCBA processing process

Includes IC version processing and LCD screen processing.

2)Pre-assembly process

Includes the assembly procedures of components like PCBA, upper and lower cover modules, LCD, button, etc., and the calibration check of the tester.

3)Functional verification

Includes warm-up verification, current measurement verification, actual verification and reliability verification.

4)Final-assembly process

Includes serial number printing, appearance parts assembly, appearance wiping, date and unit setting adjustment, test strip insertion and removal test, etc.

B. Blood glucose test strips

The manufacturing process of blood glucose test strip needs to cover the following three major production processes:

1) Manufacturing process of overlay

Includes raw material processing, rubberize, printing, and exterior punching.

2) Manufacturing process of precious metal electrodes

Includes exterior stamping and surface treatment.

3) Manufacturing process of plastic film

Includes exterior stamping and plastic injection.

4) Test piece assembly production process

Includes electrode assembly, reagent coating, and placement of overlay.

5) Test piece stability quality control

Includes setting test piece formula, measurement precision, and balance stability.

C. Continuous Glucose Monitoring System

The main electrode modules for continuous blood glucose monitoring are:

1). Die manufacturing process
2). Electrode manufacturing process
3). Coating process
4). Test strips packaging process

Implant manufacturing process

1). Cleaning/laser engraving process
2). Implant assembly
3). Sterilization packaging

(3)Supply situation of main raw materials

| Name of raw material | Supplier | Supply situation |
|---|---|---|
| Gold salt | Company F | Good |

(4) Details of suppliers (customers) accounted for more than 10% of total procurement (sales) amount in either of the most recent two fiscal years

(a) List of suppliers for procurement in the most recent two fiscal years

Unit: NT$ Thousand

| Year | 2024 | | | | 2025 | | | | Current fiscal year up to previous quarter (Note 2) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Item | Name | Amount | Percentage of annual net purchase (%) | Relationship with the issuer | Name | Amount | Percentage of annual net purchase (%) | Relationship with the issuer | Name | Amount | Percentage of annual net purchase (%) | Relationship with the issuer |
| 1 | Company F | 83,994 | 12.74 | - | Company F | 98,858 | 17.29 | - | Company F | 30,359 | 17.89 | - |
| 2 | Others | 575,475 | 87.26 | - | Others | 472,937 | 82.71 | - | Others | 139,326 | 82.11 | - |
| | Net purchase | 659,469 | 100 | | Net purchase | 571,795 | 100 | | Net purchase | 169,685 | 100 | |

Note 1: Details of suppliers accounted for more than 10% of total procurement amount in the most recent two fiscal years, where the company is prohibited by contract from revealing the name of a supplier, or where a trading counterpart is an individual person who is not a related party, it may use a code in place of the actual name.

Note 2: As of the date of publication of the annual report, if there is any financial data for the most recent period audited and attested or reviewed by a CPA for a company whose stock is listed on the stock exchange or traded over the counter, it shall also be disclosed therewith.

Description: Company F mainly supplies gold salts for test strip electrodes. Because the test strips are the main products sold by the company, Company F is the main supplier of the company's purchases.

(b) List of customers for sales in the most recent two fiscal years

Unit: NT$ Thousand

| Year | 2024 | | | | 2025 | | | | Current fiscal year up to previous quarter (Note 2) | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Item | Name | Amount | Percentage of annual net sales (%) | Relationship with the issuer | Name | Amount | Percentage of annual net sales (%) | Relationship with the issuer | Name | Amount | Percentage of annual net sales (%) | Relationship with the issuer |
| 1 | Company E | 550,945 | 28.49 | - | Company E | 530,604 | 22.24 | - | Company E | 110,870 | 27.36 | - |
| 2 | Others | 1,382,801 | 71.51 | - | Others | 1,307,984 | 77.76 | - | Others | 294,394 | 72.64 | - |
| | Net sales | 1,933,746 | 100 | | Net sales | 1,838,588 | 100 | | Net sales | 405,264 | 100 | |

Note 1: Details of customers accounted for more than 10% of total sales amount in the most recent two fiscal years, where the company is prohibited by contract from revealing the name of a customer, or where a trading counterpart is an individual person who is not a related party, it may use a code in place of the actual name.

Note 2: As of the date of publication of the annual report, if there is any financial data for the most recent period audited and attested or reviewed by a CPA for a company whose stock is listed on the stock exchange or traded over the counter, it shall also be disclosed therewith.

Description: Company E is a North African customer of our company. After establishing a local manufacturing facility, the customer has achieved stable product distribution.

3.The number of employees employed for the most recent two fiscal years, and during the current fiscal year up to the date of publication of the annual report

| Year | | 2024 | 2025 | 2026/3/31 |
|---|---|---|---|---|
| Number of Employee | R&D personnel | 147 | 188 | 183 |
| | Management and sales personnel | 219 | 216 | 215 |
| | Manufacturing personnel | 754 | 648 | 628 |
| | Total | 1,120 | 1,052 | 1,026 |
| Average age | | 35.8 | 37.0 | 37.3 |
| Average years of service | | 5.8 | 6.6 | 6.9 |
| Academic distribution percentage | Ph. D. | 0.5% | 0.4% | 0.4% |
| | Master | 13.1% | 13.5% | 14.0% |
| | College | 47.3% | 49.2% | 48.2% |
| | High School | 36.3% | 34.2% | 34.5% |
| | Below high school | 2.8% | 2.7% | 2.8% |

Note: The number of people does not include temporary personnel.

4. Information on environmental protection expenditures

The total amount of losses and penalties due to environmental pollution in the past one years and as of the date of publishing the Annual Report(including compensation and environmental protection audit results that violate environmental protection laws and regulations, it shall list the date of punishment, the code of the punishment, the violation provision of the laws and regulations, the content of the provisions, and the content of the punishment), actions to be taken in the future and the possible expenditures: None.

5. Labor relations

(1). All employee benefits, continuing education, training, retirement systems, and the status of their implementation, as well as the status of agreements between labor and management, and all measures aimed at preserving the rights and interests of employees:

(a) Employee welfare measures: Talents are the most important assets of the Company. We carefully cultivate, treasure and care for each and every colleague in order they can achieve work-life balance. The Company also adheres to the principle of profit sharing and performance-oriented to develop compensation policies in order to provide a comprehensive welfare system and measures.

A. Labor insurance and National Health Insurance.

B. Annual festival bonus, quarterly performance bonus.

C. Employee stock ownership plan, Employee stock option certificates.

D. Regularly organize employee travel and various cultural and recreational and festival activities.

E. Festival gift vouchers, wedding gifts, maternity gifts, condolence gifts, birthday celebrations and birthday vouchers.

F. Employee overtime meal allowances.

(b) Employee continuing education, training:

The Company is committed to a corporate culture of integrity and pursuit of excellence, and aims for sustainable operation and maintaining market competitiveness. To this end, it provides every employee with a comprehensive education and training program, including a 90-day training program for new employees, functional professional training for each unit, and regular cross-departmental general knowledge courses to improve employee work efficiency and performance. In addition, it also provides diverse learning channels, such as encouraging employees to make good use of digital learning platforms, participate in external training courses, and obtain professional certifications, thereby transforming new technologies and regulatory knowledge into work effectiveness. Thus, the Company spares no effort in cultivating cross-disciplinary talents with a sustainable mindset.

In 2025, a total of 18,344 hours of employee training were implemented, averaging 19 hours per person. Of this, NT$293,571 was invested in external training. Regarding the implementation of the internal training program, over 180 colleagues participated in teaching throughout the year, passing on core technologies and knowledge. This not only transforms colleagues' expertise into sustainable training resources but also helps them develop a second specialty and expand their career possibilities. We firmly believe that the growth of our colleagues is the driving force behind the Company's progress, achieving a win-win situation for both corporate development and personal growth.

① General training: Our company values all aspects of our employees' work, including workplace safety drills, creating a friendly workplace, and identifying and avoiding illegal infringements. We provide comprehensive education and training on these general concepts and guidelines to promote and create a safe, friendly, and compliant employment environment.

② New employee orientation training: After reporting to the Company, each new employee is assigned a mentor to guide and lead them. This not only helps them become familiar with the work environment but also strengthens their identification with and understanding of the Company, helping them quickly adapt to company life and integrate into the corporate culture. Each department also plans basic training courses for new employees to assist them in learning relevant

work knowledge.

③ Professional skills training: In terms of cultivating professional talents, each unit regularly holds professional skills training courses, and also encourages colleagues to participate in external learning and implements a post-training mechanism. This is to connect with the latest domestic and international industry trends, thus achieving the goals of knowledge sharing and improving job skills.

④ Management skills training: Our company plans management skills training tailored to the specific needs of managers at all levels, strengthening their leadership and management abilities and introducing effective management tools. The aim is to help managers optimize team management effectiveness, enhance team cohesion, and become more competitive.

(c). Retirement system and its implementation status:

Since the establishment of the Company, the “Supervisory Committee of Labor Pension” has been established for safeguarding the rights and interests of colleagues, taking care of the retirement life of colleagues and promoting labor relations. In addition, the Company makes a monthly pension to employees’ individual pension fund accounts at the Bureau of Labor Insurance in order to provide greater protection to the retirement life of colleagues according to the Labor Pension Statutes since July 1994.

| Pension system | Old system | New system |
|---|---|---|
| Applicable source of law | Labor Standards Act | Labor Pension Act |
| How to contribute | Appropriate 2% of the total monthly salary of the employees, and deposit in the special account of Bank of Taiwan (formerly the Central Trust Bureau) in the name of the company | According to the employee's insurance level, 6% will be allocated to the individual account of the Labor Insurance Bureau |
| Contribution | Cumulative amount of labor retirement reserve NT$ 3,208 thousand | Contribution of NT$26,752 thousand in 2025 |

(d). The status of agreements between labor and management:

① The establishment of the Employees' Welfare Committee: In addition to improve employee benefits, it also acts as an important channel for colleagues to participate in the development of the Company’s employee welfare policy. Since its establishment, colleagues have been willing to dedicate themselves to the full

play of their functions, and create a win-win situation for both colleagues and the Company.

② The convening of labor-management meetings: This is an important platform for discussion and decision-making between labor and management. All important changes in company policies or negotiations on labor conditions (such as the implementation of the 8-week variable working hours or the adjustment of shift times) need to be fully discussed through this meeting and implemented only after reaching a consensus between the representatives of both parties.

③Regularly monthly meeting: As an important channel for the Company to make public announcement for various information, as well as an important channel for colleagues to express their opinions and two-way communication.

④Mailbox for exchange of views: It is a complaint channel for colleagues which managed by dedicated personnel. It encourages colleagues to express various suggestions, which will be used as a reference for the continuous improvement of corporate policies.

(e). Measures to protect employee rights:

With different categories of surveys, the Company conducts regular employee satisfaction surveys, and analyzes and responds to the survey results. For example, when new employees have been on the job for three months, they are required to fill out a care questionnaire in accordance with company regulations to understand their adaptability and feedback issues. The Company also aims to create a friendly workplace and implements relevant improvement plans.

(2). List any loss sustained(including the incident against the Labor Standards Act according to the labor inspection results, and it shall list the date of punishment, the code of the punishment, the violation provision of the laws and regulations, the content of the provisions, and the content of the punishment) as a result of labor disputes in the past two years and as of the Annual Report publication date, disclose the estimated amount of loss incurred to date or likely to be incurred in the future, and indicate mitigation measures being undertaken or to be taken:

Since its inception, our company has always prioritized employee welfare and rights, providing diverse channels for two-way communication with employees. As of the date of publication of this annual report for 2025, only one dispute arose regarding labor insurance, which was resolved through mediation. Another civil lawsuit concerning an employee transfer dispute is currently pending a court ruling. None of these cases constitute significant labor disputes and have had a substantial impact on the Company's operations. We will continue to strengthen our labor-management communication mechanisms and risk management to establish sustainable and healthy labor relations.

6.Cybersecurity management：

(1) Describe the cybersecurity and risk management structure, cybersecurity policies, concrete management plans, and resources invested in cybersecurity managemen:

(a). Information Security and Personal Data Protection Risk Management Framework

1). The Company established a cross-departmental information security committee, with the general manager as the general convener and the deputy general manager as the management representative and serving as the chief information security officer and chief personal data protection officer at the same time.

2). Information security management objectives and policies, as well as personal data management policies are established and issued. These policies are also reviewed and revised regularly.

3). Management review meetings are held annually to assess the implementation of the information security management system and the personal data management system.

4). Our company complies with the "Personal Data Protection Act" and has established a "Personal Data Management Policy" and a "Personal Data Security Maintenance Plan." We implement rigorous personal data privacy security management and protection measures. At the same time, we have a sound internal data governance system and implement relevant access control and verification mechanisms to ensure that data is fully protected during access and sharing. This applies to our employees, subsidiaries, customers, and suppliers.

(b). Information security and personal data protection control measures

1). Information assets and personal data lists are inventoried regularly, and risk management measures are conducted based on information security and personal data risk assessments, implementing various control measures.

2). Information security and personal data protection education, training and publicity work are carried out every year, and new employees are required to sign an information security confidentiality agreement.

3). Outsourced vendors must sign a confidentiality agreement to ensure that those using the information services provided by the Company or performing related information business have the responsibility and obligation to protect the acquired and utilized information assets from the Company, preventing unauthorized access, alteration, destruction, or improper disclosure.

4). Appropriate backup, redundancy, or monitoring mechanisms are established in important information systems or equipment. Also, regular drills are conducted to maintain its availability.

5). Anti-virus software is installed in personal computers with regular checks for virus code updates. Unauthorized software is prohibited.

6). Colleagues are required to keep their accounts, passwords, and permissions secure and use them responsibly. Additionally, passwords should be changed regularly. ◦

7). Standard procedures for responding to and reporting information security incidents have been established. The Information Security Emergency Response Team is responsible for promptly handling these incidents to prevent further damage.

8). Establish a sustainable business management mechanism and conduct regular testing and drills to maintain its applicability.

9). Internal audits are regularly conducted annually to ensure the effectiveness of information security and personal information protection management systems.

(c). Cybersecurity risk and personal data protection management and review

1). In January 2026, the Company passed the annual review of ISO/IEC 27001:2022 and ISO/IEC 27701:2019 and the audit verification of ISO/IEC 27017:2015 and ISO/IEC 27018:2019 by a third-party impartial organization.

2). The scope of ISO/IEC 27701 verification mainly includes the Company's product business service processes, customer relationship management, customer case management, and product warranty personal data processing operations.

3). The introduction of ISO27001 (Information Security Management System) strengthens the ability to respond to information security incidents, thus protecting the Company and customer information assets.

4). Through the introduction of ISO27701 (Personal Information Management System), we can identify the potential risks associated with the personal data held by the Company and comply with the requirements of various national personal data protection laws and regulations to protect the security of the Company and customers' personal data.

5). Inspection and control operations of information security and personal data protection are included as annual audit items. The audit unit conducts audits at least once a year. Additionally, the Company conducts self-inspection operations annually based on the internal control system. The summary of the performance of implementing internal controls is submitted to the Board of Directors for review and confirmation. Furthermore, an internal control system statement is issued based on the evaluation results.

(d). Invest resources in information security and personal data protection management

1). Certification: Passed the third-party review of ISO/IEC 27001 information security and ISO/IEC 27701 personal information protection, and there were no deficiencies in the relevant information security and personal information protection audits. We will regularly obtain ISO 27001 certification, which is

valid from February 8, 2018 to February 7, 2027, and ISO 277001 certification, which is valid from March 3, 2021 to February 7, 2027.

2). Based on the development trend of cloud security, and to ensure the security of product information and customer data, the scope of ISO/IEC 27001 and ISO/IEC 27701 verification will be changed in 2026 to meet the internationalization requirements of CDMO (Contract Development and Manufacturing Organization), and to pass the audit verification of ISO/IEC 27017 (cloud service information security) and ISO/IEC 27018 (cloud service personal data protection).

3). Customer satisfaction: There were no major information security incidents and no complaints of loss of customer data throughout the year.

4). Education and training：All new employees completed information security and personal data protection training prior to onboarding. During the year, the Company conducted a total of four training sessions on information security (4 hours) and personal data protection (4 hours) for general employees and professional personnel, with a total attendance of 582 participants. Assessment records were maintained for each training session.；Two social engineering "phishing email" tests are conducted annually.

5). Data Leakage Prevention (DLP): The data leakage prevention (DLP) mechanism is introduced. All files above the confidential level will be automatically encrypted to protect the Company's intellectual property security.

6). The Company holds a monthly information security team meeting to review issues related to information security, personal information protection, and trade secrets. It also holds a management review meeting at the end of the year to report on the work results and indicator evaluation for the past year.

7). Considering that the Company's information security management mechanism and measures are sufficient to run the current operations and comply with relevant regulations, the Company has decided not to purchase information security insurance for the time being. In the future, the Company will decide whether to purchase this insurance based on the development of overall information security and personal information protection.

8). Completed the inventory and internal audit of trade secret business files by 2025 to strengthen the confidential file management mechanism and implement the PDCA (Plan-Do-Check-Act) cycle of trade secret management system.

(2) Losses, potential impacts, and countermeasures due to major information security incidents in the most recent year and up to the date of publication of the annual report: None.

7.Important contracts

| Nature of Contracts | Contracting parties | Commencement dates and expiration dates of contracts | Major content | Restriction clause |
|---|---|---|---|---|
| Trademark licensing contract | GE Trademark Licensing, Inc | 2020.2.1~2029.12.31 | GE Trademark licensing | Exclusive license |
| Sales contract | AFDZ01 | 2021.1.1~2030.12.31 | Middle East Product Sales | Local production of semi-finished test pieces |
| Sales contract | WEIT01 | 2020.12.7~2026.12.31 | Italian product ODM contract | Exclusive models and future derivatives |
| Sales contract | TW001 | 2025.1.1~2025.12.31 | Taiwan's retail channels | Automatic renewal for one year. |

# V. A Review and Analysis of the Company's Financial Position and Financial Performance, and a Listing of Risks

1.Financial Position

(1) Financial Statements Comparison Analysis Table Unit: NT$ Thousand

| Item \ Year | 2024 | 2025 | Difference | |
|---|---|---|---|---|
| | | | Amount | % |
| Current assets | 1,774,198 | 1,561,116 | (213,082) | (12.01)% |
| Property, plant and equipment | 2,586,364 | 2,531,120 | (55,244) | (2.14)% |
| Intangible assets | 776,081 | 919,390 | 143,309 | 18.47% |
| Other assets | 644,628 | 692,774 | 48,146 | 7.47% |
| **Total assets** | 5,781,271 | 5,704,400 | (76,871) | (1.33)% |
| Current liabilities | 2,310,998 | 2,078,308 | (232,690) | (10.07)% |
| Non-current liabilities | 1,581,257 | 1,870,480 | 289,223 | 18.29% |
| **Total liabilities** | 3,892,255 | 3,948,788 | 56,533 | 1.45% |
| Capital stock | 610,388 | 672,727 | 62,339 | 10.21% |
| Advance receipts for share capital | 1,792 | 597 | (1,195) | (66.69)% |
| Capital surplus | 1,115,593 | 1,079,304 | (36,289) | (3.25)% |
| Retained earnings | 13,060 | (167,217) | (180,277) | (1,380.38)% |
| Other Equity | 139,145 | 159,995 | 20,850 | 14.98% |
| Non-controlling interests | 9,038 | 10,206 | 1,168 | 12.92% |
| **Total shareholders' equity** | 1,889,016 | 1,755,612 | (133,404) | (7.06)% |
| Analysis of any significant change: (The change is up to 20%, and amounted to NT$10 million)<br>(i). Decrease in retained earnings: due to a decrease in profit for the current period. | | | | |

(2).Where the effect is of material significance, the annual report shall describe the measures to be taken in response: The above-mentioned changes have no material impact on finance and business.

2.Financial performance

(1)Comparison Analysis Table for Results of Operations

Unit: NT$ Thousand

| Item \ Year | 2024 | 2025 | Increased /decreased Amount | Percentage of change (%) |
|---|---|---|---|---|
| Net operating revenue | 1,933,746 | 1,838,588 | (95,158) | (4.92)% |
| Operating cost | 1,165,363 | 1,210,778 | 45,415 | 3.90% |
| Gross profit | 768,383 | 627,810 | (140,573) | (18.29)% |
| Operating expense | 923,570 | 825,166 | (98,404) | (10.65)% |
| Operating profit | (155,187) | (197,356) | (42,169) | 27.17% |
| Non-Operating revenues and expenditures | (30,524) | (52,049) | (21,525) | 70.52% |
| Net profit before tax | (185,711) | (249,405) | (63,694) | 34.30% |
| Less: Income tax expense | (59,712) | (70,085) | (10,373) | 17.37% |
| Net Income | (125,999) | (179,320) | (53,321) | 42.32% |

Analysis of any significant change: (The change is up to 20%, and amounted to NT$10 million)

(i). Increase in net operating loss: mainly due to a decrease in gross profit.

(ii). Increase in non-operating expenses: mainly due to an increase in impairment losses and disposal losses on property, plant and equipment.

(iii). Increase in loss before tax: mainly due to a decrease in operating profit.

(iv). Increase in net loss after tax: mainly due to a decrease in profit before tax.

(2) Expected sales volume and the basis thereof, as well as the possible impact on the Company's future financial and business operations and the corresponding responseplans：

According to the company's sustainable development, Bionime is committed to improving the company's competitiveness and fulfilling the corporate social responsibility. In addition to continuously promoting the automation of the production and improving the technology and quality of production based on existing operations, supplemented by the comprehensive promotion of meticulous management, the cost of department can be effectively reduced via measures such as effective improvement of manufacturing processes and operating procedures. The business strategies will continue to innovate Product and IoT development. Bionime will continue to strengthen the development of new markets, new channels, and new customers in the future, and expand the company's future operational

growth momentum. Bionime will also improve the company's overall operational performance and expand the competitive advantages. Keep abreast of the business and financial position of the invested business in order to provide the necessary resources and assistance in a timely manner.

3. Cash flow analysis

(1) Cash flow change analysis

Unit: NT$ Thousand

| Opening balance (December 31, 2024) | The cash flow generated from operating activities (2025) | The cash flow from generated from investment and financing activities (2025) | Cash flow surplus (December 31, 2025) | Cash shortage contingency plan | |
|---|---|---|---|---|---|
| | | | | Investment plan | Financing plan |
| 321,227 | 494,802 | (394,600) | 423,124 | - | - |

Cash flow change analysis in 2025 is as follow

(a). Cash inflow from operating activities of NT$494,802 thousand: Mainly due to net cash surplus from operating activities.

(b).Cash inflows from investment activities amounted to NT$286,072 thousand: Mainly due to the increase in prepaid equipment payments.

(c).The cash inflow from financing activities of NT$108,528 thousand: This is due to the decrease increase in loans.

(2) Remedial measures and liquidity analysis for cash deficit: There is no cash deficit concerns.

(3) Cash flow analysis for the coming year: Not applicable.

4. Major capital expenditures during the most recent fiscal year: None

5. Investment policy for the most recent fiscal year, the main reasons for the profits or losses, improvement plans, and investment plans for the coming year.

(1) Re-investment policy of the Company:

The re-investment policies of the Company are followed by the relevant executive departments in accordance with the internal control system - “Investment Cycle” and “Acquisition and Disposal of Assets Procedures”, etc. The above-mentioned regulations or procedures are resolved by the board of directors or shareholders meeting.

(2) The main reasons for the profits or losses, improvement plans

Unit: NT$ Thousand

| Investee Company | Current-period recognized investment gain (loss) | Principal business activity | The main reasons for profit or loss | Improvement Plan |
|---|---|---|---|---|
| Bionime Incorporated(B.V.I) | 3,853 | Investment company | This is a holding company, and its profits come from its invested companies. | - |
| Bionime GmbH | (376) | Merchandising-sector company | This is in line with the Group's operational strategy and resource integration, resulting in some business adjustments. | Group operational adjustments. |
| Bionime Australia Pty Limited | (33) | Merchandising-sector company | | |
| Bionime USA Corporation | 6,508 | Merchandising-sector company | The operating performance remains sound. | - |
| Bionime(Malaysia) Sdn Bhd | 1,783 | Merchandising-sector company | The operating performance remains sound. | - |
| Bionime (Shenzhen) Co., Ltd | 3,496 | Merchandising-sector company | The operating performance remains sound. | - |
| Bionime (Pingtan) Co., Ltd. | 4,510 | Manufacturing company | The operating performance remains sound. | - |

1) In retailers, pharmacies, doctors' clinics and diabetes educators in the United States, the subsidiary in the US every year with the stable growth in the demands and sales of test strips.

2)The Group's subsidiary in Mainland is the production base, brand promotion and customer service center of Bionime in China. Starting from the second half of 2020, the Group’s Mainland subsidiary will gradually take over the exclusive distribution rights in

some parts of China from Tonghua Dongbao. Through this approach, we expect to provide customers with more focused and prompt services. Although there was still a loss in 2021, it is expected that through the fermentation of brand benefits, the company will gradually increase its revenue every year and turn losses into profits.

3)Due to the years of operation at the subsidiary in Malaysia established in 2018, Bionime's blood glucose monitoring device has been highly recognized by many critical opinion leaders in this field in the local market. Through the promotion of clinics, hospital,chain pharmacies, individual pharmacies, distributors and other channels the company has achieved steady profitability.

4) The Swiss and Australian subsidiaries have gradually switched to unified order management by the parent company in accordance with the Group's operational strategy adjustments and resource integration, but they still incur fixed operating costs and losses in their respective locations. For the group, resource concentration and efficiency improvements are expected to optimize the group's overall performance eventually.

Also, the Company always keeps abreast of the business and financial position of the invested business in order to provide the necessary resources and assistance in a timely manner.

3. Investment plans for the coming year:

The Group's subsidiaries in mainland China, together with local distributors, continue to visit hospitals to seek business opportunities and explore e-commerce channels, and the Malaysian subsidiary will focus on developing comprehensive solutions in the coming year to provide inpatient and outpatient services and gradually increase its market penetration and market share. The US subsidiary will focus on the telemedicine market and strive for revenue.

6.Risk and evaluation in the most recent fiscal year and up to the publication of the annual

(1) The impact of changes in the interest rate, fluctuation of exchange rate, inflation rate on the Company’s profits (losses) and countermeasures to be taken in the future:

(a) The effect upon the Company's profits (losses) of interest rate fluctuations and countermeasures to be taken in the future

| Item | 2025 | 2026Q1 |
|---|---|---|
| Net operating revenue | 1,838,588 | 405,264 |
| Net income | (179,320) | (79,266) |
| Net interest income and expenditure | (60,312) | (14,251) |
| Net operating revenue ratio | (3.28%) | (3.52%) |
| Net income ratio | 33.63% | 17.98% |

In 2025, the ratio of net interest income and expenses to the revenues and net loss after tax of the Company and its subsidiaries was approximately (3.28%) and 33.63%, respectively. In the first quarter of 2026, the ratio of net interest income and expenses to the revenues and net loss after tax of the Company and its subsidiaries was approximately (3.52%) and 17.98%, respectively. Therefore, fluctuations in interest rates have a significant impact on the revenues and profitability of the Company and its subsidiaries.

In response to the risk of interest rate fluctuations, the Company will continue to pay attention to the future trends of the interest rate in the market and collect interest rate information of banks. It timely evaluates the interest rate of the current loans, and continues to establish good relations with banks. By presenting good bank financing credit record, it could obtain a relatively preferential interest rate of loans. When financing is needed, plan appropriate long-term and short-term bank loans depending on the actual capital requirements, to minimize the risks caused by fluctuations in interest rates and capital costs to the Company's operations.

(b).The effect upon the Company's profits (losses) of exchange rate fluctuations and countermeasures to be taken in the future

Unit: NT$ Thousand

| Net operating revenue | 2025 | 2026Q1 |
|---|---|---|
| Net Income | 1,838,588 | 405,264 |
| Net exchange gains and losses | (179,320) | (79,265) |
| Net operating revenue ratio | 6,991 | 969 |
| Net income ratio | 0.38% | 0.24% |
| Net operating revenue | (3.90%) | (1.22%) |

The operating revenue of the Company and its subsidiaries is mainly denominated in US dollars and Euros. Therefore, the depreciation of US dollar or the Euro against the New Taiwan dollar will result in reduction of the profit of the Company and its subsidiaries. In order to reduce the impact of fluctuation of exchange rate on the profit and loss of the Company and its subsidiaries, the Accounts Department of the Company also collects information on exchange rate at any time, focuses on the trend and changes of major currencies in the international currency market to grasp the exchange rate trend, and maintain a good interactive relationship with the bank in order to get more extensive information on foreign exchange and more favorable exchange rate quotes. In terms of strategy, the balance of foreign currency assets and liabilities should be achieved as much as possible to achieve the effect of natural hedging, and reduce the impact of exchange rate fluctuations on the Company’s profit and loss.

(c).The impact of changes in the inflation rate on the Company’s profits (losses) and countermeasures to be taken in the future

The increase in domestic and international prices will lead to an increase in the Company’s purchasing costs, which may adversely affect the Company's profitability. However, the Company has more than one supplier. In the future, the Company will pay close attention to the inflation situation, and negotiate with different suppliers to reduce the impact of inflation on the Company.

(2) The Company’s policy regarding high-risk investments, highly leveraged investments, loans to other parties, endorsements, guarantees, and derivatives transactions; the main reasons for the profits/losses generated thereby; and countermeasures to be taken in the future: None.

(3) Research and development work to be carried out in the future, and further expenditures expected for research and development work:

For information regarding research and development activities, please refer to Section IV, Operational Overview. The Company’s R&D expenses amounted to NT$354,755 thousand in 2025, and the estimated R&D expenses for 2026 are NT$617,967 thousand. The key factors affecting future R&D success include the capabilities of R&D personnel and the mastery of software and hardware system technologies. With the extensive experience accumulated by the Company’s R&D team over the years, the Company is confident in its ability to meet these challenges and continuously develop products with market competitiveness.

(4) Effect on the Company's financial operations of important policies adopted and changes in the legal environment at home and abroad, and countermeasures to be taken:

In response to the subsequent revision of the guidelines for various operations by domestic and foreign authorities, the Company has actively cooperated with it, and currently, it has no significant impact on the financial operations.

(5) Effect on the Company’s financial operations of developments in science and technology as well as industrial change, and countermeasures to be taken:

The Company has always attached great importance to the improvement of R&D capabilities, paying attention to the evolution of technology in the industry, and commencing the evaluation and R&D of various products to meet market demand. It is evaluated that the developments in science and technology have no significant impact on the Company's financial operations in the near future.

Assessment analysis of security risk and countermeasures: The Company builds the operational management mechanism by referring to the COSO structure, and measuring the factors such as the control environment, risk assessment, control activities, information and communication, and supervision. Moreover, it summarizes the functions of risk management and internal control based on the "Regulations Governing Establishment of Internal Control Systems by Public Companies".

(6) Effect on the Company's crisis management of changes in the Company's corporate image, and countermeasures to be taken:

As of the publication of the annual report, there is no major events affecting the Company’s corporate image.

(7) Expected benefits and possible risks associated with any merger and acquisitions, and countermeasures being or to be taken: None.

(8) Expected benefits and possible risks associated with any plant expansion, and countermeasures being or to be taken: None.

(9) Risks associated with any consolidation of sales or purchasing operations, and countermeasures being or to be taken:

(a) Purchasing operation: The Company’s major purchased items consist of components and related raw materials for blood glucose meters and blood glucose test strips. In 2024 and 2025, purchases from Company F accounted for 12.74% and 17.29% of the Company’s net purchases, respectively. After comprehensively considering factors such as suppliers’ production technology, product quality yield, production capacity, and cost planning, the Company selected Company F as a long-term business partner. Therefore, there has been no significant concentration risk in purchases during the most recent two fiscal years.

(b) Sales operation: In 2024 and 2025, sales to Company E accounted for approximately 28.49% and 22.24% of the consolidated net sales, respectively. Company E is the Company’s customer in North Africa. Since the customer established a local manufacturing facility and maintained stable product distribution, and as the Company’s distribution customers are located across Europe, the Americas, and Asia, there has been no significant concentration risk in sales.

(10) Effect upon and risk to the Company in the event a major quantity of shares belonging to a director, supervisor, or shareholder holding greater than a 10% stake in the Company has been transferred or has otherwise changed hands, and countermeasures being or to be taken: None.

(11) Effect upon and risk to Company associated with any change in governance personnel or top management, and countermeasures being or to be taken:

The Company’s operations are mostly proposed by the executive units, and then approved by the management, therefore, a complete operation model has been established. If there is a change in governance personnel or top management, the impact on the Company’s sustainable operation is limited.

(12) Litigation or non-litigation:

(a) Any have been determined or are including in the litigation, non-litigation or administrative litigation in which the results may have a significant effect on the Company's shareholders' equity and securities price, it should be fully disclosed in detail and include the facts of the dispute, cost of litigation, date of commencement of proceedings, litigants and the current situation regarding handling of litigation of the Company in the most recent two fiscal years and up to the date of publication of the annual report: Due to a dispute over the reassignment of an employee, the mediation by the Labor Bureau failed. Following the employee's civil lawsuit, the first court hearing was scheduled for December 3, 2025, with a planned demand for additional overseas salary and housing allowance. Despite the aforementioned litigation, the amounts involved are not material given the Company's capital and business scale, and have not had a significant impact on shareholders' equity or securities prices.

(b) Whether any of the Company’s directors, supervisors, general manager, de facto responsible person, shareholders holding more than 10% of the Company’s shares, or subordinate companies have been involved in any concluded or pending litigation, non-litigation, or administrative litigation cases during the most recent two fiscal years and up to the date of publication of the annual report, where such cases may materially affect shareholders’ equity or the price of the Company’s securities: None.

(c)The Company's directors, supervisors, general manager, de facto person in charge, majority shareholders and subordinate companies with a shareholding ratio of more

than 10% have been violated the provisions of Article 157 of the Securities and Exchange Act and the current situation regarding handling of the Company in the most recent two fiscal years and up to the date of publication of the annual report and: None.

(13) Other important risks, and countermeasures being or to be taken: None.

7.Other Important Matters: None.

## VI. Special Disclosure

1. Information related to the Company's affiliates

(1) Consolidated business reports of affiliated companies

(a) Organizational chart of affiliated companies (December 31, 2025)



(b) Basic information of affiliated companies

| Name of company | Date of incorporation | Region | Paid-in Capital | Principal business activity |
|---|---|---|---|---|
| Bionime Inc. | November 2004 | OMC Chambers, P.O. Box 3152, Road Town, Tortola, B. V. I. | USD 3,090 thousand | Investment company |
| Bionime (Shenzhen) Co., Ltd | December 2005 | Zone A, 9th Floor, Fukang Technology Building, 8 Fukang Commercial Plaza, 10th Industrial Zone, Yousong, Longhua Office, Bao'an New District, Shenzhen | USD 2,300 thousand | Merchandising-sector company |
| Bionime GmbH | April 2005 | Tramstrasse 16 9442 Berneck / Switzerland | CHF 300 thousand | Merchandising-sector company |
| Bionime USA Corp. | February 2008 | 1450 E Spruce Street, Bldg. B Ontario CA 91761-8314 | USD 11,150 thousand | Merchandising-sector company |
| Bionime Australia Pty Ltd | February 2010 | Level 7, York Street, Sydney NSW 2000 Australia | AUD 350 thousand | Merchandising-sector company |
| Bionime (Pingtan) Co., Ltd. | January 2015 | Taiwan Pioneer Park, Pingtan Comprehensive Experimental Area, Pingtan County, Fuzhou City, Fujian Province, China | RMB20,000 thousand | Manufacturing company |
| Bionime (Malaysia) Sdn Bhd | April 2018 | No.35,Lot 2735,1st&2nd Floor,Pusat Pedada,Jalan Pedada,96000 Sibu,Sarawak, Malaysia | MRY 1,620 thousand | Merchandising-sector company |

(c) Shareholders presumed to have control and subordinate relationship with the same information: None.

(d) The operating activities of affiliated companies and their association

| Industry Type | Name of company | Association with the operating activities of affiliated companies |
|---|---|---|
| Investment company | Bionime Inc. | The parent company of Bionime (Shenzhen) Co., Ltd. |
| Merchandising-sector company | Bionime (Shenzhen) Co., Ltd | The re-investment company of Bionime Inc. |
| Merchandising-sector company | Bionime GmbH | None |
| Merchandising-sector company | Bionime USA Corp. | None |
| Merchandising-sector company | Bionime Australia Pty Ltd | None |
| Manufacturing company | Bionime (Pingtan) Co., Ltd. | The re-investment company of Bionime (Shenzen) Co., Ltd. |
| Merchandising-sector company | Bionime(Malaysia) Sdn Bhd | None |

(e) Directors, supervisors and general managers of affiliated companies:

| Name of company | Position tittle | Name or representative | Shareholding | |
|---|---|---|---|---|
| | | | Number of shares ( 1000 shares) | Shareholding percentage |
| Bionime Inc. | Chairman | Bionime Corporation Representative: Huang,Chun-Mu | 3.09 | 100% |
| Bionime (Shenzhen) Co., Ltd | Legal representative | Bionime Inc. Representative: Huang, Chun-Mu | - (Note 1) | 100% |
| Bionime GmbH | Chairman | Bionime Corporation Representative: Huang,Chun-Mu | - (Note 2) | 100% |
| Bionime USA Corp. | Chairman | Bionime Corporation Representative: Huang, Chun-Mu | 1,115 | 100% |
| Bionime Australia Pty Ltd | Chairman | Bionime Corporation Representative: Huang, Chun-Mu | -((Note 3) | 100% |
| | Director | Bionime Corporation Representative: Chen, Bi-Hsuan | | |
| | | Huang, Hui Hsuan | | |
| Bionime (Pingtan) Co., Ltd. | Legal representative | Bionime (Shenzhen) Co., Ltd Representative: Huang, Chun-Mu | - (Note 1) | 100% |
| Bionime(Malaysia) Sdn Bhd | Chairman | Bionime Corporation Representative: Huang, Chun-Mu | -(Note4) | 65.09% |
| | Director | Bionime Corporation Representative:Chen, Bi-Hsuan | | |
| | | TING YIIK PUNG | | |

Note 1: A limited company established in Mainland China

Note 2: A limited company established in Switzerland

Note 3: A limited company established in Australia

Note 4: A limited company established in Malaysia

(f) Operating Overview of Affiliated Companies

Unit: NT$ Thousand

| Name of company | Capital | Total assets | Total liabilities | shareholders' equity | Operating revenues | Net profit | Net Income | EPS |
|---|---|---|---|---|---|---|---|---|
| Bionime Inc. | 98,064 | 134,388 | 0 | 134,388 | 0 | (88) | 3,853 | 1,246.93 |
| Bionime (Shenzhen) Co., Ltd | 72,289 | 124,152 | 7,456 | 116,696 | 40,492 | (1,164) | 3,496 | N/A(Note1) |
| Bionime GmbH | 7,529 | 31,182 | 176 | 31,006 | 0 | (498) | (376) | N/A(Note1) |
| Bionime USA Corp. | 343,193 | 115,361 | 1,491 | 113,870 | 75,209 | 3,257 | 6,508 | 5.84 |
| Bionime Australia Pty Ltd | 10,042 | 235 | 445 | -210 | 0 | (33) | (33) | N/A(Note1) |
| Bionime (Pingtan) Co., Ltd. | 90,016 | 159,969 | 42,542 | 117,427 | 182,788 | 4,790 | 4,510 | N/A(Note1) |
| Bionime (Malaysia) SDN BHD | 12,066 | 40,395 | 11,160 | 29,235 | 66,130 | 4,371 | 2,740 | N/A(Note1) |

Note1: The affiliated company is a limited company, so there is no earnings per share.

(2) Consolidated financial statements of affiliated companies

The companies should be included in the consolidated financial statements of affiliated enterprises of the Company in 2025(from January 1-December 31, 2025) was prepared in accordance with the "Criteria Governing Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises" are the same with the companies should be included in the parent and subsidiary consolidated financial statements in accordance with the IFRS No. 10 approved by the Financial Supervisory Commission, and the relevant information shall disclose in the consolidated financial statements of the affiliated enterprises has been disclosed, therefore, no separate consolidated financial statements of the affiliated enterprises will be presented.

2. Transaction about the Company's private placement of securities during the most recent fiscal year up to the publication of the annual report: None.

3. Other matters for which supplementary explanation is required: None.

**VII. If any of the situations listed in Article 36, paragraph 3, subparagraph 2 of the Securities and Exchange Act, which might materially affect shareholders' equity or the price of the company's securities, has occurred during the most recent fiscal year up to the publication of the annual report: None.**

**BIONIME CORPORATION**

**Chairman: Huang, Chun-Mu**

BETTER HEALTH
FOR MORE PEOPLE

BIONIME